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Abstract 
Effective immunity is fundamental to life on a dirty planet. Appropriate immune responses control 
infections and protect against cancer. Inappropriate immune responses lead to autoimmunity and 
allergy. A fine balance between aggression and tolerance is therefore central to effective immune 
function at the system level. This is a particular problem for T cells, which recognize peptide antigens 
bound to host major histocompatibility complex (MHC) molecules. Faced with a composite antigenic 
structure, the distinction between “foreign and dangerous” and “self and harmless” becomes both 
difficult and imperative, especially when the antigen persists. In this thesis, antigen-specific T cell 
responses were investigated under conditions of chronic antigenic stimulation to inform our 
understanding of this process.  
In T cell receptor transgenic mice, continuous antigenic stimulation without adjuvant lead to increased 
in vivo turnover of antigen-specific CD4+ T cells but “aborted” immune activation, characterized by 
depletion of these cells from the circulation and spleen. Full immune activation and expansion of 
antigen-specific memory/effector CD4+ T cells required the presence of adjuvant, in this case IL-1β, 
which induces an inflammatory environment.  
Further isotope labelling studies in human immunodeficiency virus-infected subjects suggested that 
the surface marker CD57 demarcates a “steady state” within the CD8+ T cell memory compartment, 
whereby CD57+ cells have lower in vivo turnover rates compared to their CD57- counterparts. These 
observations provide a potential mechanistic explanation for the preferential accumulation of 
CD57+CD8+ cells under conditions of chronic antigenic stimulation. 
Another persistent pathogen, cytomegalovirus (CMV), expresses a viral interleukin (IL)-10 homologue. 
Memory T cell inflation and antiviral cytokine production in murine CMV(MCMV)-infected mice were 
suppressed by IL-10. Conversely, IL-10 blockade or deficiency lead to the inflation of certain antigen-
specific T cell populations and reduced viral load, most likely as a consequence of the enhanced 
immune response.  
Reactivation of human CMV was also apparent in subjects with dasatinib-associated large granular 
lymphocyte expansions. Consistent with a causative association, the expanded T cell and NK cell 
populations in these subjects were oligoclonal and exhibited a late differentiated (CD27-CD57+) 
phenotype, indicative of chronic antigenic stimulation. In addition, CD8high and CD8low T cells were 
observed within both the total and CMV-specific CD8+ T cell compartments, consistent with CMV-
driven activation. 
In summary, these data show that antigen alone is not sufficient to induce full immune activation, even 
under conditions of chronic stimulation. Additional signals, such as those provided by an inflammatory 
environment, are required to trigger full T cell activation and expansion. Persistent viruses attempt to 
undermine this process, for example by the expression of homologues that mimic host immune 
regulators. Even in the presence of viral reactivation and immune system perturbations, however, the 
T cell compartment can demonstrate remarkable resilience in its ability to generate fully differentiated 
and functional expansions. The persistence of certain memory T cell subsets under such conditions 
appears to play an important role in the immune response to chronic “dangerous” antigens. 
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PBMC(s), peripheral blood mononuclear cell(s) 
PBS, phosphate buffered saline 
PCR, polymerase chain reaction 
PD-1, programmed death-1 
PFBHA, O-(2,3,4,5,6-pentafluorobenzyl)-hydroxylamine hydrochloride 
PFTA, pentafluoro tri-acetate 
Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia 
pHLA, peptide/HLA 
PMA, phorbol 12-myristate 13-acetate 
pMHC, peptide-major histocompatibility complex 
qPCR, quantitative polymerase chain reaction 
RLU, relative light units 
RNA, ribonucleic acid 
RR, ribonucleotide reductase  
RT, reverse transcriptase 
s.c., subcutaneous 
SD, standard deviation 
SEM, standard error of the mean 
SPCD4, single positive 4 
SPL, spleen  
TCR, T cell receptor 
TCRA and TCRB, α-chain and β-chain encoding TCR genes, respectively 
TCRBV, TCRB variable  
TCRBJ, TCRB joining 
TCM, central memory T (cells) 
TE, effector T (cells) 
TEM, effector memory T (cells) 
TEMRA, highly differentiated CD45RA+CD28-CCR7- effector memory T (cell) 
Tg, transgenic 
TGF, transforming growth factor 
Th, T helper 
THY, Thymus 
TM, memory T (cell) 
TN , naive T (cell) 
TNF, tumour necrosis factor 
TNFR, TNF-receptor 
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TREG, regulatory T (cell) 
UCSF, University of California at San Francisco 
UK, United Kingdom 
USA, United States of America 
vIL-10, viral IL-10 ortholog 
VL, vial load 
Wt, wild type 
zeo, zeocin 
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CHAPTER 
1 
Introduction 
1.1 The immune system 
The immune system is constructed from many different components, including organs, tissues, 
vessels, cells and molecular mediators, such as antibodies, chemokines and cytokines, all of which 
interact to provide holistic protection against external and internal threats. Appropriate immune 
responses control infections and protect against cancer. Inappropriate immune responses lead to 
autoimmunity and allergy. A fine balance between aggression and tolerance is therefore central to 
effective immune function at the system level, especially in the presence of chronic antigenic 
stimulation. The presented work addresses key aspects of the immune response under such 
conditions. 
The main organs of the immune system are the thymus, the lymph nodes, the spleen, the small and 
large intestine and, to some extent, the liver. Epithelial surfaces such as the skin and mucosae form a 
physical barrier that protects the host from invading pathogens. The epithelium and dermis of the skin, 
as well as the mucosa that lines the intestine, the mouth, the nasal cavity and the genital tract are 
colonized by immune cells that are ready to attack anything recognized as foreign and pathogenic. 
The main cell types of the immune system are macrophages, neutrophils, eosinophilic and basophilic 
granulocytes, natural killer (NK) cells, monocytes, dendritic cells, B and T lymphocytes. Classically, 
the immune system is divided into two arms at the functional level, termed innate (natural) and 
adaptive (acquired) immunity (Medzhitov and Janeway 2000).  
Innate immunity provides a first line of defence against host attack. Innate receptors or "pattern 
recognition receptors", such as Toll-like-receptors, recognize highly conserved structures expressed 
by many different pathogens (Medzhitov and Janeway 2000). Recognition of such structures can 
occur by receptors expressed on the cell surface or by intracellular receptors after phagocytosis. 
Phagocytic cells, such as macrophages and neutrophils, eosinophilic and basophilic granulocytes, and 
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NK cells are classical examples of innate immune cells. Monocytes may be precursors to antigen (Ag) 
presenting cells (APCs) and are associated with innate and adaptive immune responses. Many 
species have complement systems, including non-mammals like plants, fish and some invertebrates 
(Janeway, Travers et al. 2005). Complement is the main humoral component of the innate immune 
response (Rus, Cudrici et al. 2005). Components of the complement system assist in the killing of 
pathogens by antibodies. They also function as peptide mediators of inflammation and can recruit 
phagocytic cells, opsonize pathogens and assist in the removal of immune complexes, or form a 
membrane attack complex that can lyse cells or pathogens.  
Adaptive immune responses are mainly executed by Ag-presenting cells, B and T lymphocytes. B 
lymphocytes and their descendants, plasma cells, mediate the humoral immune response, whereas T 
lymphocytes mediate the cellular immune response. B cells recognize Ag through the B cell receptor 
(BCR). The BCR is membrane-bound immunoglobulin (Ig), and Igs of the same specificity are 
secreted as antibody by terminally differentiated B cells, termed plasma cells. Antibodies bind 
pathogens or their toxic products in the extracellular spaces of the body. The antibody molecule 
specifically binds Ags from pathogens and marks them for destruction by complement activation or for 
uptake and destruction by phagocytic cells. Neutralizing antibodies can interfere with the binding of 
pathogens to receptors and block their uptake into cells, or neutralize bacterial toxins (Mayer and 
Nyland 2006). T cells recognize specific Ag through the T cell receptor (TCR). The TCR does not bind 
Ag directly, but instead recognizes short peptide sequences of proteins from pathogens that are bound 
to major histocompatibility complex (MHC) molecules on the surface of Ag-presenting cells (APCs). 
This adds an extra dimension to Ag recognition by T cells, termed MHC restriction. In humans, MHC 
molecules are called human leukocyte Ag (HLA) molecules. They are glycoproteins that show an 
enormous degree of variation at the population level (Janeway, Travers et al. 2005). Both the BCR 
and the TCR have common structural features that can accommodate great variability in Ag 
specificity. 
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1.1.1 T lymphocytes 
T lymphocytes can be divided into subsets according to their phenotype and function. The phenotype 
of a T cell not only suggests what role it plays in immune responses, but also indicates whether it has 
come into contact with a foreign or self-derived inciting Ag. A key distinction is based on whether an 
αβTCR or a γδTCR is expressed. The focus here will be on CD4+ and CD8+ T cells that express 
αβTCRs. Beyond the primary distinction between CD4+ and CD8+ T cells, which is based on distinct 
Ag recognition properties, coreceptor usage and function, many other subsets have been 
demonstrated or proposed. For example, human CD4+ and CD8+ T cells can be divided phenotypically 
and functionally into naive, memory, effector memory or terminally differentiated effector T cells 
(Appay, van Lier et al. 2008). This categorization suggests that human T cells progress with division 
along a linear differentiation pathway. Although this is very likely, it has not yet been proven beyond all 
doubt. The terminally differentiated phenotype is less prevalent or even absent in CD4+ T cell 
populations. In general, CD8+ T cells are perceived to act as licensed killers and include cytotoxic 
CD8+ T cells, NKT cells and anti-viral and immunomodulatory cytokine-producing CD8+ T cells. 
Another proposed subset describes suppressor CD8+ T cells. CD4+ T cells are generally thought to 
provide helper functions to B cells and also contain regulatory T cells that play a role in tolerance. 
Originally, CD4+ T cells were subdivided into two T helper (Th) subsets, Th1 or Th2, depending on the 
variety of cytokines that they made and their roles in immune responses (Tada, Takemori et al. 1978). 
Broadly speaking, Th1 cells play a role in the cellular immune response by creating a proinflammatory 
environment, providing help to macrophages, other APCs and cytotoxic CD8+ T cells. In contrast, Th2 
cells play a role in the humoral immune response by providing help to B cells and determining 
antibody class switching. More recently, new subsets of Th cells have been described, including T 
follicular helper cells (Chtanova, Tangye et al. 2004), Th17 (Harrington, Mangan et al. 2006), Th22 
(Eyerich, Eyerich et al. 2009) and Th9 cells (Veldhoen, Uyttenhove et al. 2008). Another subset in the 
CD4 lineage comprises regulatory T cells (TREG). Two subtypes of TREG cells have been described, 
natural TREG that originate in the thymus (Sakaguchi 2004) and peripheral TREG that are induced by 
conversion of conventional CD4+ T cells in the periphery (Apostolou and von Boehmer 2004). 
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1.1.2. T cell activation 
T cell activation occurs via the CD3-TCR complex (Figure 1). The CD3-TCR complex interacts with 
peptide antigen presented by MHC. CD4 and CD8 serve as coreceprtors to augment antigen 
recognition (Janeway 1992; Gao, Rao et al. 2002). During T cell priming, costimulation via further cell 
surface molecules is usually required. Such costimulatory molecules include CD28, ICOS, CTLA-4, 
and adhesion molecules (Bridgeman, Sewell et al. 2012). Costimulation serves to tune the response 
elicited by activation of the CD3-TCR complex. As an example, CD28 co-ligation significantly 
enhances the response and prolongs or sustains an immune response (Smith-Garvin, Koretzky et al. 
2009). CTLA-4 and CD28 share the ligands CD80 and CD86 and can counter each other in the 
regulation of downstream effects (Smith-Garvin, Koretzky et al. 2009). The activation requirements are 
different for CD4+ and CD8+ T cells. One important aspect that contributes to this difference is the fact 
that peptide MHC (pMHC)I-specific TCRs bind with stronger affinities (mean KD = 32  µM) than 
pMHCII-specific TCRs (mean KD = 92 µM) (Bridgeman, Sewell et al. 2012). Weak or antagonistic 
TCR ligation results in the rapid phosphorylation of a protein-tyrosine phosphatase, which then 
dephosphorylates the active site of Lck resulting in cessation of the TCR signal (Stefanova, Hemmer 
et al. 2003). Therefore, it is not unexpected that to stimulate resting CD4+ T cells, signals must be 
transmitted through both the TCR and costimulatory receptors (Davis, Boniface et al. 1998). A number 
of adaptor proteins also play important roles in negatively regulating TCR signals, some of which 
mediate downregulation of the TCR following stimulation with antigenic peptides (Naramura, Jang et 
al. 2002). This dampening of TCR activation is important during the resolution of an immune response 
as well as for the maintenance of self-tolerance.  
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Figure 1. T cell activation via the CD3-TCR complex. Following engagement of the TCR-CD3 Ag 
receptor with peptide (p)MHC (1) and subsequent recruitment of the CD4/CD8 co-receptor (2), the Src 
tyrosine kinases Lck and Fyn are activated and recruited to the TCR-CD3 complex (3). Activated 
kinases then phosphorylate the tyrosine residues within the ITAM motifs of the CD3 complex (4). 
Phosphorylated ITAM in the CD3 ζ chain recruit ZAP-70 (5), which subsequently phosphorylates LAT 
and SLP-76 (6). SLP-76 and LAT mediate TCR recruitment of downstream signal transduction compo- 
nents, and thus activation of secondary signal transduction pathways (7). Co-stimulatory signals 
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mediated by ligation of CD28, ICOS and adhesion molecules with their respective ligands are 
necessary for complete T cell activation (8). Following ligation, CD28 is tyrosine phosphorylated in a 
Lck/Fyn-dependent manner, thus allowing members of the Tec family of protein tyrosine kinases 
(Tec/Itk) to associate with the CD28 cytoplasmic tail. Tec/Itk are in turn activated by Lck/Fyn-
dependent tyrosine phosphorylation (9). Co-stimulatory signals integrate with the secondary signals 
emanating from the TCR-CD3 complex (7), leading to transcriptional activation and T cell proliferation 
(10). The tyrosine kinase Abl (depicted in red) plays a role in this signalling cascade by 
phosphorylating ZAP-70 and thus effecting different downstream pathways of the latter. Tyrosine 
kinase inhibitors (boxed) may interfere with this signalling cascade by blocking specific tyrosine 
kinases as shown. Primary tyrosine kinase inhibitor actions are shown in bold, with secondary 
inhibition shown in italics. (Seggewiss, Price et al. 2008) 
 
1.1.3. T cell tolerance 
A key feature of the immune system is that it can react to non-self while tolerating self and benign 
foreign Ags. There are also mechanisms in place that dampen down the immune response when it 
has been activated by an infectious process. Immune tolerance is facilitated by central and peripheral 
mechanisms. The thymus is critical for central tolerance. In the thymus, cells that react strongly to self 
are eliminated by clonal deletion (Hogquist, Baldwin et al. 2005). Peripheral tolerance cannot be linked 
directly to a lymphoid organ, even though certain organs are enriched for suppressor and regulatory T 
cells, such as the mucosal surfaces that line the gut and the orifices of the body, which are constantly 
exposed to non-self Ags from potentially dangerous sources (Lan, Mackay et al. 2007; Hand and 
Belkaid). Murine CD8+ suppressor T cells were first described in 1978 (Cantor, Hugenberger et al. 
1978), following which their existence was doubted (Janeway 1988) and then resurrected (Chess and 
Jiang 2004; Hu, Ikizawa et al. 2004). Another subset of suppressor T cells that have extensively been 
studied in the recent years are CD4+ TREG cells (Sakaguchi, Sakaguchi et al. 1995; Sakaguchi 2004; 
Sakaguchi, Wing et al. 2009). In both mice and humans, TREG cells are characterized by high 
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expression of CD25, the IL-2 receptor α chain, low expression of CD127, the IL-7 receptor α chain, 
and high intracellular expression of the forkhead box transcription factor FoxP3. Additional markers 
can be used for the identification of TREG cells, but the three listed are the most commonly used. So-
called natural TREG cells originate in the thymus and are believed to have a relatively high avidity for 
Ag, yet still survive the deletion process. Peripheral TREG cells may be induced from conventional T 
cells (Apostolou and von Boehmer 2004). However, this was demonstrated using TCR transgenic (tg) 
mice on a RAG-/- background, which lack naturally occurring TREG cells (Curotto de Lafaille and Lafaille 
2009). In tumours, peripheral TREG cells do not share the same repertoire as non-TREG CD4+ T cells 
(Hindley, Ferreira et al.), which argues against peripheral conversion of non-TREG CD4+ T cells to TREG 
cells. After stimulation with antigen in vitro, some FoxP3+ and FoxP3- proliferating CD4+ T cells share 
the same dominant clonotypes, which suggests that individual T cell clonotypes may diversify into 
FoxP3+ and FoxP3- populations during Ag-driven immune responses. However, some dominant 
clonotypes appeared to be exclusive to FoxP3+ proliferating CD4+ T cells, suggesting that these cells 
expanded from pre-existing FoxP3+ CD4+ T cells (Melenhorst, Scheinberg et al. 2008). The latter cells 
may be naturally occurring TREG cells rather than TREG cells generated by conversion.   
 
1.1.4. TREG-mediated suppression 
Very early on in the study of TREG cells, an in vitro assay was established to measure their suppressive 
activity (Takahashi, Kuniyasu et al. 1998; Thornton and Shevach 1998). This assay measures the 
extent to which TREG cells suppress proliferation of co-cultured CD4+ or CD8+ T cells in the presence of 
specific Ag or agents that stimulate a polyclonal T cell response, such as cross-linking anti-CD3 
monoclonal antibody. It has also been shown in vivo in mice that TREG cells control: (i) peripheral CD4+ 
T cell numbers (Almeida, Legrand et al. 2002); (ii) homeostatic proliferation of peripheral CD4+ T cells 
(Shen, Ding et al. 2005); and, (iii) the size of the peripheral activated/memory T cell compartment 
(Annacker, Burlen-Defranoux et al. 2000). Their suppressive effect on activated T cells in vitro is 
dependent on cell-to-cell contact (Nakamura, Kitani et al. 2001). TREG cells may kill activated T cells by 
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a granzyme- or perforin-dependent mechanism (Gondek, Lu et al. 2005; Cao, Cai et al. 2007). 
Alternatively, they can deliver a negative signal to activated T cells by: (i) upregulating intracellular 
cyclic AMP, which inhibits T cell proliferation and IL-2 formation (Bopp, Becker et al. 2007); (ii) 
generating adenosine catalyzed by CD39 and CD73 expressed on their surface (Deaglio, Dwyer et al. 
2007); or (iii) interacting with B7 (CD80 and CD86) expressed by activated T cells (Paust, Lu et al. 
2004). TREG cells may also have an effect on the function of APCs, which in their presence may down-
regulate or fail to up-regulate the expression of CD80 and CD86, molecules that are important for 
proper T cell activation (Oderup, Cederbom et al. 2006), or express the enzyme indoleamine 2,3-
dioxygenase (IDO), which modulates tryptophan catabolism and creates the cell-toxic metabolite 
kynurenine (Grohmann, Orabona et al. 2002). Lymphocyte activation gene 3 (LAG-3), a CD4-related 
molecule that binds MHC class II, is also expressed by TREG cells and is important for their 
suppressive activity (Huang, Workman et al. 2004). In addition, TREG cells can kill B cells, which also 
function as APCs (Zhao, Thornton et al. 2006). Under certain circumstances, soluble factors such as 
IL-10 or transforming growth factor (TGF)β also play a role as mediators of suppression (Asseman, 
Mauze et al. 1999; Read, Malmstrom et al. 2000; Suri-Payer and Cantor 2001), especially in vivo; 
however, neutralization of either of these factors does not prevent suppression in vitro (Takahashi, 
Kuniyasu et al. 1998; Thornton and Shevach 1998). IL-10-producing regulatory T cells have been 
termed Tr1 cells (Asseman and Powrie 1998) and TGFβ-producing regulatory cells have been called 
Th3 cells (Fukaura, Kent et al. 1996). Although controversial, TGFβ can also act in membrane-bound 
form (Nakamura, Kitani et al. 2001). TGFβ may contribute to the differentiation of naïve / conventional 
CD4+ T cells into TREG cells or TREG cell-like cells, which has also been termed “infectious tolerance” 
(Yamagiwa, Gray et al. 2001; Jonuleit, Schmitt et al. 2002; Chen, Jin et al. 2003; Fahlen, Read et al. 
2005; Marie, Letterio et al. 2005; Andersson, Tran et al. 2008). In the latter case, TGFβ can be 
provided by a non-TREG cell source (Fahlen, Read et al. 2005). Other factors that play a role in the 
suppressive activity of TREG cells include IL-35 (Collison, Workman et al. 2007), galectin-1 (Garin, Chu 
et al. 2007), heme oxygenase-1 and carbon monoxide (Lee, Gao et al. 2007). TREG cells can also 
suppress via IL-2 consumption / cytokine-deprivation-induced apoptosis of effector CD4+ T cells 
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(Pandiyan, Zheng et al. 2007). This mechanism seems to operate before any effect on activation or 
proliferation takes place. 
 
1.1.5. In vivo T cell turnover and ways of studying it 
T cell turnover refers to the rates of T cell proliferation and cell death. Theoretically, T cell turnover can 
be studied ex vivo by staining of T cells with markers of proliferation, apoptosis and cell death. 
However, ex vivo staining will only give a snapshot of T cell proliferation, apoptosis and cell death at 
one specific moment in time. In other words, one will only be able to determine an on or off signal that 
will not reveal anything about the lifespan or the rates of proliferation and death of the cell population 
of interest. In vivo labelling can be carried out to gain more accurate estimates of T cell lifespan, rates 
of proliferation and cell death. In humans, in vivo labelling can be conducted with non-toxic stable 
isotopes such as deuterium (Hellerstein and Neese 1992; Neese, Misell et al. 2002), to determine T 
cell lifespan, proliferation and death rates of cells. Deuterated water (2H2O) or deuterated (2H-)glucose 
is administered orally or intravenously (i.v.) for different lengths of time depending on the question 
asked, then the cells of interest are isolated / sorted, the deoxyribonucleic acid (DNA) is extracted and 
derivatized, and label enrichment is measured by gas chromatography/mass spectrometry. Two 
recently published articles by Busch et al. (Busch, Neese et al. 2007) and Macallan et al. (Macallan, 
Asquith et al. 2009) outline the background of the methodology and provide detailed protocols for in 
vivo labelling with 2H2O or 2H-glucose. In addition, a very comprehensive and detailed review about 
the different mathematical models used for the interpretation of in vivo labelling data, including 
bromodeoxyuridine (BrdU) labelling data, was recently published by Borghans et al. (Borghans and de 
Boer 2007). In contrast to BrdU and tritiated[3H]-thymidine, 2H2O or 2H-glucose label DNA through the 
de novo nucleoside synthesis pathway (Hellerstein 1999).  
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Figure 2. Labelling pathways for measuring DNA synthesis and cell proliferation. GNG, 
gluconeogenesis/glycolysis; RR, ribonucleotide reductase; DNPS, de novo purine/pyrimidine synthesis 
pathway; DNNS, de novo nucleotide synthesis pathway. Modified from Neese et al. and Turner et al. 
(Neese, Misell et al. 2002; Turner 2006). 
 
This type of labelling allows the true quantification of DNA replication (Hellerstein and Neese 1992; 
Macallan, Fullerton et al. 1998) and is safe for use in humans (Hellerstein 1999). During DNA 
synthesis, deuterium is incorporated into both pyrimidines and purines, but purines are evaluated for 
label enrichment. The reason for this is that the efficiency of the de novo contribution to purine 
nucleosides is predictable and high in dividing cells (Macallan, Fullerton et al. 1998). Also, as shown in 
Fig. 2, the de novo pathway is relatively unaffected by extracellular nucleoside concentrations (Cohen, 
Barankiewicz et al. 1983; Reichard 1988; Macallan, Fullerton et al. 1998). Furthermore, stable isotope 
labelling is not influenced by post-labelling expansion. The reason for this is that after stable isotope 
labelling has been discontinued, labelled DNA strands will remain in the population, distributed among 
progeny. This is in contrast to what happens after BrDU labelling has been discontinued, as label in 
this case is diluted out and will not be detectable after approximately the third division. The latter two 
aspects, as well as the high toxicity of BrdU (Nakaguchi, Usui et al. 1971; Matsuoka, Nomura et al. 
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1990; Chaube and Murphy 1995), make deuterium labelling the favourable technique for studying 
cellular turnover. BrdU toxicities include both cytotoxic effects that can lead to skin lesions, anaemia, 
leukocytopenia, thrombocytopenia and inhibition of cell growth (the effect that I want to measure), as 
well teratogenic and mutagenic effects. The human body naturally contains deuterium and this is 
harmless. However, if a large fraction of body water (> 50%) were replaced with heavy water, then this 
would lead to cell dysfunction and death. When heavy water is used in labelling studies, the aim is to 
reach 1% deuterium enrichment of body water above background enrichment, which is safe. The only 
described side effect is tinnitus. After deuterium labelling, the labelled DNA strands remain in the 
population when cells divide, but they are distributed among the progeny cells. This means that each 
originally labelled parental DNA strand is counted as one strand, no matter whether it is found in only 
one cell or distributed among many daughter cells of the initially labelled cell. If cells change 
phenotype with cell division, labelled DNA strands will be found in other phenotypic compartments. A 
relative increase in label enrichment can therefore be found in a more differentiated phenotype, but 
this has to be paralleled by loss of label in a precursor of this more differentiated phenotype. The only 
way that label is truly lost from the studied cellular compartment is by permanent removal of labelled 
cells from the pool, which will be due to cell death unless the cells migrate to a tissue compartment 
that is not evaluated. Currently, in vivo labelling with stable isotopes is the best way to assess in vivo T 
cell proliferation and death rates in humans. BrDU labelling is not recommended for use in humans 
because of its toxicity and has several disadvantages over the deuterium labelling approach as 
mentioned above, although it can be used in animal models with the advantage that one can measure 
it directly ex vivo by flow cytometry. 
 
1.1.6. CD57 expression & cellular senescence 
Three cardinal features of cellular senescence (Latin: senescere meaning “to grow old“) have been 
described: (i) after repeated divisions, the proliferative capacity of a cell starts to dwindle and, 
eventually, ceases, for example due to shortening of telomerase if telomerase activity is not increased; 
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(ii) senescent cells develop resistance to apoptosis; and, (iii) senescent cells undergo multiple 
phenotypic and functional changes (Campisi 1996). CD57 expression has been proposed as a key 
marker of CD8+ T cell senescence (Brenchley, Karandikar et al. 2003). However, recent studies have 
shown that most CD57+ T cells do not express Programmed Death 1 (PD-1) (Petrovas, Chaon et al. 
2009), a marker expressed by exhausted T cells (Day, Kaufmann et al. 2006; Freeman, Wherry et al. 
2006; Petrovas, Casazza et al. 2006; Trautmann, Janbazian et al. 2006). T cell exhaustion is a state 
of T cell dysfunction that arises during chronic infection and cancer, defined by poor effector function, 
sustained expression of inhibitory receptors and a transcriptional state distinct from that of effector or 
memory T cells (Wherry, 2011). In addition, most CD8+CD57+ cells exhibit a highly differentiated 
CD45RA+CD28-CCR7- effector memory (TEMRA) phenotype, and TEMRA cells appear to have a long 
lifespan in vivo (Ladell, Hellerstein et al. 2008). Functionally, CD57+ memory CD8+ T cells exert 
protective effects associated with the progressive acquisition of cytolytic activity (Kern, Khatamzas et 
al. 1999; van Leeuwen, Gamadia et al. 2002; Le Priol, Puthier et al. 2006; Takata and Takiguchi 2006; 
Chong, Aicheler et al. 2008; Chattopadhyay, Betts et al. 2009). Furthermore, it has been reported that 
CD57+ CD8high T cells are enriched for Ag-specific cells that exert a regulatory function, in that they are 
capable of down-modulating cytolytic activity (Mollet, Sadat-Sowti et al. 1998). TEMRA cells, which 
incorporate the largest fraction of CD57+ memory CD8+ T cells, have also been associated with 
immune senescence (Nociari, Telford et al. 1999), but again this is controversial because many Ag-
specific cells with anti-viral activity reside within this phenotypic compartment (Appay, van Lier et al. 
2008). Furthermore, a larger proportion and absolute number of human immunodeficiency virus (HIV)-
specific TEMRA cells in early HIV infection has been linked to the control of HIV viremia and subsequent 
viral load set point, which predicts the rate of disease progression (Northfield, Loo et al. 2007). Such 
cells are also more frequently detectable in controlled compared to progressive HIV infection (Addo, 
Draenert et al. 2007). Ex vivo, using non-specific stimuli, CD57+ memory CD8+ T cells proliferate 
poorly, if at all, compared to other memory T cell subsets (Brenchley, Karandikar et al. 2003). 
However, it is not known whether these cells proliferate in vivo; a certain microenvironment or specific 
stimulus such as cognate Ag may be required for such proliferation to occur. 
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1.1.7. Detection of Ag-specific T cells 
Ag-specific cells can be detected after in vitro stimulation with Ag by measuring functional response, 
such as cytokine secretion or production, cytotoxicity and proliferation (Klenerman, Cerundolo et al. 
2002). Ag-specific cells can also be detected physically using soluble recombinant peptide-major 
histocompatibility complex (pMHC) (Garboczi, Hung et al. 1992) multimers (Altman, Moss et al. 1996), 
such as tetramers, pentamers, octamers or dextramers, attached to fluorochromes (Casalegno-
Garduno, Schmitt et al.). This technology is based on the fact that CD4+ T cells recognize peptide Ag 
in the context of MHC/HLA class II and CD8+ T cells recognize peptide Ag in the context of MHC/HLA 
class I. Ags that are presented on APC are fragments of proteins, peptides that are generated by 
proteolysis. These peptides are loaded onto the MHC/HLA and the pMHC/pHLA complex is expressed 
on the cell surface of APCs. MHC class I molecules present degradation products derived from 
intracellular (endogenous) proteins in the cytosol. MHC class II molecules present fragments derived 
from extracellular (exogenous) proteins that are located in an intracellular compartment. The 
specificity of T cells is determined by the clonotypically expressed TCR, which binds cognate pMHC 
primarily via six highly variable complementarity-determining regions (CDRs) (Wooldridge, Lissina et 
al. 2009). The TCR/pMHC interaction is very weak (KD = 0.1 to > 500 µM (Bridgeman, Sewell et al. 
2012), which is why multimeric forms of soluble pMHC molecules are required to visualize T cells that 
bear cognate Ag-specific TCRs. Schematic representations of monomeric and tetrameric pMHC 
complexes are shown in Fig. 3. 
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Figure 3. Schematics of a monomeric and tetrameric pMHC (Klenerman, Cerundolo et al. 2002).  
 
1.2. TCR tg mice 
TCR tg mice bear genes for TCRs of defined specificity (Scott, Bluthmann et al. 1989). They have 
been used to study T cell development, mechanisms of T cell tolerance and to establish basic 
principles of T cell biology (von Boehmer, Teh et al. 1989; von Boehmer and Kisielow 1990; Robey, 
Fowlkes et al. 1991; Teh, Garvin et al. 1991; Wells, Gahm et al. 1991; Miller 1992; Hogquist, Baldwin 
et al. 2005; Shen, Ding et al. 2005). Such mice have been extensively used to study central and 
peripheral T cell tolerance. In 1994, it was found that after in vivo peptide stimulation, TCR tg T cells 
respond differently in vitro to peptide stimulation compared to T cells from normal mice. This 
observation lead to the proposal that high Ag-specific precursor frequencies were non-physiological 
and that it would be better to transfer smaller numbers of TCR tg T cells into syngeneic (closely 
related, immunologically compatible) recipient or “host” mice (Kearney, Pape et al. 1994).  As shown 
in Fig. 4B, T cells from non-immunized TCR tg mice proliferated vigorously in response to the cognate 
ovalbumin (OVA) 323–339 peptide in vitro, in contrast to T cells from non-immunized BALB/c mice 
(Fig. 4A). Kearney et al. also reported that draining lymph node T cells from “intact” TCR tg mice 
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showed no evidence of enhanced responsiveness following subcutaneous (s.c.) injection of ovalbumin 
323–339 in complete Freund’s adjuvant (CFA) and it was stated that they were tolerized much less 
efficiently compared to the corresponding T cells from normal mice when injected intraperitoneally 
(i.p.) with ovalbumin 323–339 in incomplete Freund’s adjuvant (IFA) followed one week later by s.c. 
injection with ovalbumin 323–339 in CFA (compare Figures 4A and 4B). 
 
Figure 4. TCR tg mice respond differently to peptide injection compared to normal mice. 
Intraperetoneal injection of peptide in IFA induces T cell tolerance. Normal BALB/c mice (A) or TCR tg 
mice (B) were not injected (open squares); were injected s.c. with ovalbumin peptide in CFA (125 pg 
in [A], 200 ng in [B]) (closed circles); or were injected i.p. with ovalbumin peptide in IFA (300 ng), and 
then eight days later with ovalbumin peptide s.c. in CFA (125 ng in [A], 200 ng in [B]) (closed triangles: 
dashed lines). Seven days after the s.c. injection, brachial, axillary, and inguinal lymph node cells (4 x 
105 in [A] and 5 x 104 in [B]) were cultured with irradiated (3,000 rads) BALB/c splenocytes and the 
indicated peptide concentrations for 4 (A) or 3 (B) days. T cell proliferative responses were measured 
by [3H]thymidine incorporation. Results represent the mean cpm values + standard deviation (SD) of 
duplicate or triplicate determinations derived from single experiments. Similar results were obtained in 
at least two other independent experiments performed using normal BALB/c mice. [3H]thymidine 
incorporation in the absence of ovalbumin 323–339 was generally less than 2,000 cpm and never 
greater than 6,000 cpm. (Kearney, Pape et al. 1994) This figure is of low resolution as only the pdf of 
this publication was available and it was taken from this pdf. 
 
However, Martin and Bevan (Martin and Bevan 1997) have shown that adoptive transfer of small 
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numbers of mature TCR tg T cells into non-transgenic recipient mice followed by injection with 
cognate antigen led to the death of endogenous thymocytes that were not specific for that Ag. 
Therefore, many investigators have favoured the use of TCR tg mice that co-express the cognate Ag 
as an endogenous self-Ag for the modelling of negative selection of thymocytes by clonal deletion 
(Hogquist, Baldwin et al. 2005). The H-Y model is a classic example (Kisielow, Bluthmann et al. 1988). 
In this model, the TCR transgenic cells express a TCR that is specific for the male Ag H-Y. In female 
mice, these cells are positively selected in the thymus, whereas they are deleted in male mice. One 
major caveat to the use of TCR transgenic mice for the study of thymic selection is that deletion of 
TCR transgenic cells occurs early, at the double negative to double positive stage, in some TCR 
transgenic mouse strains (cortical deletion) and late, at the single positive stage, in others (medullary 
deletion) (Hogquist, Baldwin et al. 2005). One of the factors that determines when clonal deletion 
occurs is Ag location; late deletion is observed if Ag is present only in the medulla and early deletion is 
observed if Ag is also present or just present in the cortex (Hogquist, Baldwin et al. 2005). However, 
other factors, such as the affinity of the TCR for its cognate ligand (Sant'Angelo and Janeway 2002), 
also influence the timing of deletion. Thus, even when Ag is broadly expressed throughout the thymus, 
deletion happens early in some TCR transgenic mouse strains and late in others (Hogquist, Baldwin et 
al. 2005). Recently, a more physiological mouse model was developed to test whether early deletion 
occurs in normal mice. In this model, deletion was clearly induced late, at the single positive stage 
(Baldwin, Sandau et al. 2005). Doubts were raised, however, due to the fact that the temporal 
separation of TCRA and TCRB (α-chain and β-chain encoding genes, respectively) rearrangement 
dictates that Ag receptors are not formed until the double positive stage of thymocyte development 
(Hogquist, Baldwin et al. 2005). Data from other studies, including a landmark paper from the Kappler 
& Marrack group, also indicate that early deletion is a non-physiological aspect of TCR transgenic 
mice (Kappler, Roehm et al. 1987; Surh and Sprent 1994; Cho, Edmondson et al. 2003; Zhan, Purton 
et al. 2003). Recently, various TCR transgenic mouse strains have also been used to study 
mechanisms of peripheral T cell tolerance, including regulation by TREG cells (Apostolou and von 
Boehmer 2004; Shen, Ding et al. 2005; Killebrew, Perdue et al. 2011).  
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1.3. Specific Aims 
In this thesis, antigen-specific T cell responses were investigated under conditions of chronic antigenic 
stimulation to inform our understanding of this process. 
 
• To examine the in vivo turnover (rates of proliferation and cell death) of antigen-specific and 
phenotypically defined T cell populations during chronic antigenic stimulation in TCR tg mice 
stimulated continuously with antigen in the presence or absence of adjuvant. 
 
• To examine the in vivo turnover of phenotypically defined CD8+ T cell populations in HIV-
infected humans. 
 
• To examine memory CD8+ T cell expansions in MCMV infected mice and patients with 
dasatinib induced large granular lymphocyte (LGL) expansions.  
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CHAPTER  
2 
Materials & Methods 
2.1 Mice & ethics. Data shown in chapter 3 were from male and female OVA TCR tg mice (DO11.10) 
(Murphy, Heimberger et al. 1990), 6-12 weeks of age at the beginning of each experiment, purchased 
from The Jackson Laboratory (Bar Harbor, ME, USA) and held in the mouse facility at the University of 
California San Francisco (UCSF). Because these mice were not bred on a RAG-/- background, they 
have a variable fraction (2% - 32%) of non-OVA-specific CD4+ T cells dependent on age and location, 
with lower fractions in younger mice than in older mice and lower fractions in peripheral lymph nodes 
(5% - 10% of CD4+ T cells) than in the spleen (7% - 15% of CD4+ T cells). Experiments with these 
mice were conducted in San Francisco, California, USA. Most of the data shown are from a large 
experiment carried out during a collaborative visit to San Francisco in 2010. All procedures involving 
these mice were approved by the University of California at San Francisco (UCSF) Institutional Animal 
Care and Use Committee. 
For data shown in chapter 5, IL-10-/- mice were purchased from Jackson Laboratory and bred at 
Cardiff University School of Medicine, Cardiff, UK; wild-type C57BL/6 mice were purchased from 
Harlan UK. All experiments were conducted according to UK Home Office guidelines. Specifically, 
these experiments were performed under a Home Office project license granted to Ian Humphreys 
(these experiments were done in collaboration with him and his laboratory) in the Home Office-
designated facility at Heath Park, Cardiff University. 
 
2.2 Procedures carried out on mice, infections of mice and treatments. DO11.10 TCR tg mice were 
studied longitudinally for up to 7 weeks. Blood was acquired at varying time points by phlebotomy of 
the saphenous vein. Surgery was performed under general anesthesia, using ketamine/xylazine 
(Wyeth, Madison, NJ, USA and Lloyd Labs Inc., Iowa, USA). Mice were given buprenorphine (Reckitt 
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& Colman Pharmaceuticals Inc. Richmond, VA, USA) for pain relief after surgery. Alzet® mini-osmotic 
pumps (Durect Corporation, Cupertino, CA, USA) containing either the cognate OVA323-339 peptide 
(ISQAVHAAHAEINEAGR, Biopeptide, CA, USA; OVAp) in phosphate buffered saline (PBS; Life 
Technologies, Carlsbad, CA, USA) or OVAp together with murine recombinant IL-1β (PeproTech Inc., 
NJ, USA) in PBS or sterile PBS alone (referred to below as “unstimulated DO11.10 mice”) were 
placed s.c. between the scapulae of DO11.10 mice. Both 14-day (Model 1002) and 28-day (Model 
2004) pumps were used, each releasing 0.2-0.25 µl/hour of PBS or a solution containing 0.25 - 1.25 
µg/µl OVAp in PBS (for all data shown, the concentration of OVAp was 1.25 µg/µl and the total 
amount of peptide released per day was 6.6-7 µg) or 1.25 µg/µl OVAp in PBS together with IL-1β (10 
µg of IL-1β / pump model 1002 and 20 µg of IL-1β / pump model 2004; both pump models released 
approx. 0.6 µg IL-1β / day). Pumps were equilibrated in sterile PBS according to the manufacturer’s 
instructions for up to 48 hours (the duration of equilibration depended on the pump model) prior to 
implantation. For cross-sectional analyses of lymphoid tissue, mice were sacrificed by CO2 
asphyxiation followed by cervical dislocation. Thymus (THY), spleen (SPL), and inguinal, brachial and 
axillary lymph nodes (LNs) were harvested and passed through mesh filters in sterile PBS with 2% 
fetal bovine serum (FBS) to obtain a single cell suspension. The absolute number of cells per organ 
was determined using a Coulter Counter (Beckman Coulter, Fullerton, CA, USA). 
MCMV Smith strain (American Type Culture Collection, ATCC) was prepared in BALB/c salivary 
glands and titered on 3T3 cells as described previously (Banks, Rickert et al. 2005). Mice were 
infected i.p. with 5 x 104 PFU MCMV. In some experiments, wild-type mice were injected on the days 
stated in the figure legends with 250 µg of either rat IgG (Chemicon International, Temecula, Ca, USA) 
or αIL-10Rα (clone 1B1.3A, BioXCell, West Lebanon, NH, USA). 
 
2.3 Human subjects. Subjects from whom data in chapter 4 were generated were recruited by 
advertisement. Written informed consent was obtained from all subjects. Ethical approval was either 
obtained by the University of California at San Francisco Committee on Human Research, San 
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Francisco, USA or at St. George’s Hospital in London, UK. 2H2O enrichment data referred to in this 
thesis are from one HIV-negative and four antiretroviral-untreated HIV-infected subjects. 2H-glucose 
enrichment data shown in this thesis are from two healthy subjects. Some characteristics of the study 
subjects are shown in Table 2. Except for one subject, all of the labelled HIV-infected subjects were 
naïve to antiretroviral treatment. Additional immunophenotyping was carried out on these subjects. 
Subjects were excluded if, at any time within the three month period before enrolment, they had either 
used a medication (such as glucocorticoids or other immunosuppressive drugs) or been diagnosed 
with a disease (such as lymphoproliferative diseases or cancer) that might affect T cell turnover. All 
the labelled subjects came in for a screening visit, at which time they had to fill out a questionnaire and 
blood was drawn to determine their eligibility to participate in the study. Changes in the relative 
proportion of CD8+ T cell subpopulations were discerned by obtaining a complete blood count and a T 
cell phenotyping flow cytometric panel at each sort date. Both CD8+ T cell counts and the relative 
composition of CD8+ T cell subpopulations were found to be stable for individual subjects during the 
time period of study. 
For the data shown in chapter 6, frozen peripheral blood mononuclear cells (PBMCs), bone marrow 
mononuclear cells (BMMCs), and plasma from CML or Ph+ ALL patients on dasatinib therapy were 
analyzed, together with PBMC and plasma samples from healthy controls (Table 3 in chapter 6) 
(Mustjoki, Ekblom et al. 2009; Kreutzman, Juvonen et al. 2010). Measurements of plasma CMV DNA 
viral load were performed on the basis of clinical indications using a quantitative polymerase chain 
reaction (qPCR) assay with a detection limit of 250 copies/ml plasma. Dasatinib patients were grouped 
according to the presence or absence of LGL expansions, defined as an increased absolute 
lymphocyte count >3.6x109/l with morphological characteristics of LGLs. Written informed consent was 
obtained from all patients and healthy controls. The study was conducted in accordance with the 
principles of the Helsinki declaration and was approved by the Helsinki University Central Hospital 
Ethics Committee. 
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2.4 Assessment of in vivo T cell turnover. To measure the proliferation and death rates of OVAp-
stimulated T cells in vivo (data shown in chapter 3), OVAp was administered s.c. with or without IL-1β 
to DO11.10 TCR tg mice. Control mice received PBS. All DO11.10 mice received a loading dose of 
2H2O (Cambridge Isotope Laboratories Inc., Andover, MA, USA) i.p. to reach 5% body water 
enrichment (the amount injected was calculated for each individual mouse using the body weight and 
assuming that body water is 70% of body weight) immediately after pump implantation followed by 8% 
2H2O orally (ad libitum; to reach 5% body water enrichment) for a total of 3 days. At days 3, 6, 12 and 
20 after pump implantation, three mice per group from each of the three groups were sacrificed. 
Lymph nodes and spleens were collected and single cell suspensions were prepared. Cells were then 
counted and stained with fluorescently-labelled antibodies (please see section entitled “Flow cytometry 
and intracellular cytokine staining” below). Naive (TN: CD62Lhigh CD44low) and memory (TM: 
CD62LlowCD44high) OVA-specific CD4+ T cells were sort-purified so that 2H-labelling in DNA could then 
be measured by mass spectrometry. 
In an independent experiment, s.c. OVAp-stimulated or unstimulated (PBS) DO11.10 mice received a 
special mouse diet (PMI Nutrition International LLC, St Louis, MO, USA) containing 20% [6,6-
2H2]glucose (Cambridge Isotope Laboratories Inc., Andover, MA, USA) for the 3 days immediately 
following pump implantation. Mice in the OVAp-stimulated and -unstimulated groups consumed similar 
amounts of the diet and had similar body weights (range 16.5 – 19.6 grams, Table 1). The 3-day 
administration protocol of [6,6-2H2]glucose was designed to pulse-label C-H bonds in the deoxyribose 
moiety of replicating DNA in dividing cells, as described previously (Macallan, Fullerton et al. 1998) 
and shown schematically in the Introduction (Fig. 2). Blood glucose enrichments fall rapidly after 
dietary [6,6-2H2]glucose label is removed (data not shown) and re-utilization of labelled 2H-deoxyribose 
for new DNA synthesis in purine deoxyribonucleotides is minimal (Macallan, Fullerton et al. 1998; 
McCune, Hanley et al. 2000). Accordingly, this labelling protocol results in a pulse-chase incorporation 
of label into replicating DNA in vivo and allows accurate measurement of the lifespan of labelled cells. 
At days 3, 7, 12, 15, and 20 after pump implantation, three mice per group from each of the three 
groups were sacrificed. Naïve (TN: CD62Lhigh CD44low) and memory (TM: CD62LlowCD44high) OVA-
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specific CD4+ T cells from spleens and individually pooled peripheral lymph nodes were sort-purified 
so that 2H-labelling in DNA could then be measured by mass spectrometry. 
 
2.5 Labelling protocol for human subjects. All subjects enrolled for labelling (data shown in chapter 4) 
were seen either at the Clinical and Translational Science Institute Clinical Research Center (CCRC) 
at San Francisco General Hospital, San Francisco, California, USA, or at St. George’s Hospital, 
London, UK. After enrolment, subjects were provided with a sufficient number of 50 ml vials of 70% 
2H2O (Cambridge Isotope Laboratories Inc., Andover, MA, USA) for a seven-week labelling protocol. 
Subjects drank three 50 ml vials of 70% 2H2O per day for the first week of labelling followed by two 50 
ml vials of 70% 2H2O per day for the next six weeks. The first blood draw for cell sorting was obtained 
during the last week of 2H2O labelling and further blood draws were obtained at week 10 after the start 
of labelling, week 14 and week 18. Short-term 2H-glucose labelling was carried out at St. George’s 
Hospital, London, UK. B cells were positively selected by magnetic cell sorting in London and the 
leftover CD19-negative fraction was frozen and stored in 90% PBS containing 10% dimethyl sulfoxide 
(DMSO) before being shipped to Cardiff for sorting of CD57+ and CD57-negative memory phenotype 
CD8+ T cells by flow cytometry. Blood samples for sorting were collected on days 4, 10, and 21 after 
deuterated glucose labelling.  
 
2.6 Flow cytometry and intracellular cytokine staining. For data shown in chapter 3, cells from 
heparinized blood, lymph nodes, spleen, and thymus were stained for fluorescence activated cell 
sorting (FACS) analyses using combinations of the following antibodies: αCD4-Alexa700 (clone L3T4), 
αCD4-allophycocyanin-Cy7 (clone L3T4), αCD25-PE (IL-2R alpha chain, p55; clone 7D4), αCD25-
allophycocyanin-Cy7 (IL-2R alpha chain, p55; clone PC61), αCD38-PE (clone 90), αAnnexin V-FITC, 
αKi67-FITC (clone B56), and mouse BD FcBlockTM (purified rat-anti-mouse CD16/CD32) (all of the 
above from BD Pharmingen, San Jose, CA, USA), αCD8-Pacific Blue (clone 5H10) and α-mouse 
DO11.10 TCR-allophycocyanin (clone KJ1-26) (both from Caltag Laboratories, Burlingame, CA, USA), 
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αFoxP3-PE (clone FJK-16s), αCD62L-PE-Cy7 (clone MEL-14) and αCD44-PE-Cy5.5 (clone IM7) (all 
of the above from eBioscience, San Diego, CA, USA). The Live/DEAD® fixable Aqua Dead Cell Stain 
Kit for 405 nm excitation (Life Technologies) was used in conjunction with Annexin V to discriminate 
between live, apoptotic, and dead cells, and also in multi-colour flow cytometric panels for exclusion of 
dead cells. TruCount tubes (BD Biosciences, San Jose, CA, USA) were used with slight modifications 
to the manufacturer’s instructions to measure absolute peripheral blood T cell numbers. The 
modifications were necessary as more antibody conjugates than described in the manufacturer’s 
instructions were used for staining the whole blood in TruCount tubes. Cells for sorting were not fixed. 
Otherwise, cells were fixed after staining with either BD Lysing solution for TruCount analysis or with 
PBS containing 2% FBS and 1% paraformaldehyde after either surface staining alone or surface and 
intracellular staining. For intracellular staining, cells were permeabilized with BDTM Phosflow 
Perm/Wash buffer 1 (BD Biosciences), a buffer containing saponin that does not fix the cells. Using 
this buffer, the incubation time for the intracellular FoxP3 staining could be reduced to 1 hour instead 
of overnight. Events for data shown in chapter 3 were analyzed and/or sort-purified using a BD FACS 
LSR II, a Digital Vantage, or a custom-built BD FACSAria (BD Biosciences). Data were analyzed with 
FlowJo software (Tree Star Inc., Ashland, OR, USA). 
For data shown in chapter 4, fresh human PBMCs (on average, 1 x 108 and 1.7 x 108 PBMCs from 80 
ml of blood from HIV-negative and HIV-infected subjects, respectively) were obtained by density 
gradient centrifugation using Ficoll-Hypaque (Sigma-Aldrich, St. Louis, MO, USA). The frozen CD19-
negative cells (the leftover fraction after magnetic bead positive selection of CD19+ cells) from London 
were defrosted in Cardiff prior to staining. Cells were stained with the following antibodies purchased 
from BD Pharmingen (BD Pharmingen, San Jose, CA, USA): αCD3-Alexa700 or αCD3-
allophycocyanin-Cy7, αCD8-Pacific Blue or αCD8-PE-Cy7, αCCR7-PE-Cy7, αCD28-allophycocyanin, 
αIL-7 receptor(R)-PE, and αCD57-FITC. Additional antibodies used for staining were αCD45RA-ECD 
or αCD45RO-ECD and αCD27-PE-Cy5 (Beckman Coulter), and αIL-18R1-FITC (Serotec Inc., 
Raleigh, NC, USA). Live/DEAD® fixable aqua or Live/DEAD® fixable violet (Amine-reactive dye) (Life 
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Technologies) were used for the exclusion of dead cells. As many cells as possible from the relevant 
CD3+CD8+ T cell subpopulations, comprising at least one sample of 20,000 cells from each 
subpopulation and duplicates to quadruplicates of 10,000-100,000 cells, if feasible, were sorted after 
2H-glucose labelling. The minimum number of cells was 48,862 and the maximum cell number was 
458,376; higher numbers could be sorted from the CD57-negative subset. Cells were sorted on a 
triple-laser BD FACS Digital Vantage or a customized quadruple-laser BD FACSAria or FACSAria II 
(all from BD Biosciences), based on the presence or absence of CD45RA or CD45RO, CCR7, CD28, 
and/or CD57 expression or based on expression or lack of expression of CD57 on memory phenotype 
T cells. Gates for the T cell subpopulations were set based on fluorescence minus one (FMO) 
controls. 
To evaluate MCMV-specific CD8+ T cell responses (chapter 5), splenocytes and lung leukocytes were 
isolated from infected mice and incubated at 5 x 106 cells/ml for 5 hours at 37 °C with 2 µg/ml MCMV-
derived peptides (GenScript, Piscataway, NJ, USA) in the presence of either 0.7 µg/ml monensin and 
αCD107a-FITC (both BD Pharmingen; IFN-γ and CD107a detection) or 2 µg/ml brefeldin A (Sigma-
Aldrich; IFN-γ, tumour necrosis factor (TNF), and IL-2 detection). The optimal length peptides used in 
this study were as follows: 1) SSPPMFRVP (origin, M38; restriction, H-2Kb); 2) HGIRNASFI (origin, 
M45; restriction, H-2Db); 3) TVYGFCLL (origin, m139; restriction, H-2Kb); and 4) RALEYKNL (origin, 
immediate-early 3 [IE3]; restriction, H-2Kb) (Munks, Cho et al. 2006). Cells were then washed and 
incubated with Fc block (eBioscience). After incubation with peptide or medium alone as a control, 
cells were surface stained with αCD8a-allophycocyanin-H7 (BD Pharmingen). All cells were then fixed 
with 3% formalin, permeabilized with saponin buffer (PBS, 2% FCS, 0.05% sodium azide, and 0.5% 
saponin), and stained with the relevant combinations of αTNF-PE-Cy7, αIL-2-Pacific blue, and αIFN-γ-
FITC (all eBioscience). To calculate percentage of virus-specific effector function, spontaneous 
degranulation or cytokine production in medium controls were subtracted from peptide-induced 
mobilization or expression, respectively. 
To identify MCMV-specific CD4+ T cells, splenocytes and lung leukocytes were incubated for 5–16 
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hours at 37 ºC with 2 µg/ml brefeldin A (Sigma-Aldrich) and 3 mg/ml MCMV-derived peptides 
(Genscript) restricted by MHC class II as follows: 1) GYLYIYPSAGNSFDL (origin, m09); 2) 
NHLYETPISATAMVI (origin, M25); 3) TRPYRYPRVCDASLS (origin, m139); and 4) 
RSRYLTAAAVTAVLQ (origin, m142) (Arens, Wang et al. 2008). To identify IL-10 expression by B 
cells and macrophages, splenocytes were stimulated for 5 hours at 37 ºC with either 10 mg/ml 
lipopolysaccharide (LPS; macrophages) or 10 mg/ml LPS, 50 ng/ml phorbol 12-myristate 13-acetate 
(PMA), and 500 ng/ml ionomycin (B cells; all reagents from Sigma-Aldrich). Cells were then incubated 
with Fc block and surface stained with either αCD4-Pacific Blue (BD Pharmingen), αCD19-FITC or 
αCD11b-PE-Cy7 prior to permeabilization and intracellular staining with αIFN-g-FITC (CD4 analysis 
only) and αIL-10-allophycocyanin (all eBioscience). The percent virus-specific cytokine production by 
CD4+ T cells was calculated as described for CD8+ T cells. 
To assess APC accumulation, unstimulated splenocytes and lung leukocytes were incubated with Fc 
block and then stained with αCD11b-allophycocyanin-Cy7 (BD Pharmingen), αCD11c-PE-Cy7 (BD 
Pharmingen), αMHC class II-PE-Cy5 (eBioscience), αF4/80-Pacific Blue (BioLegend, San Diego, CA), 
αGr1-FITC (BioLegend), and α7/4-PE (Serotec, Oxford, UK). 
To examine the expression of surface molecules by MCMV-specific CD8+ T cells, 1 x 106 splenocytes 
were incubated with Live/Dead Fixable Aqua (Life Technologies), followed by Fc block, then stained 
with H-2Kb tetramers loaded with M38, m139, or IE3 peptides. Cells were then stained with αCD3-
PerCP-Cy5.5 (BD Pharmingen), αCD8-allophycocyanin-H7 (BD Pharmingen), and either αCD44-FITC 
(BioLegend), αCD62L-PE-Cy7 (Abcam plc, Cambridge, UK), and αCD122-PE (eBioscience) or α-killer 
cell lectin-like receptor subfamily G member 1 (KLRG-1)-FITC (Southern Biotechnology Associates, 
Birmingham, AL, USA), αCD27-PE (eBioscience), and αCD127- Pacific Blue (eBioscience). 
Data shown in chapter 5 were acquired on either a BD FACSCanto II or a 4-laser modified BD 
FACSAria II cell sorter equipped for the detection of 18 fluorescent parameters (BD Immunocytometry 
Systems, San Jose, CA). Electronic compensation was performed in all cases using Ab capture beads 
stained separately with the individual monoclonal antibodies (mAbs) used in each experimental panel. 
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A minimum of 30,000 events was acquired in each case, and data were analyzed using FlowJo 
software (Tree Star Inc.). 
For the data shown in chapter 5, total numbers of different cell populations were calculated by 
multiplying the total number of viable splenic or pulmonary leukocytes (assessed by trypan blue 
exclusion) by percent positive cells, as detected by flow cytometry. Total numbers of virus-specific T 
cells were calculated by: total T cell number (CD4+ or CD8+) x percent peptide-specific IFN-g+ cells 
(calculated as described above). Total numbers of virus-specific TNF+ or CD107a+ T cells were 
calculated similarly. 
Live/Dead Fixable Aqua or Violet dyes (Life Technologies) were used to exclude dead cells from the 
analysis of the samples described in chapter 6; αCD14 and αCD19 mAbs (Life Technologies), both 
conjugated to Pacific Blue, were used to exclude monocytes and B cells, respectively. The following 
mAbs were used for polychromatic phenotypic analyses: αCD3-allophycocyanin-H7 (BD Biosciences), 
αCD4-Cy5.5PE (Life Technologies), αCD8-Cy7PE and αCD57-FITC (BD Pharmingen), αCD8-QDot 
705 (Life Technologies), αCD27-Cy5PE, αCD45RO-ECD, αCD69-allophycocyanin, αCD127-PE 
(Beckman Coulter), and biotinylated αPD-1 (R&D Systems). For visualization of PD-1+ events, a 
secondary stain was performed with streptavidin-Pacific Blue (Life Technologies). In some 
experiments, Annexin V-FITC (BD Pharmingen) was used for the identification of apoptotic cells 
directly ex vivo; in other experiments, αCD16-PE (BD) and αCD56-allophycocyanin (Miltenyi Biotec, 
Bergisch Gladbach, Germany) were used. Stained samples for polychromatic analyses were acquired 
and recorded using a customized BD FACSAria II flow cytometer (BD Biosciences) equipped for the 
simultaneous detection of 18 fluorescent parameters; data were analyzed using FlowJo software (Tree 
Star Inc.). For experiments limited to a maximum of 4 fluorescent parameters, samples were acquired 
and recorded using a BD FACSCalibur flow cytometer (BD Biosciences); data were analyzed using 
CellQuest software (BD). All cell sorts for data shown in chapter 6 were conducted to a purity of >98% 
using the BD FACSAria II flow cytometer mentioned above. 
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2.7 Peptide/HLA-A*0201 tetrameric complexes. Fluorochrome-labelled tetrameric peptide/HLA-A*0201 
(pHLA-A*0201) complexes were produced and used as described elsewhere (Price, Brenchley et al. 
2005). ExtrAvidin-R-PE (Sigma-Aldrich), streptavidin-allophycocyanin (Prozyme, Hayward, CA, USA) 
or streptavidin-QDot 705 (Life Technologies) were used for tetramerization. 
 
2.8 Measurement and analysis of 2H enrichment in T cell DNA. The stable isotope/FACS/mass 
spectrometric method for measuring T cell proliferation has been described in detail elsewhere 
(Hellerstein 1999; McCune, Hanley et al. 2000; Neese, Siler et al. 2001). Additional precautions and 
controls required for working with low cell count samples are outlined in Busch et al. (Busch, Neese et 
al. 2007). DNA from subsets of cells sorted in the context of the study described in chapter 3 was 
extracted using the QiaAmp Micro DNA extraction kit (Qiagen, Valencia, CA, USA) and was 
hydrolyzed as described (Hellerstein 1999; McCune, Hanley et al. 2000; Neese, Siler et al. 2001; 
Busch, Neese et al. 2007). For the data shown in chapter 4, instead of using a DNA extraction kit, 
sorted cell pellets were resuspended in 200 ml PBS, boiled for 10 min to release DNA from chromatin, 
and rapidly chilled. For DNA hydrolysis, 50 ml 5x concentrated hydrolysis cocktail was added, 
containing sodium acetate buffer, pH 5, zinc sulfate, nuclease S1, and acid phosphatase (Busch, 
Cesar et al. 2004), and the mixture was incubated at 37 °C for 1-16 hours. Samples were transferred 
to screw-capped glass hydrolysis tubes. Aqueous O-(2,3,4,5,6-pentafluorobenzyl)-hydroxylamine 
hydrochloride (PFBHA) solution (1 mg/ml, 100 µl) was added, followed by 75 µl glacial acetic acid, and 
the mixtures incubated at 100ºC for 30 min. After cooling to room temperature, 1 ml of acetic 
anhydride was added to each sample, followed by 100 µl of N-methylimidazole with rapid mixing. The 
reaction was allowed to proceed for 15-20 min. After cooling, 2 ml water were added, and the 
reactions were extracted twice with 750 µl dichloromethane. The organic layers were pooled, dried 
over sodium sulphate, evaporated to dryness, reconstituted in 50 ml ethyl acetate, and transferred to 
gas chromatography (GC) vials for analysis. In addition to controls employed routinely in the stable 
isotope/FACS/mass spectometry (MS) method (Hellerstein 1999; McCune, Hanley et al. 2000; Neese, 
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Misell et al. 2002), additional sets of blanks and standards were included in each run. DNA standards 
were approximately matched to the range of cell counts in the experimental samples, assuming about 
6 pg DNA per human diploid nucleus. Labelled cell samples and DNA standards of known 2H 
enrichment were diluted and run with each preparation to verify the stability of measured enrichments 
at low sample abundance, and reagent blanks were used to assess contamination by extraneous 
deoxyribose or DNA. Before analyzing samples with low cell counts, the entire procedure was 
checked several times, using only DNA standards, blanks, and titrated amounts of cells from an 
abundant source with known 2H enrichment.  
GC/MS analysis was performed using an Agilent (Palo Alto, California, USA) model 5973 MS with a 
6890 GC and an autosampler in negative chemical ionization mode with methane as reagent gas. 
Samples were resolved on a 30-m DB-17 column or a DB-225 column (J&W Scientific, Agilent, Foster 
City, CA, USA) with helium as the carrier gas, and selected ion monitoring was used to quantify the 
fractional molar abundances of the parent ion [M – HF, = M0] (m/z 435) and the M1 mass isotopomer 
(m/z 436) of the pentafluoro tri-acetate (PFTA) derivative of dR. 2H enrichment was calculated as 
EM1, the excess fractional abundance of the M1 mass isotopomer above baseline (as determined by 
analysis of the unlabelled deoxyribose derivative, with correction for analyte abundance effects) 
(McCune, Hanley et al. 2000). The EM1 value represents isotope enrichment from 2H above natural 
abundance and is analogous to specific activity values with radioisotopes (Hellerstein 1999; Hellerstein 
and Neese 1999). Data were rejected if the signal to background ratio fell below 10, or if the M0 
abundance fell below the abundance range that generated reliable EM1 values with the diluted, 
labelled standards. 2H2O enrichments in body water were calculated as described previously 
(McCune, Hanley et al. 2000; Hellerstein, Hoh et al. 2003) by comparison to standard curves 
generated by mixing 100% 2H2O with natural abundance H2O in known proportions. 
 
2.9 Calculations of the fraction of labelled cells and the number of labelled cells per organ. For the 
data shown in chapter 3, the fraction (f) of labelled cells present in each organ was measured as 
 48 
described above. The absolute number of labelled cells per organ for every time point was calculated 
by multiplying the fraction of labelled cells by the total number of cells of that particular phenotype 
present in the organ as determined by counting all cells from the respective organ with a Coulter 
counter and determining the frequency of the respective T cell subset by flow cytometry. 
 
2.10 TCR clonotyping. Clonotypic analysis of murine (chapter 5) or human (chapter 6) Ag-specific 
CD8+ T cell populations was conducted as described previously with minor modifications (Douek, 
Betts et al. 2002; Price, West et al. 2004). Briefly, tetramer-labelled murine CD8+ T cells (median, 
3200; range, 808–5,000) or human CD8+ T cells (2,232-5,000 cells) were sorted viably into 1.5-ml 
microtubes (Sarstedt AG & Co., Nümbrecht, Germany) containing 100 ml ribonucleic acid (RNA)later 
(Applied Biosystems, Foster City, CA, USA), mRNA was extracted using a mRNA extraction kit that 
uses the magnetic separation technology developed by Miltenyi (Miltenyi Biotech) and unbiased 
amplification of all expressed TCRB gene products was conducted using a template-switch anchored 
reverse transcriptase (RT)-polymerase chain reaction (PCR) with a 3’ TCRB constant (C) region 
primer for murine cells (5’-TGGCTCAAACAAGGAGACCT-3’) or human cells  (5’-
TGCTTCTGATGGCTCAAACACAGCGACCT-3’). Amplicons were subcloned, sampled, sequenced, 
and analyzed as described previously (Price, Brenchley et al. 2005). The International 
ImMunoGeneTics Information System nomenclature is used throughout this thesis (Lefranc, Pommie 
et al. 2003).  
 
2.11 Viral genome detection. For data shown in chapter 5, genomic DNA was isolated from spleen 
and lung tissue (Qiagen, Valencia, CA), and MCMV glycoprotein B (gB) was then assayed by 
quantitative PCR using a Mini Opticon (Bio-Rad, Hercules, CA) and Platinum SYBR green mastermix 
reagent (Life Technologies). One hundred-nanogram aliquots of DNA were used as templates for 
each reaction. The primer sequences used for detection of β-actin were 5’-
GATGTCACGCACGATTTCC-3’ and 5’-GGGCTATGCTCTCCCTCAC-3’; primers used for detection of 
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gB were 5’- GAAGATCCGCATGTCCTTCAG-3’ and 5’-AATCCGTCCAACATCTTGTCG-3’. Genome 
copy numbers were calculated using a standard curve generated with the pARK25 MCMV plasmid (a 
gift from A. Redwood, University of Western Australia, Perth, Western Australia, Australia) with the 
limit of detection = 10 copies. 
 
2.12 gB and IL-10 gene expression. For data shown in chapter 5, IL-10 and gB were assayed by 
quantitative RT-PCR using a Mini Opticon and Platinum SYBR green mastermix reagent (Invitrogen / 
Life Technologies). For IL-10 expression analysis, lung and spleen cells from mock or MCMV-infected 
mice were frozen on dry ice in TRIzol reagent (Life Technologies). Thawed samples were 
homogenized, and total cellular RNA was extracted and quantified. DNase-treated RNA was then 
used to synthesize copy DNA (cDNA) with a TaqMan reverse transcription kit (Applied Biosystems). 
The primer sequences used for detection of IL-10 were 5’-AGCATGGCCCAGAAATCAAG-3’ and 5’-
CGCATCCTGAGGGTCTTCA-3’. For gB expression analysis, RNA was isolated from lung and spleen 
tissue (Qiagen); cDNA was then synthesized as described above, and gB and actin were measured 
using the primers detailed above. 
 
2.13 Virus reactivation assay. For data shown in chapter 5, virus-infected organs were divided into 
three parts and placed in separate wells in a 6-well plate containing 5 ml (spleen) or 3 ml (lung) D10 
medium. Tissue was gently minced with the end of a 2 ml syringe, and in the case of lung pieces, an 
additional 2 ml D10 was then added. Tissue pieces were then cultured for 5 weeks; 4 ml supernatant 
was collected weekly and replaced with 5 ml fresh D10. Sonicated supernatant was then assayed for 
infectious virus by plaque assay as described previously (Banks, Rickert et al. 2005). 
 
2.14 Reagents used for experiments shown in chapter 6. Dasatinib was synthesized according to the 
published procedure (Lombardo, Lee et al. 2004), dissolved in DMSO and purity tested as described 
previously (Seggewiss, Lore et al. 2005; Weichsel, Dix et al. 2008). All functional assays were 
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conducted in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin 
and 100 µg/ml streptomycin (R10 medium). DMSO as a solvent control for dasatinib was included in 
all functional assays performed ex vivo. Interleukin-2 (IL-2; Proleukin™, Chiron) was applied when 
indicated at 2,000 IU/ml. 
 
2.15 Cytokine and chemokine determination by multiplex. For data shown in chapter 6, plasma from 
patients with CML or Ph+ ALL treated with dasatinib (n=23) and healthy controls (n=10) was analyzed 
for the following soluble factors using a Human Cytokine 25-plex Panel (Life Technologies) according 
to the manufacturer’s instructions: IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-
13, IL-15, IL-17, TNF-α, IFN-α, granulocyte macrophage-colony stimulating factor (GM-CSF), 
macrophage inflammatory protein-1α (MIP-1α/CCL3), MIP-1β (CCL4), IFN-γ-inducible protein-10 (IP-
10/CXCL10), monokine induced by IFN-γ (MIG/CXCL9), eotaxin (CCL11), RANTES (CCL5), monocyte 
chemoattractant protein-1 (MCP-1/CCL2) and IFN-γ. Measurement and analysis were performed using 
the Bio-Plex™ 200 System (BioRad). 
 
2.16 Apoptosis assay. PBMCs (1x106 cells/ml; data shown in chapter 6) were either unstimulated or 
stimulated with 5 µg/ml OKT3 (Orthoclone™, Janssen-Cilag) and antibodies against the costimulatory 
molecules CD28 and CD49d (1µg/ml each; BD Pharmingen) for 4 days after overnight rest in R10 
medium. Cells were then harvested and stained with Annexin V-PE (BD Pharmingen) and 7-amino-
actinomycin D (7AAD; Sigma-Aldrich). Apoptotic cells were defined by flow cytometry as 7AAD-
/Annexin V+; late apoptotic/necrotic cells were defined as 7AAD+/Annexin V+. 
 
2.17 NK cell expansion. For data shown in chapter 6, polyclonal NK cells were generated as 
described previously (Valiante, Rengaraju et al. 1992). In brief, non-adherent PBMCs obtained from 
healthy controls after plastic adherence were co-cultured with the irradiated Epstein-Barr virus (EBV)-
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transformed B cell line RPMI 8866, a kind gift from Dr. Jörg Wischhusen, at a ratio of 4:1 for 8-11 days 
in R10 medium. NK cells were defined as CD3-, CD16+ and/or CD56+; purity was determined by flow 
cytometry using αCD3-PerCP (BioLegend) and αCD16/56-allophycocyanin (both Miltenyi Biotech). 
Experiments were performed when the purity of expanded NK cells exceeded 75%. 
 
2.18 Transfection of target cells. For data shown in chapter 6, K562 cells, a kind gift from Dr. Ulrike 
Kämmerer, were transfected at 300 V with the firefly luciferase (fLuc):zeocin (zeo) mammalian 
expression vector consisting of an engineered fusion between the fLuc and zeo resistance genes 
under the control of the CMV immediate early (IE) promoter (InvivoGen, San Diego, CA, USA) cloned 
into the pcDNA3.1(+) plasmid backbone as described previously (Brown, Wright et al. 2005). The 
vector was a kind gift from Dr. Jörg Wischhusen. K562 fLuc+ cells were cultivated in zeocin-containing 
R10 medium. 
 
2.19 NK cell cytotoxicity assay. For the modified biophotonic luciferase assay (Brown, Wright et al. 
2005) that was used to generate data shown in chapter 6, K562 fLuc+ cells were applied as target 
cells at a concentration of 5x104 cells/ml. Effector NK cell concentration was adjusted to 5x105 
cells/ml, based on the frequency of NK cells (CD3-, CD16+ and/or CD56+). Untransfected K562 cells 
served as the negative control in all assays. NK cells and target cells were incubated at effector:target 
ratios of 10:1, 2.5:1 and 0.6:1. Assays were conducted for 4 hours in the presence of 10 or 50 nM 
dasatinib, as indicated, or DMSO as a solvent control. Each condition was measured in triplicate. 
Target cell lysis was monitored by a decrease in detected luminescence flux, measured in relative light 
units (RLU) using an Orion II Microplate luminometer (Berthold Detection Systems, Pforzheim, 
Germany). 
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2.20 NK cell cytokine production and degranulation assay. For data on NK cell cytokine production 
and NK degranulation shown in chapter 6, PBMCs were pre-treated either with DMSO or with 10 or 
50 nM dasatinib for 1 h. The mAbs αCD107a-FITC and αCD107b-FITC (both BD Pharmingen) were 
then added and NK cells (CD3-, CD16+ and/or CD56+) were stimulated with untreated and 
untransfected K562 cells in the presence of brefeldin A and GolgiStopTM (BD Biosciences). After 6 h, 
the cells were surface-stained with αCD3-PerCP (BioLegend) and αCD16/56-allophycocyanin (both 
Miltenyi Biotech), then fixed/permeabilized using Cytofix/Cytoperm (BD Biosciences) and stained 
intracellularly with αTNF-α-PE and αIFN-γ-PE (BD Pharmingen). Data were acquired using a 4-colour 
BD FACSCalibur flow cytometer (BD Biosciences) and analyzed with CellQuest software (BD 
Biosciences). 
 
2.21 Carboxyfluorescein diacetate succinimidyl ester (CFSE) proliferation assay. For data shown in 
Figures 32 and 33 of chapter 6, PBMCs were suspended in PBS (PBS; 1x106 cells/ml) and labelled 
with the vital dye CFSE (Molecular Probes/Life Technoologies) at a final concentration of 0.25 µM as 
described previously (Seggewiss, Lore et al. 2005; Weichsel, Dix et al. 2008). After overnight rest, 
CFSE-labelled cells were pre-incubated with dasatinib or DMSO as indicated for 1 h, then cultured for 
4 days in the presence of 5 µg/ml OKT3 and αCD28/αCD49d (1 µg/ml each). 
 
2.22 CMV-specific CD8+ T cell proliferation, cytokine production and degranulation assays. For data 
shown in Figures 32 and 33 of chapter 6, PBMCs from HLA-A*02+ and CMV IgG seropositive LGL 
patients, a non-LGL patient and healthy donors were labelled with CFSE and stimulated with the CMV 
pp65495-503 peptide NLVPMVATV, which is restricted by HLA-A*02, at a concentration of 2 µM for 6 
days in the presence of αCD28/αCD49d (1 µg/ml each). The cells were then harvested, stained with 
the CMV pp65495-503/HLA-A*0201-allophycocyanin tetramer and αCD8-PerCP (BD Biosciences), and 
analyzed by flow cytometry as described previously (Seggewiss, Lore et al. 2005; Weichsel, Dix et al. 
2008). Expression of the degranulation markers CD107a/b, together with intracellular cytokine 
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production, in the presence or absence of dasatinib was evaluated in 5 hour assays as described 
above for NK cells. 
 
2.23 Calculations of decay constants and half-lives for CD3+CD8+CD45RA-CCR7- T cells that were 
either CD57+ or CD57- after 7 weeks of 2H2O labeling. As in previous studies (Hellerstein Nat Med 
1999, McCune JCI 2000), 2H2O kinetic calculations were based on the precursor-product relationship. 
In this pulse/chase experiment, the loss of label enrichment in cellular DNA during the de-labeling 
phase was determined for each T cell subset. 2H enrichment in cellular DNA at either sort 0 or sort 1 
(week 7 during labeling or week 10, three weeks after the last dose of 2H2O), representing the 
baseline value (or pulse) before (sort 0) or after wash-out (sort 1) of 2H2O from body water pools, was 
used as the time zero value. The latter time point was chosen because body water 2H2O enrichments 
fall with a half-life of approximately 7 days, allowing the assessment of die-away kinetics without the 
confounding effects of continued label incorporation (Ladell, Hellerstein et al. 2008). Data from sort 0 
were used for calculation, as the biggest difference between the two T cell subsets was observed 
between sort 0 and sort 1. The loss of label from cellular DNA of the two subsets was quantified 
between S0 and S1 as well as S1 and S2 (week 14). The decay constant (k) was calculated using the 
equation for exponential decay: k = -[ln(sort 1/ sort 0)]/Dt or k = -[ln(sort 2/sort 1)]/Dt, where Dt is the 
time between measurements (3 or 4 weeks, respetively). The half-life was calculated as t1/2 = ln(2)/k. 
For these calculations single-pool, single-exponential kinetics of label die-away were assumed. 
 
2.24 Statistical analysis. Statistical analysis was perfomed using GraphPad Prism software 
(GraphPad, La Jolla, CA, USA). For data shown in chapter 3, statistical differences between groups 
were determined using the two-way ANOVA for repeated measures (with Bonferroni post-tests) for 
more than two groups or the two-tailed non-parametric Mann-Whitney U Test or parametric two-tailed 
Student’s t-test for comparison of two groups. For data shown in chapter 4, statistical significance was 
determined using the two sample equal variance two-tailed Student’s t-test and the two-tailed non-
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parametric Mann-Whitney U test. For data shown in chapter 5, statistical significance was determined 
using the paired two-tailed Student’s t-test or the non-parametric Mann-Whitney U test. For data 
shown in chapter 6, statistical significance was determined using the non-parametric Kruskal-Wallis 
test, the paired two-tailed Student’s t-test or one-way analysis of variance (ANOVA). Statistical 
significance was defined as p<0.05.  
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CHAPTER 
3 
Continuous subcutaneous administration of peptide without adjuvant leads to aborted immune 
activation and Ag-specific T cell depletion in DO11.10 TCR transgenic mice 
 
3.1 Introduction 
In several contexts, it would be desirable if T cell tolerance could either be broken or induced. It would 
be beneficial if T cell tolerance could be broken in tumours and it would likewise be beneficial to 
induce tolerance in transplant patients or patients with autoimmune diseases or allergies. It is a 
general concept that co-stimulation is required in addition to the peptide MHC-TCR interaction for 
proper T cell activation to occur (Chambers, Krummel et al. 1996) and that lack of co-stimulation leads 
to either a decreased response or even to the induction of T cell tolerance or anergy (also referred to 
as unresponsiveness to Ag or T cell dysfunction) (Chen 2004). It has also been suggested that the 
route of administration determines whether CD4+ T cell activation or T cell tolerance is induced 
(Kearney, Pape et al. 1994). 
In 1994, it was described that antigenic challenge with soluble cognate peptide given i.v. or i.p. 
resulted in tolerance whereas administration by the s.c. route resulted in immunity (Kearney, Pape et 
al. 1994). However, in this study, soluble cognate peptide Ag was given i.v. without adjuvant or i.p. in 
IFA, whereas s.c. it was given in CFA. Cognate peptide Ag was not given s.c. without adjuvant, 
thereby rendering the study incomplete. Since then, discrepant results have been reported with regard 
to whether s.c. administration of cognate peptide without adjuvant leads to T cell tolerance or 
immunity. In principle, Ag-specific T cell tolerance could occur upon intrathymic deletion or active 
suppression of Ag-specific T cell clones (central tolerance), and/or TCR-mediated signalling in T cells 
in the periphery leading to the induction of CD4+CD25+FoxP3+ TREG cells or Ag-specific induction of 
activation-induced cell death (AICD) or T cell anergy. In the latter instance, antigenic stimulation in the 
absence of “second signals” (for example, as delivered by internally driven inflammatory events or by 
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externally delivered adjuvants) can be preceded by limited initial expansion of Ag-specific cells and 
accompanied by the induction of TREG cells (Read, Mauze et al. 1998; Knoechel, Lohr et al. 2006; 
Chappert, Leboeuf et al. 2008). Of note, in some contexts, in vivo CD4+ T cell tolerance induction 
versus priming is independent of the rate and number of cell divisions (Adler, Huang et al. 2000). 
Furthermore, antigenic stimulation without “second signals” may negatively affect T cell trafficking to 
non-lymphoid tissues, a process that has been proposed to facilitate peripheral tolerance (Marelli-
Berg, Okkenhaug et al. 2007). 
In related experiments addressing these potential mechanisms, others have provided cognate Ag by 
varying routes of administration to CD4+ TCR tg mice or syngeneic host mice that previously received 
TCR tg CD4+ T cells (Kearney, Pape et al. 1994; Liblau, Tisch et al. 1996; Pape, Khoruts et al. 1997; 
Reinhardt, Khoruts et al. 2001). Administration of peptide by the i.p. or i.v. route was found to induce 
central and peripheral tolerance by apoptosis (Murphy, Heimberger et al. 1990), whereas s.c. 
administration of peptide with adjuvant prompted a functional immune response (Kearney, Pape et al. 
1994; Liblau, Tisch et al. 1996). S.c. administration of peptide without adjuvant has recently been 
tested in Balb/c CD4+ TCR-HA (influenza hemagglutinin HA-specific tg TCR) Rag2-/- mice (Apostolou 
and von Boehmer 2004), in DO11.10 CD4+ TCR tg (ovalbumin-specific tg TCR) Rag2-/- mice 
(Dahlberg, Schartner et al. 2007), and in B10.BR CD4+ TCR tg mice (transgenic for the 2B4 TCR that 
recognizes pigeon or moth cytochrome c) not on a Rag-deficient background (Switzer, Wallner et al. 
1998). CD4+ TCR tg mice on a Rag-deficient background characteristically do not have natural CD25+ 
TREG cells, as endogenous TCR α-chain expression is required to drive selection of this population in 
the thymus (Itoh, Takahashi et al. 1999). However, it has been shown that peripheral TREG cells can be 
induced in Rag-deficient CD4+ TCR tg mice by continuous delivery of peptide for 14 days using 
osmotic pumps implanted s.c. or by daily s.c. injections of peptide (Apostolou and von Boehmer 2004; 
Dahlberg, Schartner et al. 2007). In 2B4 TCR tg mice not on a Rag-deficient background, repeated 
s.c. injections of peptide without adjuvant led to a tolerant state of the Ag-specific T cells without 
substantial deletion, but continuous peptide administration for one week using s.c. implanted osmotic 
pumps containing the peptide did not tolerize 2B4 TCR tg CD4+ T cells (Switzer, Wallner et al. 1998). 
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The interpretation of the data published in the studies outlined above is complicated by differences in 
experimental design, the use of different strains of mice, including mice on Rag-sufficient or Rag-
deficient backgrounds, and adoptive T cell transfer into syngeneic (closely related, immunologically 
compatible) host mice.  
A number of questions clearly remain unresolved regarding the tolerogenic effects of s.c. 
administration of peptide Ag without adjuvant. To revisit this subject, experiments were designed to 
further explore the mechanisms by which tolerance might be induced upon s.c. administration of 
peptide Ag in the absence of adjuvant.  
 
3.2 Hypotheses 
• Continuous administration of cognate peptide without adjuvant in CD4+ DO11.10 TCR tg mice 
by s.c. delivery leads to immunological tolerance. 
• Not all memory-phenotype T cell subsets are induced in CD4+ DO11.10 TCR tg mice given 
peptide without adjuvant continuously by s.c. implanted mini-osmotic pump, but are inuduced 
in CD4+ DO11.10 TCR tg that receive cognate peptide with adjuvant. 
• In vivo naïve and memory effector T cell proliferation rates differ in CD4+ DO11.10 TCR tg 
mice that continuously receive cognate peptide without or with adjuvant. 
 
3.3 Specific Aims 
• To determine whether continuous administration of cognate peptide without adjuvant leads to 
immunological tolerance or immunity in CD4+ DO11.10 TCR tg mice. 
• To determine whether memory phenotype T cells are induced in CD4+ DO11.10 TCR tg mice 
that continuously receive cognate Ag without or with adjuvant. 
• To determine whether continuous delivery of cognate Ag without or with adjuvant by s.c. 
administration is associated with thymic deletion, T cell redistribution, the induction of TREG 
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cells, or T cell activation leading to T cell depletion / cell death. 
• To determine whether the in vivo proliferative response of Ag-specific T cells and their subsets 
differs if cognate Ag is given without or with adjuvant. 
 
3.4 Results 
Subcutaneous antigenic stimulation with OVAp and IL-1β leads to distress and immune activation in 
TCR tg mice  
To study the effect of s.c. peptide stimulation without or with adjuvant, mini-osmotic pumps containing 
either sterile PBS, OVA323-339 peptide in sterile PBS (OVAp; 6.6 µg peptide released per day), or OVAp 
together with IL-1β (6.6 µg OVAp and 0.6 µg of IL-1β released per day) as adjuvant were implanted 
s.c. between the scapula of OVA DO11.10 TCR tg mice. OVA DO11.10 TCR tg mice were used 
instead of a TCR tg T cell adoptive transfer approach to ensure that sufficient numbers of T cell 
subsets could be sorted for assessment of label enrichment after in vivo stable isotope labelling. IL-1β 
was chosen as adjuvant because it induces robust and durable primary and secondary CD4+ T cell 
responses (Ben-Sasson, Hu-Li et al. 2009), because it is a dominant and proximal mediator of the 
effects of classical adjuvants such as LPS (Lachman, Page et al. 1980), and because it is more 
acceptable to administer to mice on a continuous basis.  
Within 24 hours after pump implantation, mice that received OVAp and IL-1β had scruffy fur and 
weight loss whereas those administered OVAp alone or PBS looked normal. Over the next 12 days, 
weight loss persisted in those receiving OVAp and IL-1β (Table 1). At that time, the pumps were 
discontinued (with evidence of proximal s.c. inflammation in the case of those delivering IL-1β) and the 
weight and condition of the mice improved over the next eight days.  
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Table 1. Weights of the mice in grams (medians and ranges are shown). 
Group / 
Day 
PBS OVAp OVAp and IL-1β 
0 18.0 (17.0 – 19.6) 18.8 (16.5 – 19.6) 18.0 (16.6 – 19.6) 
1 19.1 (17.3 – 20.5) 19.7 (16.9 – 21.4) 17.2 (15.8 – 19.3)* ** 
3 19.5 (18.1 – 20.6) 18.5 (18.3 – 20.4) 17.1 (15.8 – 18.0) 
6 20.0 (19.5 – 20.3) 20.0 (19.6 – 20.2) 17.5 (15.8 – 18.7)* 
12 19.6 (18.8 – 20.1) 20.4 (20.1 – 21.6) 17.8 (16.2 – 18.9)* 
20 22.7 (19.8 – 22.8) 23.8 (20.5 – 23.8) 22.4 (19.9 – 22.5) 
* p < 0.05 parametric Student’s t-test, ** p < 0.05 non-parametric Mann Whitney U test, OVAp and IL-
1β versus PBS or OVAp. For days 0 and 1, there were 13 mice per group; for days 3, 6 and 20, there 
were 3 mice per group; and, for day 12, there were 4 mice per group. 
 
Subcutaneous antigenic stimulation without adjuvant leads to depletion of circulating and splenic OVA-
specific CD4+ T cells  
Mice that received OVAp + IL-1β had significantly increased cellularity in the spleen and in pooled 
peripheral (brachial, axillary, and inguinal) LNs at days 6 and 12 (Fig. 5A and 5B), associated with 
splenomegaly that was most marked on day 12 (Fig. 6), but already apparent on day 6 as reflected by 
the cellularity of the spleen (Fig. 5A). Although mice receiving OVA alone showed increased LN 
cellularity at days 3 and 6, LN cellularity was normal by day 12 (Fig. 5B), and spleen cellularity and 
size remained normal throughout the time of investigation (Fig. 5A, Fig. 6).  
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Figure 5. Continuous administration of OVAp with IL-1β as adjuvant leads to a significant increase in 
spleen and LN cellularity, whereas OVAp without adjuvant leads to significant increase in LN cellularity 
only. Mini-osmotic pumps containing either PBS, OVAp in PBS, or OVAp together with IL-1β were 
implanted s.c. between the scapulae of DO11.10 TCR tg mice and, at the indicated time points, the 
numbers of (A) SPL cells and (B) peripheral LN (brachial, axillary, inguinal) cells were assessed. Data 
shown are from three mice per group per time point and are representative of three similar 
experiments (seven experiments were carried out in total). Shown are means and ranges. * p<0.05 
PBS versus OVAp, grey asterix p<0.05 PBS versus OVAp + IL-1β, and *# p<0.05 OVAp versus OVAp 
+ IL-1β (two-way ANOVA for comparison of more than two groups with Bonferroni post-tests to 
compare replicate means per time point). 
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Figure 6. In vivo priming of mice with OVAp + IL-1β leads to splenomegaly. Mice were implanted with 
mini-osmotic pumps (as per the legend of Fig. 4). The spleens shown on the lid of a 6-well tissue 
culture plate were harvested on day 12 and are representative for those from mice that received PBS 
(left), OVAp (middle), and OVAp + IL-1β (right). 
 
Flow cytometric evaluation of peripheral blood, spleen (representative flow data are shown in Fig. 7), 
and peripheral LNs revealed that OVAp stimulation without IL-1β resulted in a rapid and statistically 
significant decrease of OVA-specific CD4+ T cells in the blood (Fig. 8A) and spleen (Fig. 8B), but not 
in LNs (Fig. 8C), of DO11.10 TCR tg mice. This loss was mainly due to a decrease in the number of 
OVA-specific CD4+ (CD62LhighCD44low) TN cells (Figs. 8D and 8E, respectively). Even though OVA-
specific CD4+ T cells were increased at days 3 and 6 after administration of OVAp without IL-1β, there 
was a significant reduction of TN cells in LNs at days 6 that continued until the last day (day 20) of 
evaluation (Fig. 8F). Administration of OVAp + IL-1β led to a similar decrease of OVA-specific CD4+ T 
cells in the blood (Fig. 8A) and this was associated with a decrease in TN cells in the blood, spleen and 
LNs (Fig. 8D, 8E and 8F). In the spleens of mice that received OVAp + IL-1β, in contrast to those that 
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received OVAp only, all effector/memory T cell subpopulations showed substantial and significant 
increases by days 6-12 (Figs. 8H, 8K, and 8M). This included OVA-specific effector-type CD4+ TE cells 
(CD62LlowCD44low) (Thomas, Brown et al.) (Fig. 8H), classical “effector memory” CD4+ TEM cells 
(CD44highCD62Llow) (Connor, Harvie et al.) (Fig. 8K), and “central memory” CD4+ TCM cells 
(CD62LhighCD44high; Fig. 8M). OVA-specific CD4+ TE cells also increased in the blood of mice that 
received OVAp + IL-1β (Fig. 8G), but the number of OVA-specific CD4+ TEM cells or TCM cells did not 
increase in the blood in either of the other two groups (data not shown). 
As mentioned above, mice that received OVAp alone showed only an increase in the cellularity of the 
peripheral LNs at days 3 and 6 (Fig. 5B), accounted for by an increased number of OVA-specific CD4+ 
T cells that were predominantly CD4+ TE cells at day 3 (Fig. 8I) and, to a lesser extent and only at day 
6, TEM cells (Fig. 8L). Of note, in the spleens of mice that received OVAp without adjuvant, increases 
in OVA-specific “memory/effector-phenotype” OVA-specific CD4+ T cell subsets were very small and 
not sustained (Fig. 8H, 8K, and 8M). TCM cells increased substantially only in spleens and LNs of mice 
that received OVAp + IL-1β (Fig. 8M and 8N). 
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Figure 7. CD44 versus CD62L staining profiles of splenocytes from mice that received either PBS or 
OVAp in PBS or OVAp + IL-1β in PBS. Representative data shown are from day 6 after s.c. pump 
implantation. The sequence of gating was as follows: 1. Cells; 2. Singles to remove doublets; 3. 
Boolean gating to remove artefacts and aggregates; 4. Live cells; 5. CD4+ cells; 6. KJ1-26+ cells (= 
cells that express the transgenic TCR); 7. CD44 versus CD62L (depicted). CD4+KJ1-26+ T cells from 
the spleens of mice that received OVAp + IL-1β showed the lowest fluorescence for CD62L when 
compared to the other groups and gates were adjusted accordingly. The event counts refer to the 
number of CD4+KJ1-26+ events that are shown. 
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In sum, the major differences in cell composition of spleen and LNs in mice that received OVAp + IL-
1β versus those that received PBS or OVAp alone were found in the OVA-specific CD4+ TCM cell 
subpopulation (which was numerically increased at days 6 and 12 in mice that received OVAp + IL-1β) 
(Fig. 8M and 8N, respectively) and in OVA-specific CD4+ TE cells (which increased also and to a 
greater extent early on in the peripheral LNs of mice that only received OVAp) (Fig. 8I). Although 
OVA-specific CD4+ TCM cell numbers were low in the blood of mice that received OVAp or OVAp + IL-
1β (data not shown), a significant and large increase of this T cell subset was observed at days 6 and 
12 also in the spleen and LNs of mice that received OVAp + IL-1β (Fig. 8M and 8N, respectively). 
These findings suggest that s.c. antigenic stimulation without adjuvant leads to depletion of circulating 
and splenic OVA-specific CD4+ T cells, especially those with a TN phenotype, and that this depletion 
cannot be readily attributed to maturation of TN cells to memory/effector phenotype T cells or to 
redistribution of T cells to peripheral lymphoid compartments. Indeed, when peripheral CD4+ T cells 
from blood, peripheral LNs, and spleen were considered in aggregate, mice that received OVAp 
without adjuvant showed a significant depletion of CD4+ T cells by day 12 (Fig. 8J). Meanwhile, the 
presence of adjuvant led, as expected, to an increase in Ag-specific memory/effector CD4+ T cell 
subsets accompanied by a reciprocal fractional decrease in the number of Ag-specific TN cells, most 
likely due to maturation of these cells to memory/effector phenotypes. 
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Figure 8. Continuous s.c. administration of OVAp results in a rapid decrease of OVA-specific, naive 
CD4+ T cells in the periphery and this loss cannot be readily attributed to T cell maturation or 
redistribution to lymphoid compartments. Mice were implanted with mini-osmotic pumps (as per the 
legend of Fig. 5) and individual mice were bled as a function of time to measure the number of: OVA-
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specific CD4+ T cells (A) per µl of peripheral blood, (B) per SPL, or (C) per pooled (axillary, brachial 
and inguinal) lymph nodes. OVA-specific CD4+ TN cells, (D) per µl of peripheral blood, (E) per spleen, 
or (F) per pooled (axillary, brachial and inguinal) lymph nodes. OVA-specific CD4+ TE cells, (G) per µl 
of peripheral blood, (H) per spleen, or (I) per pooled (axillary, brachial and inguinal) lymph nodes. (J) 
The sum of total peripheral CD4+ T cells (from blood, spleen and peripheral LN) was calculated and is 
shown. OVA-specific CD4+ TEM cells, (K) per spleen or (L) per pooled (axillary, brachial and inguinal) 
lymph nodes. OVA-specific CD4+ TCM cells, (M) per spleen or (N) per pooled (axillary, brachial and 
inguinal) LNs. Data shown are from the same experiment as shown in Fig. 5. Shown are means and 
ranges. * p<0.05 PBS versus OVAp, grey asterix p<0.05 PBS versus OVAp + IL-1β, and *# p<0.05 
OVAp versus OVAp + IL-1β (Student’s t-test for data from PBMCs and two-way ANOVA for 
comparison of more than two groups with Bonferroni post-tests to compare replicate means per time 
point for organ counts). 
 
Subcutaneous antigenic stimulation without adjuvant does not lead to thymic involution  
Given the early and rapid drop of OVA-specific CD4+ TN cells in the periphery in mice that received 
either OVAp or OVAp + IL-1β, we explored the possibility that s.c. Ag stimulation without or with 
adjuvant might lead to thymic involution. At days 6 and 12 after pump implantation, OVAp + IL-1β-
stimulated mice showed a significant loss of thymocytes (Fig. 9A), associated with depletion of 
CD3+CD4+CD8+ (double positive, or DP) (Fig. 9B), CD3+CD4+CD8- (single positive CD4, or SPCD4) 
(Fig. 9C), and CD3-CD4-CD8- (double negative, or DN) (Fig. 9D) cells. Transient thymic involution was 
not, however, noted in those mice that received Ag in the absence of adjuvant. 
 67 
 
Figure 9. Loss of thymocytes early after s.c. OVAp with IL-1β administration. Mice were implanted 
with mini-osmotic pumps (as per the legend of Fig. 5) and, at four time points thereafter, thymi were 
removed from individual mice to count the number of: (A) total cells, (B) DP THY cells, (C) SPCD4 
THY cells, and (D) DN THY cells. Open squares: PBS group; filled circles: OVAp group; open inverted 
triangles: OVAp + IL-1β group. Data shown are from the same experiment as shown in Fig. 5. Shown 
are means and ranges. * p<0.05 PBS versus OVAp, grey asterix p<0.05 PBS versus OVAp + IL-1β, 
and *# p<0.05 OVAp versus OVAp + IL-1β (two-way ANOVA for comparison of more than two groups 
with Bonferroni post-tests to compare replicate means per time point). 
 
Subcutaneous antigenic stimulation without adjuvant leads to a rapid increase in the proportion and 
absolute number of Ki67+ CD4+ T cells in peripheral LNs, but not in the spleen.  
Since the rapid drop in peripheral TN cell numbers in mice infused with OVAp alone could not be 
explained by thymic involution, we investigated the possibility that s.c. OVAp administration might 
instead induce clonal proliferation and maturation of Ag-specific TN cells to effector/memory T cells, 
potentially resulting in depletion of the TN compartment. In mice receiving OVAp without adjuvant, the 
percentage of OVA-specific CD4+ T cells that expressed Ki67 was significantly increased in the LNs at 
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days 3 and 6 compared to mice that also received IL-1β (Fig. 10A). Compared to mice that received 
OVAp + IL-1β, those receiving OVAp alone showed a significant increase in the absolute number of 
Ki67+ CD4+ TN, TEM, TE and TCM T cells at days 3 and/or 6 (Figs. 10B, 10C, 10D and 10E). At days 6 
and 12, however, the percent and absolute number of Ki67+ OVA-specific CD4+ TN cells in the spleens 
of mice that received OVAp + IL-1β was significantly higher than in those that received either PBS or 
only OVAp (Fig. 10F and 10G). These data suggest that antigenic stimulation in the absence of 
adjuvant is associated with early rounds of TN proliferation that do not ultimately lead to the generation 
of more mature T cells. 
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Figure 10. Proliferation profiles, as measured by expression of Ki67 in OVA-specific CD4+ T cells in 
the LNs and spleen. Mice were implanted with mini-osmotic pumps (as per the legend of Fig. 5) and, 
at the indicated time points, peripheral LNs (including two brachial, two axillary, and two inguinal) were 
collected to determine (A) Ki67+ cells as percentage of OVA-specific CD4+ T cells or the absolute 
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numbers per 6 LNs of (B) Ki67+ OVA-specific CD4+ TN cells, (C) Ki67+ OVA-specific CD4+ TEM cells, 
(D) Ki67+ OVA-specific CD4+ TE cells, or (E) Ki67+ OVA-specific CD4+ TCM cells. (F) The percentage of 
Ki67+ OVA-specific TN cells in the spleen or (G) the absolute number of Ki67+ OVA-specific TN cells in 
the spleen are shown. Data shown are from the same experiment as shown in Fig. 5. Shown are 
means and ranges. * p<0.05 PBS versus OVAp, grey asterix p<0.05 PBS versus OVAp + IL-1β, and *# 
p<0.05 OVAp versus OVAp + IL-1β (two-way ANOVA for comparison of more than two groups with 
Bonferroni post-tests to compare replicate means per time point). 
 
Subcutaneous antigenic stimulation without adjuvant leads to limited proliferation and rapid loss of 
dividing cells from the T cell pool 
To explore further the proliferation and loss of OVA-specific CD4+ T cell subsets in lymphoid 
compartments during s.c. administration of peptide without or with adjuvant, in vivo oral stable-isotope 
labelling was carried out in DO11.10 mice during the first 3 days after s.c. pump implantation. 2H 
enrichment was analyzed at days 3, 6, 12 and 20 after pump implantation in the Ag-specific TN and 
classical effector memory TEM cells from peripheral LNs or spleen. In stimulated mice (mice that 
received OVAp or OVAp + IL1β), 2H enrichments in TN cells from the spleen appeared to be lower 
than in TN cells from peripheral LNs at early time points. Also, 2H enrichments were higher in TEM cells 
than TN cells in all groups of mice at early time points (compare Fig. 11A to 11C or Fig. 12A to 12C). 
TEM 2H enrichments appeared to be higher in LNs than spleen in mice that received OVAp + IL1β (for 
example at day 6, 8% versus 6% enrichment in TEM cells from LNs versus spleen from OVAp + IL1-β 
mice; compare Fig. 11C and Fig. 12C). 
 
In peripheral LNs, peak labelling of OVA-specific CD4+ TN cells was reached at day 12 in mice that 
received PBS, but 2H enrichments were higher at days 3 or at days 3 and 6 in mice that received 
either OVAp alone or OVAp + IL-1β, respectively (Fig. 11A). Peak labelling of OVA-specific CD4+ TN 
cells from spleens was reached on day 12 in both OVAp-stimulated and unstimulated (PBS) DO11.10 
mice (this was the case after either 2H2O labelling (Fig. 12A) or [6,6-2H2]glucose; data not shown). 
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However, peak labelling of OVA-specific CD4+ TN cells in spleens of mice that received OVAp + IL-1β 
was only reached at day 20 (Fig. 12A), likely due to early and rapid conversion of TN cells into 
effector/memory T cells and/or due to trafficking of the primed TN cells to non-lymphoid inflamed tissue 
/ the effector site at the earlier time points. The delay in peak labelling of OVA-specific CD4+ TN cells 
from PBS-treated mice in both LNs and spleen possibly reflects the movement of cells labelled in the 
thymus to these peripheral lymphoid tissues. 
  
In mice that received OVAp, the fraction and absolute number of labelled TN cells was significantly 
increased in LNs at day 3 and, by day 6, the absolute number of labelled TN cells dropped to the same 
level as in mice that received PBS (Fig. 11B). In contrast, in mice that received OVAp + IL-1β, the 
fraction and absolute number of labelled TN cells remained significantly elevated at day 6 (Fig. 11E 
and 11B, respectively). Of note, the fraction of labelled cells or absolute numbers of labelled cells per 
organ can only be calculated during the period of label incorporation and not during delabelling, as the 
labelled cell population during delabelling is not representative of the whole cell population (Asquith, 
Debacq et al. 2002). In the spleen, 2H enrichments and the fraction of labelled TN cells were similar in 
all the three groups of mice (Fig. 12E). The absolute number of labelled TN cells appeared to be higher 
at day 6 in mice that received PBS (Fig. 12B), because these mice in contrast to mice that received 
OVAp or OVAp + IL-1β did not loose TN cells and their TN cell number in the spleen increased slightly 
between days 3 and 6 (Fig. 8E). 
 
In the LNs and spleen of mice that received OVAp or OVAp + IL-1β, OVA-specific CD4+ TEM cells 
showed peak labelling at day 6 and 2H enrichments in this subset were highest at days 3 and 6 in TEM 
cells from mice that received OVAp + IL-1β (Fig. 11C and Fig. 12C). The highest fractions and 
absolute numbers of labelled TEM cells were observed at day 6 in the LNs and spleens of mice that 
received OVAp + IL-1β (Fig. 11F, 11D and 12F, 12D). 2H enrichments in TEM cells from both LNs and 
spleens of mice that received OVAp + IL-1β decreased after day 6 (Fig. 11C and 12C). However, 2H 
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enrichments in TEM cells from the LNs decreased only after day 12 in mice that received OVAp alone 
(Fig. 11C and 11G), indicating that TEM cells were not lost from the peripheral LNs by cell death or 
trafficking or were replenished by conversion / differentiation of local or thymic precursors labelled 
previously. Alternatively, as the labelled population during delabelling is not representative of the 
whole population, this result could represent a proportionate loss of both labelled and unlabelled cells. 
This is likely because LN cellularity in mice that received OVAp decreased after day 6, as did the 
number of Ag-specific TEM cells (Fig. 5B and Fig. 8L, respectively). Of note, even though the frequency 
of Ki67+ OVA-specific CD4+ T cells was highest at days 3 and 6 in mice that received OVAp (Fig. 
10A), 2H enrichments were highest in, especially, TEM cells of OVAp + IL-1β mice at day 6 in both LNs 
(Fig. 11C) and spleen (Fig. 12C). In addition, and as mentioned above, TEM cells that had incorporated 
label (new cells) were not as rapidly lost in LNs of OVAp only mice between days 6 and 12, but 
declined rapidly thereafter (Fig. 11G). It is possible that these cells survived for longer and failed to 
exit the LNs due to the lack of an appropriate signal two that would be necessary for "proper“ T cell 
activation and the migration of cells from the LNs to non-lymphoid tissue (reviewed in (Marelli-Berg, 
Okkenhaug et al. 2007)). The more rapid loss of new TEM cells from LNs in OVAp mice after day 12 
may be due to aborted activation. 
 
In the spleen, newly divided OVA-specific CD4+ TEM cells lost label more steadily in all groups, 
although the early loss (between days 6 and 12) of labelled cells was greatest in mice that received 
OVAp + IL-1β (Fig. 12G). Mice that received OVAp + IL-1β lost OVA-specific TEM cells more steadily 
and at earlier time points also in LNs (Fig. 11G). This kinetic analysis indicates that T cell turnover is 
highest in mice that receive peptide + adjuvant (OVAp + IL-1β). Together with the cell counts 
described above, these data show that cells divide after s.c. administration of OVAp, but that in 
contrast to administration of OVAp + IL-1β, proliferation is limited and does not lead to sustained 
peripheral T cell expansion, and cells are lost from the T cell pool. In other words, sustained rounds of 
cell proliferation that lead to expansion of the T cell pool are not observed in mice stimulated with 
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OVAp alone. 
 
Figure 11. 2H enrichment labelling profiles, as measured after in vivo 2H2O labelling of OVA-specific 
CD4+ T cells in peripheral LNs following pump implantation. Mice were labelled orally with 2H2O 
provided in drinking water for the initial 72 hours that they carried s.c. mini-osmotic pumps delivering 
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PBS, OVAp or OVAp + IL-1β. The percentage of 2H enrichment in DNA over time from OVA-specific 
CD4+ (A) TN or (C) TEM cells from peripheral LNs of PBS, OVAp-, or OVAp + IL-1β-stimulated DO11.10 
mice. The absolute numbers of labelled OVA-specific CD4+ (B) TN or (D) TEM cells per 6 peripheral 
LNs (2 each of brachial, axillary and inguinal; the fraction of labelled cells was multiplied by the 
number of cells of the respective phenotype). The fraction of OVA-specific CD4+ (E) TN or (F) TEM 
cells, and (G) the percentage of new OVA-specific CD4+ TEM cells remaining in LNs at the indicated 
times. Open squares: PBS group; filled circles: OVAp group; open inverted triangles: OVAp + IL-1β 
group. Data shown are from the same experiment as shown in Fig. 5. Shown are means and ranges. * 
p<0.05 PBS versus OVAp, grey asterix p<0.05 PBS versus OVAp + IL-1β, and *# p<0.05 OVAp versus 
OVAp + IL-1β (two-way ANOVA for comparison of more than two groups with Bonferroni post-tests to 
compare replicate means per time point). 
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Figure 12. 2H enrichment labelling profiles, as measured after in vivo 2H2O labelling of OVA-specific 
CD4+ T cells in spleens following pump implantation. Mice were labelled orally with 2H2O provided in 
drinking water for the initial 72 hours that they carried s.c. mini-osmotic pumps delivering PBS, OVAp 
or OVAp and IL-1β. The percentage of 2H enrichment in DNA over time from OVA-specific CD4+ (A) 
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TN or (C) TEM SPL cells of PBS, OVAp-, or OVAp + IL-1β-stimulated DO11.10 mice. The absolute 
numbers of labelled OVA-specific CD4+ (B) TN or (D) TEM per spleen (the fraction of labelled cells was 
multiplied by the number of cells of the respective phenotype). The fraction of OVA-specific CD4+ (E) 
TN or (F) TEM cells, and (G) the percentage of new OVA-specific CD4+ TEM cells remaining in the 
spleen at the indicated times. Open squares: PBS group; filled circles: OVAp group; open inverted 
triangles: OVAp + IL-1β group. Data shown are from the same experiment as shown in Fig. 5. Shown 
are means and ranges. * p<0.05 PBS versus OVAp, grey asterix p<0.05 PBS versus OVAp + IL-1β, 
and *# p<0.05 OVAp versus OVAp + IL-1β (two-way ANOVA for comparison of more than two groups 
with Bonferroni post-tests to compare replicate means per time point). 
 
Subcutaneous antigenic stimulation without adjuvant leads to a rapid increase in the proportion and 
absolute number of CD4+ TREG cells in peripheral LNs. 
Since CD4+ TREG can negatively impact upon TN cell proliferation (Annacker, Pimenta-Araujo et al. 
2001; Almeida, Legrand et al. 2002; Dahlberg, Schartner et al. 2007), they might be responsible for 
the relative suppression of T cell proliferation when OVA is provided in the absence of adjuvant. 
Indeed, an early and sustained increase in the fraction (Fig. 13A) and absolute number (Fig. 13B) of 
OVA-specific CD4+FoxP3+ TREG cells was observed in LNs after the initiation of antigenic stimulation. 
A very early (day 3) fractional increase of CD4+ FoxP3+ TREG cells was also observed in spleen (Fig. 
13E). In a different experiment where an OVAp + IL-1β group of mice was not included, a large 
fraction of proliferating Ki67+ OVA-specific FoxP3+CD4+ TREG cells was observed in the peripheral LNs 
of OVAp-stimulated mice and was sustained through day 10 (Fig. 13C), during which time the 
frequency of Ki67+FoxP3- OVA-specific CD4+ T cells was returning to normal (Fig. 13D). Examples of 
flow cytometric data depicting FoxP3 against Ki67 expression in OVA-specific CD4+ T cell populations 
are shown for representative mice from each group (Fig. 14). Of note, in mice that received OVAp 
without adjuvant, both the fraction and absolute number of TREG cells in LNs remained elevated for 
more than 30 days when 4-week s.c. mini-osmotic pumps were implanted (data not shown). These 
findings suggest that, in mice given OVA without adjuvant compared to those receiving adjuvant, the 
induction of Ag-specific FoxP3+CD4+ TREG cells is greater and more sustained. 
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Figure 13. Early and sustained increases in LN FoxP3+CD4+ TREG cells are observed after 
administration of s.c. OVAp in the absence of adjuvant. (A) The frequency of FoxP3+CD4+ T cells in 
peripheral LNs increased significantly early after pump implantation and remained high thereafter in 
OVAp only mice. (B) Although the frequency of FoxP3+CD4+ T cells remained high, their absolute 
number decreased to almost normal levels between days 6 and 12. (C) Bar graphs showing the 
percentage of OVA-specific CD4+ T cells that are Ki67+FoxP3+ over time. (D) Bar graphs showing the 
percentage of OVA-specific CD4+ T cells that are Ki67+FoxP3- over time. (E) The percentage of OVA-
specific CD4+ T cells in the spleen positive for FoxP3. Open squares or white columns: PBS group; 
filled circles or grey columns: OVAp group; open inverted triangles: OVAp + IL-1β group. Data shown 
in (A), (B) and (E) are from the same experiment as shown in Fig. 5. Data shown in (C) and (D) are 
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from 5 mice per group per time point, except for day 10 where the PBS group consisted of 4 mice. 
Shown in (A), (B) and (E) are means and ranges and in (C) and (D) median values and IQRs. The 
latter data are representative of 2 similar experiments. * p<0.05 PBS versus OVAp, grey asterix 
p<0.05 PBS versus OVAp + IL-1β, and *# p<0.05 OVAp versus OVAp + IL-1β (two-way ANOVA for 
comparison of more than two groups with Bonferroni post-tests to compare replicate means per time 
point or two-tailed non-parametric Mann-Whitney U Test for comparisons between two groups; ** 
p<0.01). 
 
 
Figure 14. Representative flow cytometry plots showing the percentages of OVA-specific CD4+ T cells 
from PBS or OVAp only mice that express or do not express Ki67 and/or FoxP3 at day 7 after pump 
implantation. The gating depicted here was used to calculate the data shown as bar graphs in Fig. 
13C and 13D. 
 
3.5 Discussion 
The data in this chapter show that immunological tolerance through “aborted” immune activation rather 
than immunity is established in DO11.10 CD4+ TCR tg mice after and during s.c. administration of 
peptide without adjuvant. Ag-specific CD4+ T cells in mice that receive OVAp without adjuvant are 
initially primed, but both priming and peripheral expansion of Ag-specific T cells appear to be limited 
and confined to the peripheral LNs. This could potentially be due to a lack of T cell trafficking (Marelli-
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Berg, Okkenhaug et al. 2007), perhaps related to differential regulation of activation marker 
expression (Shiow, Rosen et al. 2006) when peptide is given without or with adjuvant. Conversion of 
TN to memory/effector phenotype T cell subsets was also limited and not sustained, and TREG cells 
were induced and increased both numerically and relatively in peripheral LNs as well as relatively in 
PBMCs and spleen in mice that received peptide without adjuvant. In addition, a significant transient 
depletion of CD4+ T cells was observed in mice that received peptide only and this might have 
contributed to immunological tolerance. The data described here also show that cognate Ag given with 
adjuvant leads to the systemic induction and expansion of all memory/effector phenotype T cell 
subsets studied (at the expense of naïve T cells) in CD4+ TCR tg mice and that this immunological 
response is accompanied by typical symptoms such as scruffy fur and weight loss suggestive of a 
state of heightened immune activation. Furthermore, pumps were discontinued due to inflammation at 
the pump release site only in mice that received peptide with adjuvant.  
The significant loss of Ag-specific CD4+ T cells, especially TN cells, in the peripheral blood of 
stimulated mice warranted further investigation. Thymic deletion of Ag-specific T cells could, at least in 
part, have been responsible for the peripheral loss of OVA-specific TN cells, at least if the peptide or 
peptide-loaded APCs reached the thymus (Bonasio, Scimone et al. 2006). In the original paper using 
DO11.10 mice, for example, three relatively high dose i.p. injections of OVA323-339 peptide induced 
thymic deletion by apoptosis (Murphy, Heimberger et al. 1990). In the current study, no significant 
differences were observed in the number of total, DP, SPCD4+, or DN thymocytes in mice that 
received PBS versus those that received peptide without adjuvant. Also, even though mice that 
received peptide with adjuvant presented with transient thymic involution, which could have been due 
to a stress reaction associated with the observed weight loss (Table 1) (Hogquist, Baldwin et al. 2005) 
and/or due to direct effects of IL-1β (Morrissey, Charrier et al. 1988), their overall peripheral CD4+ T 
cell numbers remained stable. Thus, it seems unlikely that the rapid loss of peripheral Ag-specific 
CD4+ T cells in mice that received peptide without adjuvant was due to thymic deletion. 
The rapid drop in OVA-specific CD4+ TN cells in the peripheral blood could instead have been due to 
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their redistribution to lymphoid tissues or the skin as the effector site, or to their increased 
differentiation into more mature T cell phenotypes. However, the increase in cellularity observed in the 
LNs of OVAp-stimulated mice was small, transient and insufficient to account for the massive decline 
of CD4+ TN cell numbers in the peripheral blood and spleen. This in contrast to mice that received 
OVAp + IL-1β where redistribution of differentiated CD4+ T cells can explain the decrease in TN cell 
numbers. More detailed examination of the increase in LN cellularity in OVAp-stimulated mice 
revealed that it was due in part to a small but significant numerical increase of TE and TEM cell subsets. 
It is known that both TE and TEM subsets show substantially lower capacity for further expansion than 
TCM cells (Thomas, Brown et al. 2010), and a marked and sustained TCM cell increase was only 
observed in the LNs and spleens of mice stimulated with OVAp + IL-1β. These observations suggest 
that effector memory T cells are generated by s.c. peptide administration without adjuvant in the LNs 
of TCR tg mice, but that such cells fail to differentiate into TCM cells or populate the periphery in the 
absence of adjuvant. In addition, the small changes observed in LN cellularity and composition, and 
the fact that the skin at the pump release site remained intact in TCR tg mice that received peptide 
without adjuvant, suggest that peripheral T cell depletion in mice that received OVAp without adjuvant 
is not likely due to redistribution. 
Low naïve T cell numbers in the periphery could also be explained by an expansion of CD4+ TREG 
cells, as these cells can inhibit proliferation of T cells (Annacker, Pimenta-Araujo et al. 2001; Almeida, 
Legrand et al. 2002; Dahlberg, Schartner et al. 2007). Indeed, the loss of OVA-specific CD4+ T cells 
from the blood and spleen was accompanied by a fractional increase of TREG cells in the blood and 
spleen as well as a fractional and numerical increase of TREG cells in peripheral LNs. This finding 
supports the notion that OVA323-339 peptide has high agonist activity and may convert some naïve T 
cells into TREG cells (Apostolou and von Boehmer 2004; Kretschmer, Apostolou et al. 2005; Polansky, 
Kretschmer et al. 2008; Daniel, Weigmann et al.) or preferentially select TREG cells in the thymus 
(Jordan, Boesteanu et al. 2001). Of note, while proliferation of FoxP3-negative Ag-specific CD4+ T 
cells returned to normal by day 10, proliferation of FoxP3+ Ag-specific CD4+ T cells remained elevated, 
which may indicate that the latter were maintained in high numbers due to continuous turnover. Thus, 
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to the extent that CD4+ TREG cells may play a role in naïve T cell homeostasis (Annacker, Pimenta-
Araujo et al. 2001; Almeida, Legrand et al. 2002), the CD4+ T cell depletion observed after 
administration of peptide without adjuvant may, at least in part, be attributable to their induction. 
Finally, the possibility was explored that the T cell depletion observed in these experiments might be 
due to one or more forms of Ag-induced T cell activation: “functional” activation leading to the 
expansion of Ag-specific CD4+ T cells followed by AICD (Green, Droin et al. 2003) and “aborted” 
activation that would be accompanied by a more limited number of rounds of cell division before AICD. 
It has been proposed that AICD might also contribute to the establishment of peripheral tolerance 
(Kabelitz and Janssen 1997). We carried out in vivo stable isotope labelling in mice that received 
OVAp without adjuvant, OVAp with IL-1β or PBS continuously by s.c. mini-osmotic pump. As 
expected, 2H enrichment was higher in classical effector memory TEM than TN phenotype T cells 
(Tough and Sprent 1994). Interestingly, similar to TN phenotype T cells from human peripheral blood 
(Hellerstein, Hoh et al. 2003), 2H enrichments increased over time in TN cells from peripheral LNs and 
spleen of control mice that received only PBS. This increase possibly reflects the movement of cells 
labelled in the thymus to these peripheral lymphoid tissues. In both LNs and spleen, the rate of 
proliferation and loss of Ag-specific CD4+ TEM cells was highest in mice that received OVAp together 
with IL-1β, even though Ki67 expression at the same time points was lower than in mice that received 
OVAp alone. This may indicate that most of the cell division in mice that received OVAp + IL-1β had 
already occurred before day 3, the earliest time point at which cells were examined for Ki67 
expression or label enrichment, and that peak labelling of TEM cells from OVAp + IL-1β mice was 
mostly due to conversion of labelled TN cells. Interestingly, Ki67 expression was close to absent in T 
cells derived from the spleens of mice from all groups, but Ki67 expression was detected in LNs, even 
though cells in the spleen showed similar label enrichment to those from peripheral LNs. In theory, 
one could explain this result if cells were labelled before they populated the spleen. TN and TEM cells in 
the LNs of mice that received OVAp only showed high Ki67 expression, but also incorporated more 
label at early time points than TN and TEM cells in LNs of mice that received PBS, indicating that cells 
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were dividing. In contrast to mice that received OVAp + IL-1β, label was not lost as rapidly from LN-
derived TEM cells from mice that received OVAp without IL-1β. This could have been due to cells being 
stuck in cell cycle (Ki67 could still be expressed in this case, as it is expressed in all stages of the cell 
cycle except for G0 (Scholzen and Gerdes 2000)) and lack of trafficking of labelled T cells to other 
peripheral lympoid tissues such as the spleen or the skin as the effector site. This could explain, at 
least in part, why splenomegaly was observed in mice that received OVAp + IL-1β, but not in those 
that received OVAp alone. This finding would also be in line with “aborted T cell activation”, as it would 
indicate that sustained rounds of cell proliferation leading to expansion of the T cell pool were not 
induced by peptide alone. Lymphopenia-induced proliferation (Martin, Bourgeois et al. 2003; Neujahr, 
Chen et al. 2006; Voehringer, Liang et al. 2008) in mice that received OVAp without adjuvant probably 
did not account for the proliferation profile observed in these mice, as peripheral CD4+ T cell depletion 
was not yet significant at days 3 and 6, the days when Ki67 expression was highest. TREG cells have 
been shown to have high proliferation rates (Vukmanovic-Stejic, Zhang et al. 2006) and often display a 
memory phenotype (Rallon, Lopez et al. 2009). Therefore, it is also possible that proliferation of TREG 
cells contributed to a great extent to the label enrichments observed in TEM cells from mice that 
received OVAp without adjuvant. In support of this, at early time points, 40% of CD25highFoxP3+ TREG 
cells in LNs of mice that received peptide only expressed Ki67, which was approximatey twice as high 
as in mice that received peptide with adjuvant (data not shown). Given these data, we can most 
conservatively conclude that functional T cell activation leading to T cell expansion did not occur after 
stimulation of mice with peptide only. Instead, continued s.c. infusion of OVAp was associated with 
cells in the LNs that entered cell cycle, then most likely retained label and remained Ki67+, but did not 
divide or exit the LNs, and eventually underwent cell death possibly due to lack of survival signals and 
/ or degradation of the peptide in the pumps. Of note, in the original article where the DO11.10 tg TCR 
model was described, in vitro Ag sensitivity of the transgenic T cells appeared to be greatest for 
OVA323-339 rather than the other altered peptide ligands tested, but proliferation tailed off with higher 
doses of this peptide (Murphy, Heimberger et al. 1990). Having speculated that the peptide 
concentration could have dropped due to degradation of the peptide in the pumps, we assessed 
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stability of the peptide under different conditions and found that OVAp in PBS was most stable when 
kept sterile in the fridge for 20 days and less stable when kept sterile at 37 ºC (Fig. 15).  
 
Figure 15. OVAp in PBS is most stable when kept sterile at 4 ºC and degrades to some extent when 
kept sterile at 37 ºC, especially during the first 3 days. Peptide concentrations were measured using 
MS by the company (Biopeptide, CA, USA) that synthesized the peptide. The percentage of original 
abundance was calculated. 
 
The peptide concentration appeared to be much lower in the remaining pump content removed from 
pumps that were implanted s.c. in mice (data not shown). The latter was very likely skewed due to 
measurement errors when very small volumes are analyzed and due to the fact that the pump content 
was not sterile anymore after the pumps were explanted and opened to retrieve the content, which 
could have resulted in increased degradation of the peptide during transit before analysis at the 
company that synthesized the peptide. 
The results described here are in line with the finding from a previous study that continuous s.c. 
administration of Ag using osmotic pumps to TCR tg mice on a Rag-deficient background led to the 
induction of Ag-specific suppressor T cells (Apostolou and von Boehmer 2004). These data are also 
consistent with studies demonstrating that serial s.c. administration of peptide in a non-inflammatory 
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context leads to the induction of TREG cells (Dahlberg, Schartner et al. 2007). However, these results 
are dissimilar to those of Switzer et al., who reported that Ag-specific tolerance did not develop in 2B4 
TCR tg mice given peptide without adjuvant by s.c. osmotic pumps (Switzer, Wallner et al. 1998). 
There may be several reasons for this discrepancy, the most important being that Switzer et al. 
administered a much higher dose of peptide and only examined ex vivo responsiveness of Ag-specific 
CD4+ T cells, as opposed to the kinetics of cell division in vivo. 
In summary, this study shows that continuous s.c. administration of peptide without adjuvant leads to 
the induction of a form of immunological tolerance that could be called aborted activation, with the 
predominant mechanisms at play being very limited memory T cell expansion, transient peripheral 
deletion, lack of TCM cell generation, possible insufficient egress of T cells from the peripheral LNs, 
and the induction of TREG cells. These findings suggest that continuous s.c. administration of peptide 
without adjuvant can lead to persistent immunologic tolerance in vivo. In addition, this study shows 
that a systemic expansion of memory/effector-phenotype T cells (at the expense of TN cells) is 
observed when peptide is given with adjuvant even in TCR tg mice with a non-physiological and 
extremely high Ag-specific precursor frequency. 
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CHAPTER 
4 
In vivo turnover of human CD57+ and CD57- memory CD8+ T cells in HIV-infected subjects and 
healthy volunteers 
 
4.1 Introduction 
A better understanding of the human memory T cell compartment is needed to advance the 
development of protective T cell vaccines. In HIV infection, increasing evidence suggests that 
qualitative rather than quantitative measures of Ag-specific T cell responses provide the key to 
antiviral efficacy (Gea-Banacloche, Migueles et al. 2000; Betts, Nason et al. 2006; Appay, van Lier et 
al. 2008). An important prerequisite for long-term immunological T cell memory appears to be a long 
lifespan or the potential for long-term self-renewal within a subset of memory T cells. Recent 
evidence indicates that increased rates of clonal senescence and succession in immunodominant 
HIV-specific CD8+ T cell populations are associated with progressive loss of immune control in HIV 
infection (Almeida, Price et al. 2007). Replicative senescence and loss of dominant clonotypes can 
have disastrous effects on the immune system (Davenport, Fazou et al. 2002). Although CD57 
expression has been associated with CD8+ T cell senescence (Brenchley, Karandikar et al. 2003), a 
recent study found that most CD57+ T cells do not express PD-1 (Petrovas, Chaon et al. 2009), a 
marker expressed by exhausted T cells (Day, Kaufmann et al. 2006; Freeman, Wherry et al. 2006; 
Petrovas, Casazza et al. 2006; Trautmann, Janbazian et al. 2006). Most CD57+ cells display the 
highly differentiated RA+CD28-CCR7- CD8+ effector memory RA revertant (TEMRA) phenotype, and 
TEMRA cells appear to have a long lifespan (Ladell, Hellerstein et al. 2008). It has also been shown 
that CD57+ memory CD8+ T cells exert protective effects associated with the progressive acquisition 
of cytolytic activity (Kern, Khatamzas et al. 1999; van Leeuwen, Gamadia et al. 2002; Le Priol, 
Puthier et al. 2006; Chong, Aicheler et al. 2008; Chattopadhyay, Betts et al. 2009). Furthermore, it 
has been reported that CD57+ CD8high T cells are enriched for Ag-specific cells that exert a 
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regulatory function, in that they are capable of down-modulating cytolytic activity (Mollet, Sadat-
Sowti et al. 1998). The highest fraction of CD57+ cells is found within the TEMRA phenotype. TEMRA 
cells have also been associated with immune senescence (Nociari, Telford et al. 1999), but this 
again is controversial because many Ag-specific cells with anti-viral activity reside within this 
phenotypic compartment (Appay, van Lier et al. 2008). Furthermore, a larger proportion and 
absolute number of HIV-specific TEMRA cells in early HIV infection has been linked to the control of 
HIV viremia and, indeed, predicted the subsequent viral load set point (Northfield, Loo et al. 2007); 
such cells are also more frequently detectable in controlled compared to progressive HIV infection 
(Addo, Draenert et al. 2007). Ex vivo, using non-specific stimuli, CD57+ memory CD8+ T cells appear 
to proliferate much less than other memory T cell subsets (Brenchley, Karandikar et al. 2003). 
However, it is not known whether these cells proliferate in vivo. They may require a certain 
microenvironment or specific stimuli, such as cognate Ag. Here, as a first step towards learning 
more about this subset of T cells, the lifespan and proliferation rates of CD57+ memory CD8+ T cells 
were investigated in vivo in humans with or without chronic viral infections using non-toxic 2H-
glucose or 2H2O labelling. 
 
4.2 Hypothesis 
CD57+ memory CD8+ T cells proliferate less than CD57- memory CD8+ T cells. 
 
4.3 Specific Aim 
To study in vivo the turnover (rates of proliferation and cell death) of CD57+ memory CD8+ T cells 
and CD57- memory CD8+ T cells. 
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4.4 Results 
After 7 weeks of 2H2O labelling, high fractions of CD3+CD8+CD45RA-CCR7- T cells that were either 
CD57+ or CD57- incorporated deuterium. However, the CD57- cells appeared to loose label more 
rapidly than the CD57+ cells after labelling was discontinued (Fig. 16A and 16B). Half-lives were 
calculated between sort 0 and sort 1 (when label enrichments differed the most between T cell 
populations) using the formula for exponential decay for CD3+CD8+CD45RA-CCR7-CD57- T cells 
from all four HIV-infected individuals (half-life in days, 31 (open triangles), 32 (inverted open 
triangles), 33 (open squares), 84 (open circles)) and for CD3+CD8+CD45RA-CCR7-CD57+ T cells 
from three HIV-infected individuals, as for one individuals the label enrichment at sort 0 was not 
available (half-life in days, 342 (open triangles), 167 (open squares), 696 (open circles)). For such 
small sample sizes, non-parametric statistical tests are not powerful and paramtetric statistical test 
are not robust. Therefore, both, the two-tailed Student’s t-test and the two-tailed Mann Whitney U 
Test were carried out to determine whether the above stated half-lives are significantly different. The 
half-lives of CD3+CD8+CD45RA-CCR7-CD57- T cells were significantly lower than those of 
CD3+CD8+CD45RA-CCR7-CD57+ T cells when the Student’s t-test was used (p=0.042). There was 
no significant difference when the Mann Whitney U Test was used (p=0.057). The formula for 
exponential decay should not really be used for half-life calculations between sorts 0 and 1, as sort 0 
was done during the last week of labelleing and sort 1 was done three weeks after labelling was 
stopped and this time frame is considered the 2H wash-out phase (body water during this time may 
still be enriched with 2H). Half-lives calculated between subsequent sorts ( e.g. between sorts 1 and 
2) were not significantly different. The reasoning behind initially studying CD3+CD8+CD45RA-CCR7-
CD57+ or CD3+CD8+CD45RA-CCR7-CD57- T cells was that TEMRA phenotype T cells would contribute 
substantially to the labelled population if they were included, because almost all of the cells with this 
phenotype express CD57, and TEMRA labelling data has already been published (Ladell, Hellerstein 
et al. 2008). In two healthy subjects who received short-term oral 2H-glucose labelling and in whom 
the whole memory CD8+ T cell compartment was divided into CD57+ and CD57- cells, deuterium 
incorporation in CD57+ memory phenotype CD8+ T cells was low (Fig. 17 and Fig. 18). In one of the 
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two healthy subjects, deuterium incorporation was higher in CD57- memory phenotype CD8+ T cells 
at days 4 and 10 (Fig. 17); in the other subject, deuterium enrichment appeared (“appeared, as the 
replicate values for this time point were variable) to be higher in CD57- memory phenotype CD8+ T 
cells at day 4 (Fig. 18). In both healthy subjects, deuterium enrichment in CD57+ memory phenotype 
CD8+ T cells appeared to rise at the latest time point (21 days post-labelling). The characteristics of 
study subjects are shown in Table 2. 
 
Table 2. Characteristics of study subjects. 
Group Symbol Age VL 
(copies / 
ml) 
Years              
HIV-
infected 
CD4  
count / µl  
of blood 
CD8  
count / µl  
of blood 
2H2O 
labeling  
(weeks) 
2H-glucose  
labeling 
(hours)  
CMV 
Ig 
HIV-
negative 
Black 
diamond 
27 - - 586 376 7 ND - 
 # ND - -$ 1377 769 ND 10 ND 
          
 # ND - -$ 1060 357 ND 10 ND 
HIV-
infected  
Inverted open 
triangles 
40 2,059 NA 852 3388 7 ND + 
(not on  
HAART) 
Open  
Circles 
38 30,851 NA 431 1646 7 ND + 
 Open  
Squares 
36 448,343 NA 349 2445 7 ND + 
 Open 
triangles 
53 74,199 NA 330 1397 7 ND + 
# Stated in the relevant Figure legends. VL, viral load; $ low risk, as assessed by risk assessment; 
ND, not done. 
 
 89 
 
Figure 16. Raw labelling data from 4 HIV-infected subjects (open symbols) and 1 HIV non-infected 
subject (closed symbols) labelled for 7 weeks with deuterated (2H2O) water. Sort 0 was performed 
during the last week of labelling to determine maximum label enrichment in the two distinct T cell 
subsets. Sort 1 was performed 3 weeks after labelling was discontinued, as label remains present in 
the body water for this length of time. Sorts 2 and 3 were performed at successive one-month 
intervals. Cells were sorted on a BD FACS Digital Vantage or a BD FACS Aria I. DNA was extracted, 
hydrolyzed and derivatized, and label enrichment was assessed by gas chromatography mass 
spectrometry. 
 
 
Figure 17. Label incorporation in memory phenotype CD8+CD57+ (filled blue diamonds) or memory 
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phenotype CD8+CD57- (filled pink squares) T cells from healthy subject C33 labelled for 10 hours 
orally with 2H-glucose. Sort samples were collected on days 4, 10 and 21. Cells were sorted on a 
customized 20-parameter BD FACSAria II. DNA was extracted, hydrolyzed and derivatized, and label 
enrichment was assessed by gas chromatography mass spectrometry. 
 
 
 
 
Figure 18. Label incorporation in memory phenotype CD8+CD57+ (filled blue diamonds) or memory 
phenotype CD8+CD57- (filled pink squares) T cells from healthy subject C34 labelled for 10 hours 
orally with 2H-glucose. Sort samples were collected on days 4, 10 and 21. Cells were sorted on a 
customized 20-parameter BD FACSAria II. DNA was extracted, hydrolyzed and derivatized, and label 
enrichment was assessed by gas chromatography mass spectrometry. 
 
4.5 Discussion 
Stable isotope labelling with 2H-glucose or 2H2O in humans is a very sophisticated technique for the 
measurement of lymphocyte turnover in vivo (Macallan, Fullerton et al. 1998; Neese, Misell et al. 
2002). Importantly, this type of labelling is non-toxic and can be carried out safely in humans over 
long periods of time without side effects (Neese, Misell et al. 2002). In combination with fluorescence 
activated cell sorting (FACS) and mass spectrometric (MS) analysis, in vivo studies with this 
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labelling technique have shown that the turnover of bulk CD8+ T cells is increased in HIV-infected 
individuals and that this increase in turnover takes place mainly in memory/effector CD8+ T cell 
subpopulations (Mohri, Perelson et al. 2001; Hellerstein, Hoh et al. 2003). More recently, as 
described above, it was shown that central memory CD8+ T cells are preferentially lost and that more 
differentiated CD45RA-expressing effector CD8+ T cells accumulate in HIV-infected subjects (Ladell, 
Hellerstein et al. 2008). Until recently, analytic limitations (for example cell numbers below detection 
limits and low isotope enrichments) have made it difficult to measure directly the lifespan of Ag-
specific T cell subpopulations. However, recent refinements to the stable isotope/FACS/MS method 
now allow reliable measurements from fewer than 50,000 cells (Busch, Neese et al. 2007; Ladell, 
Hellerstein et al. 2008).  
The preliminary data from a pilot long-term in vivo 2H2O labelling study carried out in HIV-infected 
subjects showed that high fractions of CD8+ CD45RA-CCR7- T cells that were either CD57+ or CD57- 
incorporated deuterium after labelling for 7 weeks and that the CD8+ CD45RA-CCR7-CD57- cells 
appeared to loose label more rapidly compared to the CD8+ CD45RA-CCR7-CD57+ cells after 
labelling was discontinued. Although these findings may be interpreted in different ways, some 
features of the data suggest that the CD8+ CD45RA-CCR7-CD57- cells may be precursors of the 
CD57+ cells. Possible interpretations of the data include: (i) high label enrichment at the end of the 7-
week 2H2O labelling period could be due either to a high rate of proliferation in the two T cell 
phenotypes or to labelled cells from an earlier differentiation phenotype entering these phenotypes; 
(ii) the higher label enrichment at the end of the labelling period (sort 0 in Fig. 16) in the CD57- cells 
may indicate that they proliferate more than the CD57+ cells; and, (iii) stable label in CD57+ cells 
during the wash-out phase (= during the three weeks after labelling was stopped) may indicate that 
remaining label in the circulation is still being incorporated or that previously labelled cells from an 
earlier differentiation state enter this phenotype. Alternatively, label could be stably retained because 
the labelled cells do not divide or die during this short period of time. This latter possibility may be 
the most likely, as the “true” de-labelling curves (the curves excluding data from sort 0, as body 
water would have still been enriched with deuterium between sort 0 and sort 1 (during the wash-out 
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phase) of the CD57+ cells appear to be slightly less steep than those of the CD57- cells.  
Levels of deuterium incorporation in CD57+ memory phenotype CD8+ T cells were low in the two 
healthy subjects labelled short-term with 2H-glucose, which suggests slow turnover of these cells. In 
one of the two subjects, deuterium incorporation was higher in CD57- memory phenotype CD8+ T 
cells at both days 4 and 10, which is in line with higher turnover rates for these cells compared to 
their CD57+ counterparts. However, deuterium incorporation was also low in CD57- memory 
phenotype CD8+ T cells from the other subject (Fig. 18), and this may be a hint that short-term 2H-
glucose labelling is not the ideal approach to study turnover of these T cell subsets (longer labelling 
might be necessary to get more reliable results). Interestingly, enrichment in CD57+ memory 
phenotype CD8+ T cells appeared to rise at the latest time point studied (21 days post-labelling), 
which would be consistent with phenotype transition from CD57- to CD57+, although other 
explanations are also possible. Other explanations for increased enrichment in a cell population at a 
later time point include the movement of cells with a particular phenotype from one compartment to 
another, e.g. from lymphoid or extravascular tissue into the peripheal blood, or the death of 
unlabeled cells, which would make enrichment of the remaining cells appear higher artificially. These 
data are preliminary. Taken together, however, it appears to be the case that CD57+ memory 
phenotype CD8+ T cells indeed show low/slow turnover and that this population is either fed by a 
"younger“ pool of memory phenotype CD8+ T cells or that CD57+ memory phenotype CD8+ T have a 
longer lifespan than their CD57-negative counterparts. 
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CHAPTER 
5 
Interleukin-10 maintains latent murine cytomegalovirus infection by restricting the 
expansion and function of memory CD8+ T cells  
 
5.1 Introduction 
Human cytomegalovirus (HCMV) is a β-herpesvirus that infects approximately 70% of the human 
population. Although primary HCMV infection is typically asymptomatic, it causes multi-organ disease 
in unborn children and immune compromised seronegative adults (Sweet 1999). HCMV also 
establishes a latent infection that is generally well contained by healthy hosts. However, in individuals 
with impaired immune function, such as transplant recipients receiving immunosuppressive drugs, 
latent virus can reactivate and induce severe clinical disease (Riddell 1995; Fishman, Emery et al. 
2007). Furthermore, indirect effects such as acute and chronic graft rejection can be triggered by 
these events (Fishman, Emery et al. 2007). 
CD8+ T cells are critical mediators of antiviral immune responses to HCMV. Viral reactivation in 
immunosuppressed individuals is associated with a numerical and functional impairment of virus-
specific CD8+ T cells (Quinnan, Kirmani et al. 1982; Reusser, Riddell et al. 1991), and adoptive 
transfer of CD8+ T cells affords protection from virus reactivation and viremia (Riddell, Watanabe et al. 
1992; Walter, Greenberg et al. 1995; Einsele, Roosnek et al. 2002; Cobbold, Khan et al. 2005). In 
addition, using the murine CMV (MCMV) model of infection, it has been shown that adoptive transfer 
of CD8+ T cells protects immunosuppressed hosts from infection (Reddehase, Weiland et al. 1985; 
Reddehase, Mutter et al. 1987; Reddehase, Jonjic et al. 1988; Podlech, Holtappels et al. 1998). 
Critically, MCMV reactivation from latency is also controlled by CD8+ T cells (Polic, Hengel et al. 
1998).  
CMV-specific CD8+ T cells expand to unusually high frequencies in immune competent humans and 
mice (Gillespie, Wills et al. 2000; Sylwester, Mitchell et al. 2005), a phenomenon that has been termed 
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“memory inflation” (Karrer, Sierro et al. 2003). During MCMV infection, the memory CD8+ T cell pool 
consists of “stable” memory T cells that are present at low numbers and “inflationary” memory T cell 
populations that expand to high frequencies as infection progresses (Holtappels, Pahl-Seibert et al. 
2000; Karrer, Sierro et al. 2003; Munks, Cho et al. 2006). Inflation of memory T cells is Ag-dependent 
(Snyder, Cho et al. 2008), and phenotypic analysis suggests that these cells are highly differentiated 
and have recently been exposed to Ag (Holtappels, Pahl-Seibert et al. 2000; Appay, Dunbar et al. 
2002; van Leeuwen, Gamadia et al. 2002; Sierro, Rothkopf et al. 2005; Munks, Cho et al. 2006); thus, 
it appears that periodic viral reactivation events drive the expansion of these cells. However, it is 
unclear whether immunological factors also regulate this process. 
IL-10 is an immune regulatory cytokine that suppresses T cell responses primarily via effects mediated 
on APCs; specifically, IL-10 inhibits the expression of pro-inflammatory cytokines and chemokines, 
MHC class II and costimulatory molecules by APCs (Moore, O'Garra et al. 1993; O'Garra, Barrat et al. 
2008). During viral infections, IL-10 has paradoxical functions. In models of acute influenza (Sun, 
Beilke et al. 2009) and herpes simplex infection (Sarangi, Sehrawat et al. 2008), IL-10 limits 
immunopathology. In contrast, IL-10 antagonizes protective immunity following high dose influenza 
challenge (McKinstry, Strutt et al. 2009) and MCMV persistence in the salivary glands (Humphreys, de 
Trez et al. 2007). Moreover, IL-10 induction during chronic lymphocytic choriomeningitis virus infection 
promotes functional dysregulation of T cells and lymphopenia, thereby enabling prolonged viral 
replication (Brooks, Trifilo et al. 2006; Ejrnaes, Filippi et al. 2006). The expression of a functional IL-10 
ortholog (vIL-10) by HCMV indicates the importance of IL-10 in the suppression of HCMV-specific 
immunity (Kotenko, Saccani et al. 2000; Slobedman, Barry et al. 2009). Intriguingly, in vitro 
experiments have demonstrated vIL-10 gene expression during latent HCMV infection (Jenkins, 
Abendroth et al. 2004) and suggest that vIL-10 may inhibit memory CD4 T cell recognition of latently 
infected cells (Cheung, Gottlieb et al. 2009). To date, however, nothing is known regarding the role of 
IL-10 in the regulation of CMV-specific memory T cell responses in vivo. 
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5.2 Hypotheses 
• The anti-inflammatory cytokine IL-10 reduces memory T cell inflation during MCMV infection. 
• The anti-inflammatory cytokine IL-10 inhibits memory T cells during chronic/latent MCMV 
infection. 
 
5.3 Specific Aims 
• To study the effect of IL-10 on memory T cell inflation during MCMV infection. 
• To determine the effect of IL-10 on the functional and phenotypic characteristics of memory 
CD8+ T cells, including Ag-specific memory CD8+ T cells, using two approaches: (i) MCMV-
infected knockout (IL-10-/-) mice; and, (ii) IL-10 receptor blockade. 
 
5.4 Results 
IL-10 limits memory CD8+ T cell expansion during MCMV infection 
In our C57BL/6 mouse model of MCMV infection, productive replication (data not shown) and late viral 
gene expression (Fig. 19A) were undetectable in the spleen and lung by 60 days post-infection. In 
contrast, viral DNA was present in both organs and virus could reactivate ex vivo in cultures of spleen 
and lung isolated as late as 110 days post-infection (Fig. 19B), thereby suggesting that MCMV 
persisted in these organs primarily in the form of latent virus.  
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Figure 19. MCMV latency is established by day 60 post-infection. (A) RNA was extracted from the 
spleen and lung, and gB (glycoprotein B) expression was measured by quantitative RT-PCR at days 7 
(n=3), 30 (n=5), 60 (n=4) and 90 (n=4) post-MCMV infection. The positive control comprised RNA 
extracted from salivary glands at day 7 post-infection. Results are expressed as mean +/- SEM. N/D, 
not detected. (B) Spleens (filled circles) and lungs (open circles) from MCMV-infected mice at day 100 
post-infection were mashed and incubated for 35 days. Every 7 days, the presence of replicating virus 
was detected by plaque assay. Results are shown as % organ pieces with viral reactivation from 5 
mice per group. The data in this figure and this figure were produced by co-investigators. 
 
Despite the absence of detectable MCMV replication from day 60, expression of IL-10 in the spleen 
(but not lung) was increased compared with uninfected mice (Fig. 20A). Flow cytometric analyses 
revealed IL-10 protein production by splenic IFN-γ+IL-17- MCMV-specific CD4+ T cells after peptide 
stimulation directly ex vivo (Fig. 20B). The frequency of IL-10-producing cells within MCMV-specific 
CD4+ T cell populations was substantially higher than that observed in IFN-γ- CD4+ T cells (3.7-8.3%, 
mean = 6.3 versus 0.08-0.3%, mean = 0.19%; p < 0.01). Splenic B cells (CD19+) and 
monocytes/macrophages (CD11b+) derived from mice 90 days post-infection were also capable of 
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producing IL-10 following ex vivo non-specific stimulation; in the case of CD11b+ cells, but not CD19+ 
cells, this MCMV-associated IL-10 production was significantly increased compared to cells derived 
from naïve mice (Fig. 20C).  
The hypothesis was that IL-10 acts to inhibit systemic and mucosal antiviral T cell responses during 
MCMV infection. To test this, the accumulation of both “stable” memory CD8+ T cells specific for a 
peptide derived from the M45 protein that is immunodominant during acute infection and “inflationary” 
memory CD8+ T cells specific for peptides derived from the M38, m139 and IE3 proteins (Munks, Cho 
et al. 2006) were measured in both wild-type C57BL/6 and IL-10-/- mice. Expression of these viral 
proteins in infected cells is thought to occur during productive replication rather than viral latency 
(Munks, Cho et al. 2006; Munks, Gold et al. 2006). During acute infection, there were comparable 
numbers of MCMV-specific CD8+ T cells in the lungs and spleens of wild-type and IL-10-/- mice (Fig. 
20D); furthermore, as infection progressed, the numbers of M45-specific memory CD8+ T cells 
remained low in the absence of IL-10 (Fig. 20D). Consistent with previously published data (Munks, 
Cho et al. 2006), high frequencies of CD8+ T cells specific for M38, m139 and IE3 were observed in 
wild-type mice at day 90 post-infection; strikingly, however, the corresponding frequencies at the same 
time-point were even higher in IL-10-/- mice (Fig. 20D). The accumulation of IE3-specific CD8+ T cells 
was most notable, representing ∼15% of all CD8+ T cells in IL-10-/- mice at day 90 post-infection (Fig. 
20E) and reaching up to 30% in some individual mice (data not shown). 
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Figure 20. IL-10 limits memory CD8+ T cell inflation during MCMV infection. (A) IL-10 expression in 
spleen extracts from naive C57BL/6 wild-type (wt) mice and wt mice infected for 90 days with MCMV 
was measured by quantitative RT-PCR and normalized to β-actin. Results represent the mean +/- 
SEM of four mice from two independent experiments. * p <0.05 with the Mann-Whitney U-test. (B) 
IFN-γ and IL-17 expression by CD4+ T cells derived from spleens of wt mice 90 days post-infection 
(top panels) following ex vivo stimulation for 16 hours with (top left panel) or without (top right panel) 
m09, M25, m139 and m142 peptides. Values in quadrants represent percent cytokine+CD4+ cells. 
Expression of IL-10 by IFN-γ+ peptide-specific CD4+ T cells from wt (bottom left panel) and IL-10-/- 
(bottom right panel) mice. Quadrants were set using fluorescence minus one controls. Results are 
representative of two experiments, each comprising four mice per group. (C) IL-10 expression by 
splenic CD19+ and CD11b+ cells derived from naïve (closed bars) and MCMV-infected (day 60 post-
infection; open bars) mice following ex vivo stimulation with LPS and PMA/ionomycin (CD19+) or LPS 
alone (CD11b+). Results are shown as the mean +/- SEM derived from two independent experiments, 
each comprising four mice per group. Ex vivo stimulation of B cells from MCMV-infected mice (day 90 
post-infection) did not induce significant apoptosis (6.6 +/- 0.4% AnnV+) as compared with freshly 
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isolated CD19+ cells (8.2 +/- 2.2% AnnV+). (D and E) Wt (closed circles) and IL-10-/- (open circles) 
mice were infected with MCMV and peptide-specific CD8+ T cells were quantified by intracellular IFN-γ 
detection. (D) Numbers of CD8+ T cells specific for M38, M45, m139 and IE3 on days 0, 7, 14, 30 and 
90 post-infection in spleen (left) and lung (right). Results are expressed as mean +/- SEM cells/organ 
of four to six mice per group, and each time-point represents four to seven experiments. * p <0.05 with 
Student's t-test. (E) Representative bivariate flow cytometry plots showing IFN-γ expression by IE3-
reactive CD8+ T cells in the spleens (top panels) and lungs (bottom panels) of wt (left panels) and IL-
10-/- (right panels) mice at day 90 post-infection. The percent CD8+ T cells expressing IFN-γ is shown; 
gates were set using the fluorescence minus one control for FITC. Results are representative of seven 
experiments, each comprising four to six mice per group. These data were generated in collaboration 
with Dr. Ian Humphreys and his laboratory. 
 
IL-10 limits the oligoclonal expansion of IE3-specific CD8+ T cells 
To investigate further the profound expansion of IE3-specific CD8+ T cells, a comprehensive and 
unbiased analysis of T cell receptor (TCR) gene usage was undertaken within the cognate populations 
isolated directly ex vivo from both wild-type and IL-10-/- mice (Fig. 21 and, for complete data set, Fig. 
22). In both sets of mice at day 90 post-infection, the IE3-specific TCR repertoires were oligoclonal 
and highly skewed towards the usage of only a few dominant clonotypes; this is consistent with 
previous studies of HCMV-specific CD8+ T cell populations (Price, Brenchley et al. 2005). Moreover, a 
diverse array of clonotypic structures was apparent in both wild-type and IL-10-/- mice, although with a 
strong bias towards TRBV16 usage (Fig. 21 and Fig. 22). Similar patterns were observed as late as 
day 282 post-infection, at which time IE3-specific CD8+ T cells dominated the response in IL-10-/- mice 
(Figs. 23, 24 and 25). In addition, a substantial degree of differentially encoded inter-individual TCR 
sharing was apparent (Figs. 21, 22, 24 and 25); this is consistent with recent studies demonstrating 
the role of convergent recombination in the generation of "public" clonotypes, which can affect the 
outcome of infection in certain circumstances (Venturi, Price et al. 2008; Price, Asher et al. 2009). 
Overall, these data suggest that the enhanced inflation of IE3-specific CD8+ T cells in IL-10-/- mice is 
due to the expansion of clonotypes selected within the memory pool rather than the recruitment of 
greater numbers of cognate clonotypes from the naïve pool (Vezys, Masopust et al. 2006). 
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Figure 21. Oligoconal expansion of IE-3 specific CD8+ T cells during MCMV infection. TCRB CDR3 
amino acid sequences, TCRBV (TCRB variable) and TCRBJ (TCRB joining) usage, and the relative 
frequencies of individual clonotypes within viable CD3+CD8+IE3-tetramer+ cell populations isolated by 
flow cytometric sorting from wt (A) and IL-10-/- (B) mice at day 90 post-MCMV infection. Three 
representative mice are shown per group; coloured boxes represent shared clonotypes that were 
detected in other individual mice. The full data set is shown in Fig. 22; analyses from later time-points 
are shown in Fig. 24 (day 142 post-infection) and Fig. 25 (day 282 post-infection).  
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Figure 22. Clonotypic analysis of IE3-specific CD8+ T cell populations at day 90 post-MCMV infection. 
TCRB CDR3 amino acid sequences, TCRBV and TCRBJ usage, and the relative frequencies of 
individual clonotypes within viable CD3+CD8+IE3-tetramer+ cell populations isolated by flow cytometric 
sorting from wt (A) and IL-10-/- (B) mice at day 90 post-MCMV infection. Coloured boxes depict shared 
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clonotypes that were detected in other individual mice. 
 
 
Figure 23. Increased accumulation of IE3-specific CD8+ T cells in IL-10-/- mice 10 months post-
infection. Wt (closed bars) and IL-10-/- (open bars) mice were infected with MCMV; peptide-specific 
CD8+ T cells were detected by IFN-γ expression 282 days later. (A) Representative bivariate flow 
cytometry plots showing IFN-γ expression by IE3-specific CD8+ T cells from spleens of wt (top panel) 
and IL-10-/- (bottom panel) mice. (B) Splenic peptide-specific CD8+ T cells were enumerated. Results 
are expressed as mean +/- SEM of three to four mice per group and are representative of 2 
independent experiments. Significance is indicated by *, which represents p <0.05 with Student's t-
test. These data were generated in collaboration with Dr. Ian Humphreys and his laboratory. 
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Figure 24. Clonotypic analysis of IE3-specific CD8+ T cell populations at day 142 post-MCMV 
infection. TCRB CDR3 amino acid sequences, TCRBV and TCRBJ usage, and the relative 
frequencies of individual clonotypes within viable CD3+CD8+IE3-tetramer+ cell populations isolated by 
flow cytometric sorting from wt (A) and IL-10-/- (B) mice at day 142 post-MCMV infection. Coloured 
boxes depict shared clonotypes that were detected in other individual mice. 
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Figure 25. Clonotypic analysis of IE3-specific CD8+ T cell populations at day 282 post-MCMV 
infection. TCRB CDR3 amino acid sequences, TCRBV and TCRBJ usage, and the relative 
frequencies of individual clonotypes within viable CD3+CD8+IE3-tetramer+ cell populations isolated by 
flow cytometric sorting from wt (A) and IL-10-/- (B) mice at day 282 post-MCMV infection. Coloured 
boxes depict shared clonotypes that were detected in other individual mice. 
 
Enhanced MCMV-specific CD4+ T cell and professional APC accumulation in IL-10-/- mice during 
MCMV infection 
CD4+ T cells promote MCMV-specific memory CD8+ T cell expansion (Humphreys, Loewendorf et al. 
2007; Snyder, Loewendorf et al. 2009). Therefore, the accumulation of virus-specific memory CD4+ T 
cell populations was measured in wild-type and IL-10-/- mice, investigating previously described 
distinct CD4+ T cell populations with specificities for four different viral proteins (m09, M25, m139, 
m142) that are associated with active viral replication (Arens, Wang et al. 2008). Interestingly, it was 
found that enhanced CD8+ T cell accumulation in IL-10-/- mice at day 90 post-infection was 
accompanied by a large increase in the number of IFN-γ-expressing CD4+ T cells in the spleen (Fig. 
26A and 26B) and lung (Fig. 26C and 26D), detected following ex vivo stimulation with MCMV-derived 
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MHC class II-restricted peptides (Fig. 26A and 26C) or PMA and ionomycin (Fig. 26B and 26D). IL-10 
can inhibit CD4+ T cells by suppressing the function of professional APCs (Moore, O'Garra et al. 1993; 
O'Garra, Barrat et al. 2008) and MCMV-induced IL-10 inhibits MHC class II expression (Redpath, 
Angulo et al. 1999). In accordance, more splenic DCs (Fig. 26E and 26F), splenic inflammatory 
monocytes (Fig. 26G), and pulmonary macrophages (Fig. 26H) were observed in IL-10-/- mice 
compared to wild-type mice. In contrast, B cell accumulation was comparable in spleens and lungs of 
wild-type and IL-10-/- mice (data not shown). 
 
Figure 26. Elevated CD4+ T cell accumulation at day 90 following MCMV infection of IL-10-/- mice. 
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IFNγ-expressing CD4+ T cells in the spleens (A, B) and lungs (C, D) of wt (closed bars) and IL-10-/- 
(open bars) mice at day 90 post-infection following stimulation with peptide (A, C) or PMA and 
ionomycin (B, D). Undetectable virus-specific CD4+ T cells were expressed as an arbitrary value of 1 
cell for statistical analyses. (E) Representative flow cytometric analyses of splenic CD11chiMHCII+ 
dendritic cells from wt (left panel) and IL-10-/- (right panel) mice at day 90 post-infection. Splenic 
CD11chiMHCII+ dendritic cells (F), CD11b+CD11c-Gr1lo/-7/4+ monocytes (G), and lung 
CD11cintCD11b+Gr1lo/-F4/80+ macrophages (H) from wt (closed bars) and IL-10-/- (open bars) mice at 
day 90 post-infection were enumerated. Results represent mean +/- SEM of two to three independent 
experiments, each comprising four mice per group. * p <0.05 with Student's t-test. These data were 
generated in collaboration with Dr. Ian Humphreys and his laboratory. 
 
IL-10 inhibition of CD8+ T cell memory occurs during acute and chronic/latent MCMV infection 
MCMV-specific memory CD8+ T cell populations are derived both from cells primed during acute 
infection and from more recent thymic emigrants (Snyder, Cho et al. 2008). Given that IL-10 is 
expressed during acute MCMV infection (Arens, Wang et al. 2008; Oakley, Garvy et al. 2008; Walton, 
Wyrsch et al. 2008; Madan, Demircik et al. 2009), and enhances CD4+ (Oakley, Garvy et al. 2008) 
and, in some models, CD8+ T cell responses (Madan, Demircik et al. 2009), the time point at which IL-
10 exerts its inhibitory effect was examined next. 
Blockade of IL-10R signalling during initial T cell priming using a monoclonal antibody at the time of 
infection did not significantly influence CD8+ T cell numbers specific for M38 and m139 at day 96 post-
infection (Fig. 27A). However, IE3-specific CD8+ T cells, which are generally undetectable in the first 
week of infection (Munks, Cho et al. 2006; Snyder, Cho et al. 2008), were enhanced ~2-fold at the day 
96 time point (Fig. 27A). This was accompanied by a transient expansion of MCMV-specific CD4+ T 
cell numbers at day 7 (Fig. 27B) but not day 90 (data not shown) post-infection. 
Next, IL-10R signalling was inhibited from day 60 post-infection. Importantly, CD8+ T cell populations 
specific for M38, m139 and IE3 were all substantially increased (3- to 4-fold) following late IL-10R 
blockade (Fig. 27C and 27D), as were MCMV-specific CD4+ T cells (Fig. 27E). In the case of IE3-
specific CD8+ T cells, this increased accumulation was more dramatic than that observed after early 
 107 
IL-10R blockade (Fig. 27A). Thus, IL-10 primarily limits memory T cell accumulation during the 
chronic/latent phase of infection. 
 
Figure 27. IL-10 inhibits memory CD8+ T cells during acute and chronic/latent MCMV infection. (A, B) 
MCMV-infected wt mice were treated with IgG (closed bars) or αIL-10R (open bars) on day 0, and 
peptide-specific CD8+ (A) and CD4+ (B) T cells were enumerated at day 96 (A) and day 7 (B) post-
infection. (C-E) Wt mice were treated with IgG or αIL-10R on days 60, 67, 74, and 81 post-infection. 
(C) Representative bivariate flow cytometry plots showing IFN-γ expression by CD8+ T cells specific 
for M38, m139 and IE3 at day 90 post-infection from mice treated with IgG (top panels) or αIL-10R 
(bottom panels). Peptide-specific CD8+ (D) and CD4+ (E) T cells were enumerated at day 90 post-
infection. MCMV-specific CD4+ T cells were stimulated with pooled m09, M25, m139 and m142 
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peptides. Results are expressed as the mean +/- SEM of two independent experiments, each 
comprising four mice per group. * p <0.05 with Student's t-test. These data were generated in 
collaboration with Dr. Ian Humphreys and his laboratory. 
 
CD27 expression is down-regulated by MCMV-specific CD8+ T cells from IL-10-/- mice 
In contrast to the phenotypic heterogeneity of the total CD8+ T cell population (Fig. 28A), inflationary 
MCMV-specific memory CD8+ T cells from wild-type mice were CD44hiCD62Llo (Fig. 28A), consistent 
with an effector memory status. Furthermore, these highly differentiated cells expressed high levels of 
KLRG-1 and low levels of CD27 (Fig. 28A). Memory CD8+ T cells specific for MCMV from IL-10-/- mice 
were also CD44hiCD62Llo (Fig. 28A). Notably, however, the frequency of KLRG-1+CD27- MCMV-
specific CD8+ T cells was even higher in IL-10-/- mice (Fig. 28A, 28B) and down-regulation of CD27 
was more pronounced (Fig. 28A, 28C). In addition, receptors for the homeostatic cytokines IL-7 and 
IL-15 were not up-regulated by CD8+ T cells from IL-10-/- mice (data not shown). Collectively, these 
data suggest that IL-10 does not inhibit memory CD8+ T cells via the regulation of inhibitory or 
cytokine receptor expression; furthermore, it seems that the enhanced expansion of inflationary 
MCMV-specific CD8+ T cells in the absence of IL-10 is associated with more advanced differentiation. 
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Figure 28. IL-10-/- MCMV-specific CD8+ T cells are highly differentiated. MCMV-specific CD8+ T cells 
from spleens of wt and IL-10-/- mice were detected with cognate tetramers and co-expression of CD27, 
KLRG-1, CD44, and CD62L was examined. (A) Co-expression of CD27 and KLRG-1 (left panels), and 
CD62L and CD44 (right panels), by CD3+CD8+tetramer+ cells (coloured dots) and total CD3+CD8+ 
cells (black/grey) from spleens of wt (left panels in each set) and IL-10-/- (right panels in each set) 
mice. (B, C) The frequencies of KLRG-1+CD27- CD3+CD8+tetramer+ cells (B) and the median 
fluorescence intensity (MFI) of CD27 expression by CD3+CD8+tetramer+ cells (C) were assessed. In 
IL-10-/- mice, the percent KLRG-1+CD27- cells in the total CD3+CD8+ population was not significantly 
decreased (wt = 23.5, IL-10-/- = 24.1; p = 0.91) nor was the CD27 MFI (wt = 2564.75, IL-10-/- = 1979.5; 
p = 0.22). Results are expressed as the mean +/- SEM of three experiments, each comprising three to 
four mice per group. * p <0.05 with Student's t-test. These data were generated in collaboration with 
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Dr. Ian Humphreys and his laboratory. 
 
IL-10 restricts the accumulation of functional MCMV-specific CD8+ T cells 
Next, it was hypothesized that IL-10 limits the accumulation of functional antiviral memory CD8+ T 
cells. Hence, cytokine production by MCMV-specific CD8+ T cells was examined. A low proportion (6-
10%) of wild-type MCMV-specific IFN-γ+ CD8+ T cells co-expressed IL-2 following ex vivo peptide 
stimulation and this was further reduced (2-4%) in IL-10-/- mice (Fig. 29A). In contrast, IL-10 deficiency 
increased both the proportion (Fig. 29A) and the total number (Fig. 29B) of MCMV-specific IFN-γ+ 
CD8+ T cells capable of co-expressing the antiviral cytokine TNF. Recent degranulation based on cell 
surface CD107a mobilization was also quantified and greater numbers of CD107a+ MCMV-specific 
CD8+ T cells were observed in the spleens and lungs of IL-10-/- mice compared to wild-type mice after 
ex vivo peptide stimulation (Fig. 29C). Importantly, IL-10R blockade in wild-type mice from day 60 
post-infection also led to an increase in the numbers of virus-specific CD8+ T cells that expressed TNF 
(Fig. 29D) and degranulated (Fig. 29E) in response to peptide stimulation. Collectively, these data 
suggest that IL-10 restricts the accumulation of functional memory CD8+ T cells. 
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Figure 29. IL-10 limits the accumulation of functional antiviral CD8+ T cells during MCMV infection. 
TNF, IL-2 and CD107a expression by IFN-γ+ MCMV peptide-specific CD8+ T cells from wt and IL-10-/- 
mice (A-C) and wt mice treated with IgG or αIL-10R (D, E) was assessed at day 90 post-infection. (A) 
Representative bivariate flow cytometry plots showing TNF versus IL2 expression by IFN-γ- CD8+ T 
cells (control) and IFN-γ+ peptide-specific splenic CD8+ T cells from wt (top panels) and IL-10-/- (bottom 
panels) mice. Results are representative of four experiments, each comprising four to five mice per 
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group. (B-E) Numbers of peptide-specific CD8+ T cells expressing TNF (B, D) and surface CD107a 
(C, E) in the spleens (left panels) and lungs (right panels) of wt (closed bars) and IL-10-/- (open bars) 
mice (B, C) and wt mice treated with IgG (closed bars) or αIL-10R (open bars) on days 60, 67, 74 and 
81 post-infection (D, E). All results are representative of three experiments and show the mean +/- 
SEM of evaluations conducted with four to five mice per group. * p <0.05 with Student's t-test. These 
data were generated in collaboration with Dr. Ian Humphreys and his laboratory. 
 
Latent virus load is reduced in the absence of IL-10R signalling 
To determine whether the increased CD8+ T cell responses in IL-10-/- mice reduced latent viral load, 
MCMV genome content in the lung and spleen was examined. No significant differences were 
observed at the peak of the primary T cell response (day 7 post-infection, data not shown) or at day 60 
post-infection (Fig. 30A). Critically, however, viral DNA load was significantly reduced in both the 
spleens and lungs of IL-10-/- mice at day 90 post-infection (Fig. 30B). Importantly, late (from day 60 
onwards) blockade of IL-10R in wild-type mice also led to a reduction in viral DNA load in spleen and 
lung at this time (Fig. 30C).  
 113 
 
Figure 30. IL-10 increases latent MCMV load during infection. Genomic DNA was isolated from the 
spleens and lungs of wt (closed bars) and IL-10-/- (open bars) mice at days 60 (A) and 90 (B) post-
infection. (C) Infected wt mice were treated on days 60, 67, 74 and 81 with IgG (closed bars) or αIL-
10R (open bars) and genomic DNA was isolated from the spleens and lungs at day 90 post-infection. 
MCMV gB was detected by quantitative PCR and data expressed as genome copy number per 100 ng 
genomic DNA; horizontal dashed lines depict the lower limit of detection. Results are representative of 
two independent experiments and show the mean +/- SEM of evaluations conducted with five to 
fifteen mice per group. * p <0.05 with the Mann-Whitney U-test. These data were generated in 
collaboration with Dr. Ian Humphreys and his laboratory. 
 
5.5 Discussion 
Herein, it is reported that IL-10 suppresses CMV-specific memory T cell inflation. The key findings of 
this study were that: (i) chronic/latent MCMV infection was associated with IL-10 production by 
macrophages and virus-specific IFN-γ-expressing CD4+ T cells; (ii) mice deficient in IL-10 exhibited a 
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profound increase in MCMV-specific CD8+ T cell accumulation and antiviral cytokine production; (iii) 
IL-10 suppressed the oligoclonal expansion of memory CD8+ T cells; (iv) MCMV viral genome load 
was reduced in IL-10-/- mice; and, (v) the enhanced memory CD8+ T cell expansion and reduced viral 
load observed in IL-10-/- mice was recapitulated by delayed IL-10R blockade in wild-type mice. 
Collectively, these data demonstrate that IL-10 restricts the accumulation of functional MCMV-specific 
memory T cells during MCMV infection.  
In vivo, MCMV infection leads to chronic activation of APCs (Barton, White et al. 2007) and the 
generation of highly differentiated, activated memory CD8+ T cells (Sierro, Rothkopf et al. 2005; 
Snyder, Cho et al. 2008); these observations suggest that, after the resolution of acute infection, mice 
harbour non-replicating, reactivating and, possibly, low levels of chronically replicating CMV that drives 
the immune activation (Klenerman and Hill 2005; Reddehase, Simon et al. 2008; Virgin, Wherry et al. 
2009). In the current study, 3.7%-8.3% of splenic IFN-γ+ MCMV-specific memory CD4+ T cells from 
MCMV-infected mice expressed IL-10. The production of IL-10 by Th1-like cells is triggered by chronic 
stimulation in parasitic infections (Anderson, Oukka et al. 2007; Jankovic, Kullberg et al. 2007), and 
prolonged stimulation of HCMV-specific CD4+ T cells in vitro induces IL-10/IFN-γ co-expression 
(Haringer, Lozza et al. 2009). Similarly, it was observed that MCMV infection led to an increased 
frequency of IL-10-expressing CD11b+ cells. Although one cannot exclude the possibility that MCMV 
may encode a protein(s) that selectively induces IL-10 expression by these cell subsets, the data 
imply that IL-10 expression by MCMV-specific CD4+ T cells and monocytes/macrophages is a 
consequence of chronic activation which, in this model, is likely to be provided by persistent viral 
reactivation from latency and, possibly, undetectable chronic replication.  
B cells are a significant source of IL-10 during acute systemic MCMV infection (Madan, Demircik et al. 
2009). Although chronic/latent infection did not increase the proportion of IL-10-producing CD19+ cells 
in the spleen as compared with naïve mice, the possible importance of this cell subset cannot be 
exlcuded. Intracellular cytokine staining is a relatively insensitive technique and may therefore 
underestimate the frequency of IL-10-producing CD19+ cells. Furthermore, given that ~50% of 
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splenocytes were CD19+ at day 90 post-infection (unpublished observation), even the small 
percentage of CD19+ IL-10 producers suggested by our data could have a significant impact on 
antiviral immunity.  
Interestingly, although IL-10 expression was detected in the lungs of mice at day 90 post-infection, this 
was not increased compared to naïve controls (data not shown). Whether or not this reflects the small 
numbers of virus-specific CD4+ T cells in the lungs of chronic/latently infected mice in our model, or 
the presence of IL-10-producing interstitial macrophages (Bedoret, Wallemacq et al. 2009) in both 
uninfected and infected mice, is not clear.   
The amplification of CD8+ T cell inflation in IL-10-/- mice was striking and maintained 10 months post-
infection without causing overt signs of disease (weight loss and cachexia) or pathology (unpublished 
observation). In some models, IL-10 directly inhibits CD8+ T cells (Taga and Tosato 1992; Rohrer and 
Coggin 1995), whereas in other situations IL-10 actually promotes primary (Kang and Allen 2005) and 
memory CD8+ T cell responses (Kang and Allen 2005; Foulds, Rotte et al. 2006). In our system, 
inflationary CD8+ T cells expressed low levels of IL-10R (data not shown), thereby suggesting that 
these cells might be refractory to direct IL-10-mediated effects. Interestingly, enhanced CD8+ T cell 
responses in IL-10-/- mice were accompanied by increased numbers of CD4+ T cells and APCs. 
Inflationary CD8+ T cell responses are partially dependent upon CD4+ T cells (Humphreys, 
Loewendorf et al. 2007; Snyder, Loewendorf et al. 2009), thereby implying that elevated CD4+ T cell 
help in IL-10-/- mice promoted CD8+ T cell expansion. Interestingly, IE3-specific CD8+ T cells, which 
are more sensitive to CD4+ T cell depletion than other memory CD8+ T cells (Snyder, Loewendorf et 
al. 2009), were preferentially expanded in IL-10-/- mice. Collectively, these data suggest that IL-10 
limits memory CD8+ T cell expansion via the abrogation of effective CD4+ T cell help. 
Expansion of CD8+ T cell numbers was not observed 7 days post-infection, as reported previously 
(Oakley, Garvy et al. 2008). Primary MCMV-specific CD8+ T cell responses occur independently of 
CD4+ T cell help (Humphreys, Loewendorf et al. 2007; Snyder, Loewendorf et al. 2009), suggesting 
that IL-10-mediated inhibition of CD4+ T cells only limits memory CD8+ cells. Interestingly, however, B 
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cell-derived IL-10 inhibits primary CD8+ T cell responses following sub-cutaneous infection (Madan, 
Demircik et al. 2009). Whether or not these differences reflect the different mouse strains or infection 
routes used in this study, variation in how peptide-specific CD8+ T cells were enumerated 
(percentages versus total numbers of splenic CD8+ T cells) or the fact that the IL-10-/- mice were 
housed in specific pathogen-free conditions (and subsequently no colitis was observed in aged naïve 
mice or mice infected with MCMV for 14 months; data not shown), is unclear.  
The increased expansion of CD8+ T cells in IL-10-/- mice was not due to altered expression of cytokine 
receptors (CD122, CD127) or the absence of inhibitory molecules (KLRG-1). However, it is known that 
virus-specific CD8+ T cells down-regulate CD27 during latent MCMV infection (Baars, Sierro et al. 
2005; Sierro, Rothkopf et al. 2005), and expression of this surface marker was further reduced in IL-
10-/- mice. One possible functional consequence of CD27 down-regulation in this study was reduced 
IL-2 production in response to Ag stimulation; this is consistent with previous studies linking cellular 
differentiation to the loss of IL-2 expression (Precopio, Betts et al. 2007; Usharauli and Kamala 2008) 
and suggests a role for CD4+ T cell help in the maintenance of polyfunctional memory CD8+ T cells 
(Matter, Claus et al. 2008). Furthermore, highly differentiated CD8+ T cells express high levels of 
granzyme and perforin (Baars, Sierro et al. 2005; Takata and Takiguchi 2006; Chattopadhyay, Betts et 
al. 2009), thereby suggesting that these cells are cytotoxic. The increased accumulation in IL-10-/- 
mice of CD8+ T cells that degranulate more readily on cognate Ag encounter further supports the 
conclusion that IL-10 restricts MCMV-specific cytotoxic T cell responses.  
In chronic lymphocytic choriomeningitis virus infection, dysregulated TNF production by CD8+ T cells 
is rescued in IL-10-/- mice (Brooks, Trifilo et al. 2006). However, in MCMV infection, virus-specific CD8+ 
T cells sustain pro-inflammatory cytokine expression during latency (Snyder, Cho et al. 2008). Indeed, 
60-70% of virus-specific IFN-γ-producing CD8+ T cells in wild-type mice co-expressed TNF. Therefore, 
enhanced TNF production by IL-10-/- CD8+ T cells probably reflects increased activation rather than 
reversal of defective function. Furthermore, CD8+ T cell functionality was not enhanced on a per cell 
basis following IL-10R blockade in wild-type mice (data not shown), highlighting that the qualitative 
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restriction of CD8+ T cell function by IL-10 was comparatively small as compared to the large effect on 
T cell numbers. Collectively, these data suggest that IL-10 predominately regulates inflationary CD8+ T 
cell responses by inhibiting cellular accumulation at sites of viral infection.  
Importantly, MCMV burden was reduced in IL-10-/- mice and wild-type mice treated with an IL-10R 
blocking antibody. Expanded CD8+ T cells in both situations were reactive to several viral proteins 
expressed during active replication, thereby implying that these cells do not directly recognize latently 
infected cells. Of particular interest was the expansion of IE3-specific CD8+ T cells. IE genes are 
expressed during the early stages of viral replication, and IE3 is a checkpoint gene involved in the 
maintenance of latency (Kurz and Reddehase 1999). Patrolling IE-specific CD8+ T cells may detect 
early reactivation events (Simon, Seckert et al. 2006). It is therefore possible that the increased 
frequency of Ag recognition by IE3-specific cells may contribute to the more dramatic effect of IL-10 on 
this population. In support of this hypothesis, latent MCMV infection of BALB/c mice induces the 
inflation of IE1-specific CD8+ T cells (Holtappels, Pahl-Seibert et al. 2000; Karrer, Sierro et al. 2003) 
that terminate viral reactivation in vivo (Simon, Holtappels et al. 2006). Alternatively, however, it is 
conceivable that enhanced memory T cell responses in the absence of IL-10R signalling may inhibit 
low levels of undetectable chronic replication which, in turn, restricts the establishment of latent 
infection in the spleen and lung.  
The exact mechanism by which expanded CD8+ T cells reduced viral load following IL-10 gene 
deletion or IL-10R blockade is also unclear. Both approaches led to enhanced numbers of CD8+ T 
cells in the spleen and lung that could degranulate efficiently; in conjunction with the reduced levels of 
CD27 expression, this implies an enhanced capability to kill cells harbouring reactivating and/or 
replicating virus. Indeed, elevated TNF secretion by CD8+ T cells in the absence of IL-10R signalling 
may promote splicing of IE3 transcripts and subsequent viral reactivation (Simon, Seckert et al. 2005). 
In this situation, which could be implied by the preferential expansion of IE3-specific CD8+ T cells in IL-
10-/- mice, increased numbers of cytotoxic T cells would detect and kill cells harbouring this 
reactivating virus. Alternatively, increased accumulation of T cells expressing IFN-γ and TNF might 
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directly inhibit late gene expression during viral reactivation and/or replication (Gribaudo, Ravaglia et 
al. 1993; Lucin, Jonjic et al. 1994; Presti, Pollock et al. 1998), and may also activate secondary 
antiviral mechanisms mediated by other cell types, such as macrophages and NK cells (Weigent, 
Stanton et al. 1983; Heise and Virgin 1995; Orange and Biron 1996).  
The factors that determine whether an MCMV-specific CD8+ T cell population inflates are currently 
unknown. However, the observation that inflationary but not stable memory CD8+ T cells are 
enhanced in IL-10-/- mice implies that IL-10 is not a determining factor in this process. Rather, IL-10 
appears to limit the expansion of memory CD8+ T cells that are already dividing during chronic/latent 
infection.  
The data presented here provide evidence that, as suggested previously (Jenkins, Garcia et al. 2008; 
Cheung, Gottlieb et al. 2009), IL-10 orthologs expressed by herpesviruses including HCMV (Kotenko, 
Saccani et al. 2000) and Epstein-Barr virus (Hsu, de Waal Malefyt et al. 1990) may function to 
preserve latent viral load within the host. It should be noted, however, that MCMV does not encode an 
obvious IL-10 ortholog, and the kinetics and locality of expression of host and viral IL-10 proteins may 
differ in vivo. Furthermore, HCMV (Spencer, Cadaoas et al. 2008) and Epstein-Barr virus (Rousset, 
Garcia et al. 1992) IL-10 orthologs promote B cell growth and differentiation, whereas in this model no 
effect of murine IL-10 on B cell accumulation was observed. Although it was hypothesized that the 
increased numbers of CD4+ T cells in IL-10-/- mice may compensate for the absence of direct IL-10R 
signalling in B cells, the possibility cannot be excluded that mammalian and viral IL-10 proteins could 
function differently in vivo. Irrespective, these data clearly highlight the previously unappreciated role 
for mammalian IL-10 in the regulation of memory T cell inflation in vivo and suggest that this immune 
regulatory pathway could be manipulated to promote the accumulation of functional antiviral memory T 
cells.   
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CHAPTER 
6 
Expansion of highly differentiated CD8+ T cells or NK cells in patients treated with dasatinib is 
associated with cytomegalovirus reactivation 
 
6.1 Introduction 
Chronic myeloid leukaemia (CML) epitomizes the concept of a haematological malignancy caused by 
dysregulated signal transduction. More than 90% of all CML patients have the translocation t(9;22), 
which leads to the formation of a BCR–ABL fusion protein with continuous tyrosine kinase activity that 
is responsible for the malignant phenotype. Specific tyrosine kinase inhibitor therapy with imatinib 
(Glivec/Gleevec, Novartis, Basel, Switzerland) is the gold standard for the treatment of CML (Druker, 
Guilhot et al. 2006). However, as imatinib resistance or intolerance may occur, second-line tyrosine 
kinase inhibitors have entered the clinic; examples include nilotinib (Tasigna, Novartis) (Kantarjian, 
Giles et al. 2007), which is highly selective, and dasatinib (Sprycel, Bristol-Myers Squibb, New York, 
NY, USA) (Hochhaus, Baccarani et al. 2008). In addition to BCR-ABL, dasatinib also targets SRC and 
TEC kinases that are known to be key players in the regulation of immune responses (Bantscheff, 
Eberhard et al. 2007; Rix, Hantschel et al. 2007). The broader target profile of dasatinib implies less 
susceptibility to the development of resistance, but also the potential for more potent modulation of 
immune cell subsets. Indeed, immunosuppressive effects on T cells and NK cells have been 
described in vitro for dasatinib (Fei, Yu et al. 2008; Schade, Schieven et al. 2008; Weichsel, Dix et al. 
2008; Fraser, Blake et al. 2009) and other tyrosine kinase inhibitors (Seggewiss, Lore et al. 2005; 
Chen, Schmitt et al. 2008; Blake, Lyons et al. 2009). This is in line with observations in single center 
clinical case series (Sillaber, Herrmann et al. 2009). However, in large phase II/III clinical trials, 
increased infection rates due to immunosuppression have not been observed (Kantarjian, Shah et al. 
2010). 
Recently, in a subset of CML or Ph+ ALL patients receiving dasatinib, the development of a chronic, 
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oscillating lymphocytosis has been observed in vivo. This dasatinib-induced lymphocytosis typically 
comprises monoclonal or oligoclonal CD8+ T cell or NK cell LGL expansions and is associated with 
enhanced, long-lasting therapeutic responses in patients with advanced leukaemia (Kim, Kamel-Reid 
et al. 2009; Mustjoki, Ekblom et al. 2009). The CD8+ T cell or NK cell clones are present during the 
diagnostic phase of the disease and expand with dasatinib therapy, leading to a numerical and 
fractional lymphocytosis (Kreutzman, Juvonen et al. 2010). Thus, dasatinib does not induce these 
clones, but rather appears to promote their preferential expansion. 
 
6.2 Hypotheses 
• Lymphocyte populations in dasatinib-associated LGL patients are differentiated effector 
memory T cells or NK cells. 
• LGL patients have elevated cytokine/chemokine levels due to a direct or indirect 
immunostimulatory effect of dasatinib treatment.  
• The LGL expansions that are linked to a favourable outcome during dasatinib therapy are 
associated with CMV reactivation. 
 
6.3 Specific Aims 
• To determine the phenotypic characteristics of T cell subsets and NK cells in patients on 
continuous dasatinib treatment with and without LGL expansions using polychromatic flow 
cytometry.  
• To elucidate the mechanisms underlying dasatinib-associated LGL expansions in more detail 
by measuring directly ex vivo T cell and NK cell effector functions such as activation, 
proliferation, degranulation, cytotoxicity and the secretion of soluble factors in PBMC samples 
treated in vitro with clinically relevant doses of 10 and 50nM, thereby mimicking peak and 
steady state concentrations (Brave, Goodman et al. 2008; Weichsel, Dix et al. 2008). 
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• To assay plasma samples for soluble immune mediators and CMV load. 
 
6.4 Results 
Association of LGL expansions with CMV seropositivity, CMV reactivation and elevated plasma levels 
of IP-10, IL-6, MIG and IL-2R 
15/16 patients in our cohort with LGL expansions were CMV IgG seropositive (IgG serostatus only 
unknown for patient 9), whereas only 3/9 non-LGL patients were CMV IgG seropositive (Table 3). 
Most patients with LGL expansions also exhibited high frequencies of CMV-specific CD8+ T cells 
(range, 0.7-15.6% of the total CD3+ T cell pool) as determined by staining with pHLA-A*0201 
tetrameric complexes bearing the immunodominant pp65-derived (residues 495-503) epitope 
NLVPMVATV (Table 4). Of note, 5/16 LGL patients and 0/9 non-LGL patients experienced 
symptomatic (persistent low-grade fever) CMV reactivations (Table 3), which were confirmed by PCR. 
However, it should be noted that CMV load measurements were not performed in asymptomatic 
patients. There was no evidence for reactivation of other herpes viruses. In addition, significantly 
elevated levels of IP-10 (CXCL10), IL-6, MIG (CXCL9) and IL-2R were present in the plasma of 
patients with LGL expansions compared to healthy controls (Fig. 31). Notably, the highest plasma 
levels of these soluble factors were detected in the patients who experienced symptomatic CMV 
reactivations during dasatinib therapy (Fig. 31). These data are consistent with previous studies, which 
have demonstrated increased levels of IFN-γ stimulated gene products, such as IP-10 and MIG, in the 
plasma of patients with LGL expansions unrelated to dasatinib treatment (Wlodarski, Nearman et al. 
2008). There were no significant differences between groups for any of the other 21 soluble factors 
measured in plasma. Thus, the cytokine perturbations in patients with dasatinib-associated LGL 
expansions are restricted and may reflect virus-specific responses dominated by IFN-γ rather than 
general immune activation. 
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Table 3. Characteristics of study patients with and without LGL expansions during treatment with 
dasatinib for CML or ALL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Dg, diagnosis; ALL, acute lymphoblastic leukaemia; Ph+, positive Philadelphia 
chromosome; CML, chronic myeloid leukaemia; CP, chronic phase; BC, blast crisis; CCgR; complete 
cytogenetic response; CMR, complete molecular response; MMR, major molecular response; CHR, 
complete haematological response; CMV, cytomegalovirus; copies/mL, genome copies/mL of plasma; 
Pt 
no  
Dg Age* 
(yrs) 
Gender Therapy 
response 
Duration 
(months) 
LGL 
lymphocytosis 
and 
phenotype 
Clonality 
status** 
CMV 
serology 
CMV 
reactivation 
(copies/mL) 
HLA-
A*02 
1 ALL 
t(1;9) 
43 Male CCgR 35a Yes; T cell TCRγ 
TCRδ 
Pos Yes, max 700 Pos 
2 Ph+ 
ALL 
48 Male CMR 5 Yes; T cell TCRγ  Pos Yes max 
2500 
Pos 
3 Ph+ 
ALL 
52 Female CMR 6  Yes; T cell ND Pos NS Pos 
4 Ph+ 
ALL 
70 Female CCgR 23 a Yes; T + NK 
cell 
ND Pos NS Neg 
5 Ph+ 
ALL 
76 Female MMR 4 a Yes; T + NK 
cell 
ND Pos NS Neg 
6 CML 
BC 
62 Female CMR 16 Yes; T + NK 
cell 
TCRγ 
TCRδ 
Pos Yes, max 
7500 
Pos 
7 CML 
BC 
43 Male CMR 45 Yes; T cell TCRγ 
TCRδ 
Pos Yes, max 
6200 
Pos 
8 CML 
CP 
48 Female MMR 19 a Yes; NK cell ND Pos NS Neg 
9 CML 
CP 
52 Female MMR 6 a Yes; T cell TCRγ ND NS ND 
10 CML 
CP 
58 Female CMR 48 Yes; NK cell TCRδ Pos NS Pos 
11 CML 
CP 
61 Female MMR 6 a Yes; T + NK 
cell 
TCRγ 
TCRδ 
Pos NS Pos 
12 CML 
CP 
64 Female CMR 6 Yes; T cell ND Pos Yes, max 
15100 
Neg 
13 CML 
CP 
65 Female MMR 36 a Yes; T + NK 
cell 
TCRγ 
TCRδ 
Pos NS Pos 
14 CML 
CP 
52 Male CMR 7 Yes; T cell TCRγ Pos NS Pos 
15 CML 
CP 
60 Male CMR 39 Yes; T cell TCRγ 
TCRδ 
Pos NS Pos 
16 CML 
CP 
76 Male CMR 59 Yes; NK cell TCRγ 
TCRδ 
Pos NS Pos 
17 CML 
CP 
29 Female CMR 58 a No TCRγ Pos NS Pos 
18 CML 
CP 
64 Female MMR 37 a No TCRγ Neg NS Pos 
19 CML 
CP 
71 Female CMR 6 a No ND Pos NS Pos 
20 CML 
CP 
27 Male MMR 22 No No Neg NS Pos 
21 CML 
CP 
40 Male MMR 54 a No TCRγ Neg NS Pos 
22 CML 
CP 
49 Male CCgR 57 a No TCRγ Pos NS Neg 
23 CML 
CP 
61 Male CMR 25 a No No Neg NS Neg 
24 CML 
CP 
66 Male MMR 20 a No ND Neg NS Neg 
25 CML 
CP 
71 Male CHR 21 a No ND Neg NS Pos 
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NS, no symptoms, plasma CMV DNA viral load not analyzed; ND, not done. *Age at the time of 
sampling. a Therapy ongoing. ** Clonality of lymphocytes was confirmed by analyzing T cell receptor 
(TCR) γ- and δ-gene rearrangements by PCR as described earlier (Kreutzman, Juvonen et al. 2010). 
Of note, clonal TCR rearrangments were found in most LGL and non-LGL CML patients (Kreutzman, 
Juvonen et al. 2010). Positive products (confirmed by sequencing) are marked in the table.  
 
Table 4. Phenotypic features of CD8+ and CD4+ T cell populations. 
Phenotype T LGL* 
n=5 
NK LGL* 
n=5 
T + NK LGL*a 
n=1 
No LGL* 
n=3 
CD8+ (% of CD3+ T cells) 76.0 (31.6-80.3) 36.8 (33.8-42.6) 35.3 30.9 (27.3-48.9) 
CD4+ (% of CD3+ T cells) 17.1 (14.0-57.8) 42.2 (29.8-61.1) 37.4 54.2 (35.1-67.7) 
CD57+ (% of CD8+ T cells) 78.2 (51.9-83.8) 47.3 (26.5-70.3) 76.1 12.2 (8.0-16.6) 
PD-1+CD57- (% of CD8+ T cells) 3.4 (0.9-7.6) 9.4 (1.4-15.6) 14.9 18.9 (5.5-22.1) 
PD-1+CD57+ (% of CD8+ T cells) 5.2 (1.0-19.3) 7.1 (0.5-17.2) 23.9 3.7 (0.7-4.0) 
CD45RO+CD27- (% of CD8+ T cells) 80.5 (63.8-90.5) 54.8 (27.2-80.6) 90.5 17.6 (15.6-29.0) 
CD57+ (% of CD8+ CD45RO+CD27-) 86.2 (55.2-87.6) 78.9 (73.9-81.2) 79.4 30.0 (20.4-34.2) 
CD57+ (% of CD4+ T cells) 39.4 (21.6-80.7) 4.5 (1.3-72.6) 67.6 2.3 (1.0-5.6) 
CD45RO+CD27- (% of CD4+ T cells) 79.1 (35.1-87.6) 14.6 (4.2-90.8) 90.1 16.5 (5.8-26.7) 
CD57+ (% of CD4+ CD45RO+CD27-) 65.6 (44.9-88.0) 23.5 (6.6-78.8) 73.8 11.1 (3.1-14.2) 
CD8+NLV+ (% of CD3+ T cells) 7.9 (3.7-11.2)b 2.6 (0.7-4.2)c 15.6 - 
CD45RO+CD27- (% of NLV+ T cells) 84.8 (79.4-88.9) 53.3 (39.9-76.2) 93.2 - 
CD57+ (% of NLV+ T cells) 39.8 (26.6-88.1) 29.7 (24.8-46.8) 70.6 - 
CD57+ (% of NLV+ CD45RO+CD27-) 41.6 (27.7-89.6) 46.3 (30.6-54.2) 72.4 - 
a Patient 13; longitudinal values for patient 6 are shown in Fig. 36. b Patient 12 did not have an NLV-
specific CD8+ T cell population due to the absence of HLA-A*02. c Patient 8 did not have an NLV-
specific CD8+ T cell population due to the absence of HLA-A*02. * Medians with ranges in parenthesis 
are shown. NLV+, CMV pp65495-503/HLA-A*0201 tetramer-labelled CD3+ T cells. 
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Figure 31. Plasma IP-10, IL-6, MIG and IL-2R levels in CML and Ph+ ALL patients treated with 
dasatinib. Plasma levels of 25 cytokines were measured with a multiplex bead-based cytokine assay 
(Luminex®) in healthy controls (n=10), dasatinib-treated patients with LGL expansions (LGL+, n=15) 
and patients without LGL expansions during dasatinib therapy (LGL-, n=8). Patients who experienced 
CMV reactivations during dasatinib therapy (Table 3) are identified with unfilled symbols. Comparisons 
between groups were performed using the non-parametric Kruskall-Wallis test. Statistically significant 
differences were observed between healthy controls and LGL patients for IP-10 (p=0.0011), IL-6 
(p=0.0077), MIG (p=0.0090) and IL-2R (p=0.0186) levels; these differences held irrespective of the 
sampling time point (data not shown). In the IL-6 graph, one data point in the LGL- group was out of 
range (3576.5 pg/ml) and is not shown. The horizontal lines in the graphs denote medians. The data in 
this figure and this figure were produced by collaborators. 
 
Increased apoptotic susceptibility of T cells from patients with LGL expansions 
In vitro, CD3+ T cells from LGL patients (n=8) demonstrated significantly higher rates of apoptosis 
compared to non-LGL patients (n=6) or healthy controls (n=4) after 4 days without stimulation (p<0.05 
for both comparisons); no significant differences for NK cells were observed between the 3 groups 
(data not shown). The CD3+ T cells from LGL patients were also more sensitive to AICD after 
stimulation with the murine mAb OKT3, which cross-links the CD3 component of the CD3/TCR 
complex, leading to significantly higher rates of apoptosis compared to healthy controls (p<0.05) and a 
trend towards higher rates of apoptosis compared to non-LGL patients. In contrast, no differences 
were observed in either untreated or OKT3-stimulated T cells with regard to the fraction of late 
apoptotic/necrotic cells (7AAD+/annexin V+; data not shown). Thus, with the caveat that in vitro 
conditions do not necessarily recapitulate the complexity of cellular signalling networks in vivo, it 
appears that enhanced survival does not explain the T cell expansions observed in dasatinib-
associated LGL lymphocytosis; instead, these data point towards a proliferative basis for the observed 
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T cell expansions. Thus, the effects of dasatinib on T cell and NK cell activation, proliferation and 
function directly ex vivo were examined. 
 
Ex vivo modulation of T cell activation, proliferation, degranulation and cytokine production by 
dasatinib 
Initially, the effects of dasatinib on CD3+, CD4+ and CD8+ T cell subsets stimulated non-specifically 
with OKT3 ex vivo were examined. Consistent with previous studies, significant dose-dependent 
inhibitory effects on T cell activation, proliferation, degranulation and cytokine production were 
observed in all subsets (Fig. 32). Importantly, no differences in dasatinib sensitivity were observed 
with respect to any of these effects between LGL patients, non-LGL patients and healthy controls 
(data not shown). Notably, during these experiments, a dichotomy within the CD8+ T cell compartment 
of LGL patients was observed. Specifically, two distinct CD8+ T cell subpopulations, CD8high and 
CD8low, could be discerned based on differential CD8 expression levels (Fig. 32C, 32D). The CD8high 
subset exhibited substantially greater degranulation and cytokine production in response to OKT3 
stimulation compared to the CD8low and CD4+ subsets (Fig. 32C-E). Moreover, distinct CD8high and 
CD8low T cell subsets were not observed in healthy controls or non-LGL patients, with the exception of 
one non-LGL patient in whom LGL expansions may still develop. 
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Figure 32. Effects of dasatinib on the activation and proliferation of T cells from LGL patients in 
response to OKT3 and costimulation. (A) T cells from LGL patients were either untreated or pre-
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incubated with dasatinib at 10 or 50 nM for 1 hour as indicated, then stimulated for 24 hours with 5 
µg/ml OKT3 under the same conditions. CD69 expression in gated live lymphocytes from 9 
independent experiments is shown as the mean +/- SEM for CD3+ T cells (white), CD4+ T cells (light 
grey) and CD8+ T cells (dark grey). Dasatinib led to a significant dose-dependent inhibition of CD69 
up-regulation in CD3+, CD4+ and CD8+ T cells (p<0.001 for all comparisons of stimulated alone vs. 
stimulated in the presence of dasatinib at 10 or 50 nM). (B) PBMCs from LGL patients were labelled 
directly ex vivo with 0.25 µM CFSE, then either untreated or pre-incubated with 10 or 50 nM dasatinib 
for 1 hour prior to stimulation with 5 µg/ml OKT3 in the presence of  αCD28/αCD49d at 1 µg/ml each 
(CS: costimulation) for 4 days under the same conditions. The % proliferating T cells in gated live 
lymphocytes from 8 independent experiments is shown as the mean +/- SEM for CD3+ T cells (white), 
CD4+ T cells (light grey) and CD8+ T cells (dark grey). A significant dose-dependent inhibition of 
OKT3-induced T cell proliferation in CD3+, CD4+ and CD8+ T cells was observed (p<0.0001 for all 
comparisons of stimulated alone vs. stimulated in the presence of dasatinib at 10 or 50 nM). (C-E) 
Frequencies of CD8high, CD8low and CD8- T cells from LGL patients that expressed CD107a/b and 
produced IFN-γ/TNF-α in response to stimulation with 5 µg/ml OKT3 and αCD28/αCD49d at 1 µg/ml 
each (CS: costimulation) in 5 hour assays directly ex vivo. (C & D) Representative plots are shown 
from patient 14. Gates were set on live lymphocytes, then CD3+CD8+ (C) or CD3+CD8- (D) cells. (E) 
CD107a/b expression (left graph) and IFN-γ/TNF-α production (right graph) in gated live lymphocytes 
from 8 independent experiments are shown as mean values +/- SEMs for CD3+ T cells (white), CD4+ T 
cells (light grey; gated as CD8-), CD8low T cells (dark grey) and CD8high T cells (black). The CD8high 
subset appeared to be marginally more resistant to dasatinib inhibition compared to the CD8low T cell 
subset, as cytokine production was not completely suppressed at 10 nM dasatinib; however, the 
fractional decrease in cytokine functionality induced by dasatinib was similar compared to the CD8low 
and CD4+ subsets, and was significant (p<0.0001 for all comparisons) in all cases. Dasatinib led to a 
significant reduction of CD107a/b expression only in the CD8high subset (p<0.0001); there was minimal 
CD107a/b mobilization in the CD8low and CD4+ subsets, even in the absence of dasatinib. The data in 
this figure and this figure were produced by co-investigators. 
 
As CD8+ T cell-mediated immunity is essential for the long-term control of persistent DNA viruses, and 
5/16 LGL patients experienced symptomatic CMV reactivation (Table 3), CD8+ T cell proliferation was 
evaluated in response to the CMV pp65495-503 peptide Ag (NLVPMVATV) over a period of 6 days. 
CMV-specific CD8+ T cell proliferation was suppressed in vitro in the presence of 50 nM dasatinib 
(p<0.001); however, in contrast to bulk CD8+ T cell populations (Fig. 32B), no inhibition was observed 
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with 10 nM dasatinib (Fig. 33A). No differences were observed when LGL patients (n=4) were 
compared with either healthy controls (n=2) or a non-LGL patient (patient 19, Table 3). Of note, the 
majority of non-LGL patients in our cohort were either HLA-A*02- or CMV IgG seronegative; thus, only 
extremely limited CMV-specific functional studies were possible in this group (Fig. 33A, 33D). 
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Figure 33. Effects of dasatinib on activation and proliferation of CMV-specific CD8+ T cells from LGL 
patients and healthy controls in response to cognate viral Ag directly ex vivo. (A) PBMCs were 
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labelled with CFSE, then stimulated with the CMV pp65495-503 peptide NLVPMVATV (NLV) at a 
concentration of 2 µM for 6 days in the presence of αCD28/αCD49d at 1 µg/ml each (CS: 
costimulation). Ag-specific proliferation in the absence and presence of dasatinib at 10 or 50 nM was 
evaluated for CD8+ T cells that stained with the CMV pp65495-503/HLA-A*0201 tetramer. Data are 
shown as the mean +/- SEM for LGL patients (n=4, grey), healthy controls (n=2, white) and a non-LGL 
patient (n=1, black). (B) Direct ex vivo functional analysis of CMV-specific CD8+ T cell populations 
from healthy controls. CD107a/b expression (left panel) and IFN-γ/TNF-α production (right panel) in 
gated live lymphocytes from 3 independent experiments are shown as mean values +/- SEMs for 
CD3+CD8+ T cells specific for the NLVPMVATV (NLV) peptide (white). (C) Direct ex vivo functional 
analysis of CMV-specific CD8+ T cell populations from LGL patients. CD107a/b expression (left panel) 
and IFN-γ/TNF-α production (right panel) in gated live lymphocytes from 8 independent experiments 
are shown as mean values +/- SEMs for NLVPMVATV-specific (NLV+) CD3+CD8+ T cells (white), 
NLVPMVATV-specific (NLV+) CD3+CD8low T cells (light grey) and NLVPMVATV-specific (NLV+) 
CD3+CD8high T cells (dark grey). (D) Direct ex vivo functional analysis of CMV specific CD8+ T cell 
populations from a non-LGL patient (patient 19, Table 3). CD107a/b expression (left panel) and IFN-
γ/TNF-α production (right panel) in gated live lymphocytes from a single experiment are shown for 
CD3+CD8+ T cells specific for the NLVPMVATV (NLV) peptide (white). The data in this figure and this 
figure were produced by co-investiagtors. 
 
Strikingly, distinct CD8high and CD8low subsets were observed within the NLVPMVATV-specific CD8+ T 
cell populations in patients with LGL expansions (n=8). In healthy controls (n=3) and one non-LGL 
patient (patient 19, Table 3), only NLVPMVATV-specific CD8high subpopulations were detected; the 
distinct CD8low subpopulation was confined to LGL patients (Fig. 34A, 34B). When NLVPMVATV-
specific CD8+ T cells were stimulated with cognate peptide, both the CD8high and CD8low subsets 
exhibited degranulation and cytokine production; these functions were inhibited by dasatinib in a dose-
dependent fashion, with minimal and almost complete suppression at concentrations of 10 and 50 nM, 
respectively (Fig. 33B-D). Of note, in LGL patients, both degranulation and cytokine production were 
significantly more pronounced in the CD8high subset (n=8; Fig. 33C). Furthermore, dasatinib effectively 
abrogated downregulation of both TCR and CD8 in the CD8high subpopulation in vitro, which could be 
a contributing factor in the generation and maintenance of persistent LGL expansions (data not 
shown) (Lissina, Ladell et al. 2009). Importantly, the dominant TCR clonotypes and phenotypic 
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features of the CD8high and CD8low NLVPMVATV-specific subsets were similar (Fig. 34), thereby 
indicating that these cells were derived from the same precursors and that the observed CD8 
downregulation likely reflected a state of recent activation. One minor deviation from this general 
observation occurred in patient 13, in whom the NLVPMVATV-specific CD8low population appeared 
more differentiated (CD45ROdimCD57+) and expressed greater levels of programmed death-1 (PD-1); 
this is consistent with Ag-driven effects in the context of combined T cell and NK cell LGL expansions. 
 
Figure 34. Phenotypes and clonotypes of CMV-specific CD8high and CD8low T cell subsets in LGL 
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patients. (A & B) Phenotypic profiles of NLVPMVATV-specific CD8high and CD8low T cell populations 
from four representative LGL patients (1 x NK LGL, 2 x T + NK LGL, 1 x T LGL). Coloured dots depict 
individual NLVPMVATV-specific CD8high (red) and CD8low (yellow) T cells super-imposed on density 
plots showing the phenotypic profile of the overall CD8+ T cell population. (A) CD27 vs. CD45RO; (B) 
CD57 vs. PD-1. Inset plots in (B) display the CMV pp65495-503/HLA-A*0201 tetramer-labelled CD3+ T 
cell populations in each case. The magnitudes (% values with respect to the total CD3+ T cell 
population) of the tetramer-labelled (NLV) CD8high and CD8low subpopulations, respectively, were: 
2.28% and 1.12% for patient 16, 10.1% and 4.6% for patient 13, 2.04% and 3.06% for patient 6, and 
2.67% and 0.85% for patient 7. (C) Clonotypic composition of NLVPMVATV-specific CD8high T cells 
from patient 6. (D) Clonotypic composition of NLVPMVATV-specific CD8low T cells from patient 6. The 
clonotype sequence data shown are derived from 2385 and 4055 sorted cells, respectively. TRBV and 
TRBJ usage, CDR3 amino acid sequence and percent frequency are shown for each distinct 
clonotype. *TRBV12-3 and TRBV12-4 could not be distinguished. 
 
Ex vivo modulation of expanded NK cell cytotoxic activity, degranulation and cytokine production by 
dasatinib 
A modified biophotonic luciferase assay was used to measure NK cell cytotoxic activity against 
transiently transfected K562 cells. Expanded NK cells from LGL patients showed significantly impaired 
cytotoxic activity against K562 cells compared to NK cells from non-LGL patients or healthy controls 
(p<0.05 for both comparisons, Fig. 35A). Of note, insufficient numbers of NK cells were available from 
LGL patients with CD8+ T cell expansions to conduct this assay. The impaired in vitro cytotoxic activity 
of NK cells from LGL patients may be due to exhaustion based on excessive in vivo proliferation or a 
state of reversible anergy. In line with this hypothesis, NK cell cytotoxic activity was restored to a 
substantial extent after pre-treatment with IL-2 for 18 hours (Fig. 35B). The cytotoxic activity of NK 
cells, either with or without IL-2 pre-treatment, was inhibited by dasatinib in all three groups 
irrespective of differences in activity (Fig. 35C, 35D). In contrast, when PBMCs were stimulated with 
untransfected K562 cells without IL-2 pre-treatment, no differences in NK cell degranulation and 
cytokine production were observed for NK LGL patients (n=5; Fig. 35E, 35F) compared to non-LGL 
patients (n=3) or healthy controls (n=3). Dasatinib led to a significant reduction in CD107a/b 
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expression and cytokine production in NK LGL patients and healthy controls at a concentration of 10 
nM (p<0.01 for all comparisons); however, significant inhibition was not achieved at this concentration 
in non-LGL patients, which may reflect the small sample size (n=3). Degranulation and cytokine 
production were completely inhibited by dasatinib at a concentration of 50 nM in all three groups. The 
contrasting cytotoxicity and degranulation data could reflect differential assay conditions or differences 
in the cytotoxic arsenal available for deployment. 
 
Figure 35. Effects of dasatinib on the functionality of NK cells from LGL patients, non-LGL patients 
and healthy controls. (A-D) Target cell lysis mediated by NK cells was monitored by a decrease in 
detected luminescence flux (RLU) in a biophotonic luciferase assay. RLU in the condition without 
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effector cells was set as 100% to establish relative values for other evaluations. (A) The cytotoxic 
activity of NK cells from healthy controls (n=4), non-LGL patients (n=3) and NK LGL patients (n=5) 
was measured at the indicated effector:target (E:T) ratios. Sorted CD3+ T cells from a healthy control 
were included as a negative control. (B) NK cells were pre-treated with 2000 IU/ml IL-2 for 18 h. The 
cytotoxic activity of NK cells from healthy controls (n=4), non-LGL patients (n=3) and NK LGL patients 
(n=5) was then measured at the indicated E:T ratios. Sorted CD3+ T cells from a healthy control were 
included as a negative control. (C) NK cell cytotoxic activity at the indicated E:T ratios in the presence 
of dasatinib at the indicated doses is shown for NK LGL patients (n=3) and non-LGL patients (n=2), 
and compared to expanded NK cells (n=2) or untreated NK cells from healthy controls (n=3). (D) NK 
cells were pre-treated with 2000 IU/ml IL-2 for 18 h. The cytotoxic activity of NK cells at the indicated 
E:T ratios was then measured in the presence of dasatinib at the indicated doses for NK LGL patients 
(n=3), non-LGL patients (n=2), healthy controls (n=5) and expanded polyclonal NK cells (n=1) as a 
positive control. (E & F) PBMCs (1.5x105 CD16+/CD56+ NK-cells) from NK LGL patients (n=5), non-
LGL patients (n=3) and healthy controls (n=3) were stimulated with K562 cells (2x104) at an E:T ratio 
of 7.5:1. CD107a/b expression (E) and IFN-α/TNF-α production (F) were measured in the absence or 
presence of dasatinib at the indicated concentrations after 5 h. Mean values +/- SEMs are shown. The 
data in this figure and this figure were produced by co-investigators. 
 
Detailed phenotypic characterization of T cells and NK cells in subjects with or without LGL 
expansions 
Analyzed directly ex vivo, patients with dasatinib-associated T LGL expansions had higher frequencies 
of CD8+ T cells and lower frequencies of CD4+ T cells compared to non-LGL patients or patients with 
NK LGL or T + NK LGL expansions (Table 4). Although the frequencies of PD-1+CD57- cells in the 
CD8+ T cell compartment were highest in non-LGL patients, subjects with LGL tended to have higher 
frequencies of PD-1+ cells that also expressed CD57. Annexin V was only expressed by very few cells 
in patients with or without LGL expansions, and there were no differences between groups (data not 
shown). The majority of CD8+ and CD4+ T cells from patients with T or T + NK LGL expansions were 
CD45RO+CD27- and many of these cells, especially in the CD8+ T cell compartment, co-expressed 
CD57 (with lower percentages in CD4+ T cells; Table 4). As described above, high frequencies of 
CMV-specific CD8+ T cells were observed in patients with LGL expansions; these cells also exhibited 
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a predominant CD45RO+CD27- phenotype and many co-expressed CD57 (Table 4). The latter could 
not be assessed in non-LGL patients, as they were mostly either HLA-A*02- or CMV IgG seronegative. 
Collectively, these phenotypic features indicate that these cells are primed, late differentiated effector 
memory T cells (Appay, van Lier et al. 2008). The majority of NK-cells exhibited a CD45RO-CD27-
CD57+ phenotype, especially in patients with NK or T + NK LGL expansions (Table 5). This phenotype 
is typical for terminally differentiated effector memory cells that are characterized by replicative 
senescence and are found at higher frequencies in chronic viral infections (Cooper, Elliott et al. 2009; 
Sun, Beilke et al. 2009). Of note, 3 LGL patients (patients 1, 3 and 7; Table 3) had CD8+ T cell 
populations specific for the PR1 leukaemia-associated peptide derived from proteinase 3 (1.1%, 0.6% 
and 0.05% of the total CD8+ T cell population, respectively); of these, >90% were CD45RO+CD27- and 
the majority (71-100%) were also CD57+. All of these patients had advanced disease (ALL and CML in 
blast crisis) that had relapsed after allogeneic BM transplantation and, in 2 patients (patients 1 and 7; 
Table 3) the disease had subsequently quiesced into prolonged remission (>2 years) with dasatinib 
monotherapy, suggesting an unexpectedly good response to treatment. In other patients studied, no 
PR1-specific CD8+ T cells were observed. Overall, these analyses demonstrate that T cells and NK 
cells in dasatinib-associated T, NK and T + NK LGL expansions characteristically display a late or 
terminally differentiated phenotype (CD45RO+/-CD27-CD57+). 
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Table 5. Phenotypic features of NK cells (either gated on CD16+ or CD56+ first) in patients with T, NK 
or T + NK LGL expansion. 
Phenotype T LGL* 
n=4 
NK LGL* 
N=3 
T + NK LGL* 
n=4 
No LGL* 
n=2	  
CD16+ (% of live CD14– CD3– cells) 27.7 (3.5-84.2) 91.8 (64.3-97) 63.4 (49.4-72.7) 9.6 (7.0-12.2) 
CD57+ (% of CD16+ NK cells) 53.1 (15.3-90.0) 83.3 (76.3-88.2) 76.9 (30.4-85.9) 73.5 (65.9-81.0) 
CD45RO+CD27- (% of CD16+) 21.4 (17.4-36.8) 22.0 (15.8-33.5) 10.9 (7.6-20.3) 26.6 (21.7-31.5) 
CD45RO-CD27- (% of CD16+) 77.1 (58.7-80.6) 78.0 (66.3-84.2) 88.6 (78.8-90.7) 71.8 (67.5-76.1) 
CD57+ (% of CD16+CD45RO-CD27-) 54.8 (47.6-92.2) 85.1 (82.8-89.2) 79.4 (31.4-88.4) 80.6 (69.9-91.3) 
CD56+ (% of CD16+ NK cells) 68.9 (25.8-75.5) 30.3 (19.5-77.8) 42.9 (29.0-70.7) 55.9 (32.9-78.8) 
CD57+ (% of CD16+CD56+ NK cells) 55.5 (25.8-91.8) 81.9 (77.8-89.7) 77.3 (29.0-85.9) 86.6 (83.0-90.1) 
CD45RO+CD27- (% of CD16+CD56+) 17.5 (13.4-23.6) 28.5 (23.5-33.5) 10.5 (7.5-20.8) 9.9 (6.1-13.7) 
CD45RO-CD27- (% of CD16+CD56+) 77.6 (75.1-83.4) 71.4 (66.3-76.5) 88.5 (77.6-90.5) 88.4 (83.7-93.0) 
CD56+ (% of live CD14– CD3– cells) 28.7 (6.2-65.0) 28.5 (19.8-93.7) 37.1 (29.7-59.6) 12.5 (8.3-16.7) 
CD57+ (% of CD56+ NK cells) 31.6 (24.6-90.1) 78.4 (78.3-88.4) 67.6 (27.7-75.1) 61.4 (53.4-69.4) 
CD45RO+CD27- (% of CD56+) 20.7 (12.0-31.9) 38.0 (27.0-40.0) 14.1 (11.1-22.4) 12.0 (11.1-12.9) 
CD45RO-CD27- (% of CD56+) 72.2 (67.5-76.7) 61.8 (59.7-72.8) 83.5 (73.8-86.1) 83.4 (81.2-85.6) 
CD57+ (% of CD56+CD45RO-CD27-) 40.6 (26.2-90.9) 81.6 (79.4-88.8) 73.0 (26.1-81.3) 75.9 (70.1-81.6) 
CD16+ (% of CD56+ NK cells) 59.7 (36.2-95.1) 96.7 (77.1-98.2) 73.8 (65.5-88.0) 43.9 (27.9-59.8) 
CD57+ (% of CD56+CD16+ NK cells) 55.2 (31.4-91.8) 81.9 (77.2-89.7) 77.2 (30.9-85.2) 86.4 (83.0-89.7) 
CD45RO+CD27- (% of CD56+CD16+) 30.7 (11.0-40.6) 45.6 (35.6-46.5) 19.6 (17.1-33.9) 18.2 (13.1-23.2) 
CD45RO-CD27- (% of CD56+CD16+) 66.2 (59.3-80.9) 54.2 (53.4-64.3) 79.5 (64.6-81.5) 80.6 (74.6-86.5) 
* Medians with ranges in parenthesis are shown. 
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Longitudinal phenotypic characterization of T cell subsets in a patient with combined T and NK LGL 
expansion 
To increase our understanding of the LGL phenomenon, a longitudinal examination of T cell subsets 
was conducted in one patient (patient 6, CML in blast crisis; Table 3) with T + NK LGL expansion 
(TCRδ rearrangement in NK-cells and TCRγ rearrangement in CD8+ T cells) (Kreutzman, Juvonen et 
al. 2010). Dramatic expansions of both total and NLVPMVATV-specific CD8+ T cells were observed; 
the latter comprised up to 14.2% of the total CD3+ T cell population in PBMCs and up to 15.1% in 
BMMCs (Fig. 36A). The clonal T + NK LGL expansions emerged 12 weeks after dasatinib was first 
administered (time point 2; Fig. 36). This paralleled the expansion of NLVPMVATV-specific CD8+ T 
cells. A high fraction of CD8+ T cells expressed CD45RO, but not CD27 (Fig. 36B); furthermore, a very 
high fraction of CD8+ T cells expressed CD57, but relatively few expressed or co-expressed PD-1 (Fig. 
36C). The latter was also true for CD4+ T cells (Fig. 36H). Only a minority of total CD8+ T cells and 
NLVPMVATV-specific CD8+ T cells exhibited an activated phenotype (CD69+), but more activated 
cells were present at the first time point (Fig. 36D, 36G). Similarly, the majority of total CD8+ T cells 
and NLVPMVATV-specific CD8+ T cells were CD127- during the period of study, although higher 
expression of this homeostatic memory marker was apparent at the first time point (Fig. 36D, 36G). 
Most NLVPMVATV-specific CD8+ T cells (both CD8high and CD8low) expressed CD45RO, but not CD27 
(Fig. 36E); a high fraction also expressed CD57 (Fig. 36F). However, in contrast to the total CD8+ T 
cell population, a high fraction of NLVPMVATV-specific CD8+ T cells expressed both PD-1 and CD57; 
this PD-1+CD57+ fraction was less prominent at time points characterized by higher CMV loads, 
whereas the PD-1+CD57- fraction displayed the opposite pattern (Fig. 36F). Overall, these data are 
consistent with the contrasting effects of an Ag-driven activation and differentiation process attenuated 
by the inhibitory effects of dasatinib. 
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Figure 36. Longitudinal phenotypic characterization of T cell subsets in a patient with combined T and 
NK LGL expansion. (A) Frequencies of CD8+, CD4+ and NLVPMVATV-specific (pp65+) CD8+ T cells 
longitudinally in PBMCs and in bone marrow (BM). The CD8+ T cell counts (x 106/L) were calculated 
using the absolute lymphocyte count and the percentage of CD8+ T cells in PBMCs as determined by 
flow cytometry. (B) CD45RO and CD27 expression profiles of CD3+CD8+ T cells. (C) Fraction of 
CD3+CD8+ T cells that expressed CD57, PD-1 and CD57, or PD-1 without CD57. (D) CD69 and 
CD127 expression profiles of CD3+CD8+ T cells. (E) CD45RO and CD27 expression profiles of 
NLVPMVATV-specific (NLV+) CD3+CD8+ T cells. (F) Fraction of NLVPMVATV-specific (NLV+) 
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CD3+CD8+ T cells that expressed CD57, PD-1 and CD57, or PD-1 without CD57. (G) CD69 and 
CD127 expression profiles of NLVPMVATV-specific (NLV+) CD3+CD8+ T cells. (H) Fraction of 
CD3+CD4+ T cells that expressed CD57, PD-1 and CD57, or PD-1 without CD57. PBMCs or BMMCs 
were stained sequentially with a live/dead fixable dye, CMV pp65495-503/HLA-A*0201-allophycocyanin 
tetramer, and one of two different polychromatic surface marker-specific mAb panels; for one of the 
surface marker-specific mAb panels, cells were then also stained with streptavidin-Pacific Blue. Data 
were acquired on a 20-parameter FACSAria II flow cytometer and analyzed with FlowJo software. The 
time points were: 1 = 46 days, 2 = 107 days, 3 = 117 days, 4 = 138 days, 5 = 358 days, 6 = 446 days, 
7 = 463 days, 8 = 488 days, 9 = 491 days; 11 = BM sample from 358 days after the start of dasatinib 
therapy. The CMV load (copies/ml) is shown in all panels. All analyses were conducted with 
cryopreserved samples from patient 6 (Table 3). 
 
6.5 Discussion 
The dose-dependent immunosuppressive effects of dasatinib observed in vitro are at odds with 
apparent immunostimulatory effects observed in vivo. These differences may be explained, at least in 
part, by the short half-life of dasatinib in vivo, which leads to intermittent kinase-mediated target 
inhibition (Shah, Kantarjian et al. 2008). Previously, it was shown that CD4+ regulatory TREG cell 
numbers were significantly lower in CML patients compared to healthy controls; this distinction was 
especially marked in LGL patients, who exhibited substantially lower TREG cell numbers compared to 
non-LGL patients (data not shown) (Mustjoki, Ekblom et al. 2009; Rohon, Porkka et al. 2010). 
However, the observation herein that LGL expansions in dasatinib-treated patients are associated with 
CMV reactivation provides additional insight into these seemingly contradictory observations. 
In this study, high frequencies of CD8+ T cells specific for the CMV pp65495-503 peptide Ag 
(NLVPMVATV) were observed in LGL patients; furthermore, a high proportion of LGL patients (31%) 
experienced symptomatic CMV reactivation during dasatinib therapy, while there was no evidence for 
reactivation of other herpes viruses. It is feasible that CMV reactivation was triggered in these patients 
by the immunosuppressive effects of dasatinib, subsequently leading to the preferential expansion of 
individual CD8+ T cell or NK cell clones with properties that rendered them more resistant to dasatinib-
mediated inhibition in the context of enhanced viral antigenic load. Our dasatinib sensitivity studies 
 140 
support this hypothesis (Figs. 32 and 33). Furthermore, monoclonal or oligoclonal LGL expansions 
have been described in states of reduced immunity, for example after allogeneic stem cell 
transplantation (Mohty, Faucher et al. 2002), and during chronic viral infections (Strickler, Movahed et 
al. 1990; Rossi, Franceschetti et al. 2007). After allogeneic stem cell transplantation, LGL expansions 
typically occur within 3-15 months and are primarily observed in the context of chronic viral infections. 
This indicates that chronic Ag-driven T cell stimulation may contribute to, or even cause, LGL 
expansions. Of note, LGL expansions have been associated with long-term remission in leukaemic 
states (Mohty, Faucher et al. 2002). Indeed, this favourable outcome also applies to dasatinib-treated 
patients with monoclonal or oligoclonal LGL expansions (Table 3) (Kim, Kamel-Reid et al. 2009; 
Mustjoki, Ekblom et al. 2009; Kreutzman, Juvonen et al. 2010). It is tempting to speculate that cross-
reactive CD8+ T cells (Nahill and Welsh 1993; Burrows, Khanna et al. 1994), driven by viral 
recrudescence and fortuitously targeting leukaemia-associated Ags, might mediate these beneficial 
effects. In this light, it is notable that the majority of LGL patients (11/16) in this study were HLA-A*02+, 
which might restrict both virus-specific and leukaemia-associated Ag-specific epitopes in this setting. 
Previous descriptions of improved survival associated with HLA-A*02+ and CMV IgG seropositivity in 
the allogeneic transplantation setting are consistent with this notion (Nachbaur, Bonatti et al. 2001).  
All LGL patients exhibited distinct CD8+ T cell populations comprising both CD8high and CD8low T cells. 
This was true for both the total and NLVPMVATV-specific CD8+ T cell populations. The CD8high T cell 
subset was uniformly the most functionally responsive on restimulation. A similar phenotypic 
dichotomy (CD8high vs CD8low) has been described previously for HIV-specific CD8+ T cells, both 
during the initiation and discontinuation of antiretroviral therapy (Oxenius, Gunthard et al. 2001). Thus, 
dynamic perturbations of viral load can elicit such phenotypic patterns within the cognate CD8+ T cell 
population. Consistent with this explanation, both the CD8high and CD8low NLVPMVATV-specific CD8+ 
T cell populations were phenotypically and clonotypically similar within individuals, thereby indicating 
that the same Ag-specific clonotypes can exist in different states of activation during dasatinib-
associated LGL expansion. Of further note in this regard, it has been shown previously that CMV-
specific CD8+ T cells can dominate the memory pool in IgG seropositive individuals (Sylwester, 
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Mitchell et al. 2005; Scheinberg, Melenhorst et al. 2009); thus, CMV reactivation could potentially 
explain the dichotomous pattern of CD8 expression within the total CD8+ T cell population, as the 
NLVPMVATV-specific response likely only measures a small fraction of the overall CD8+ T cell 
response to CMV. In addition, high CD8 expression may reflect the inhibition of co-receptor 
downregulation by dasatinib (Weichsel, Dix et al. 2008; Lissina, Ladell et al. 2009). CD8low T cells have 
been observed primarily in chronic infections with persistent antigenic stimulation, such as HIV 
infection (Schmitz, Forman et al. 1998; Keir, Rosenberg et al. 2002), and may represent long-lived 
anergic cells in some cases (Blish, Dillon et al. 1999).  
In LGL patients, an increased frequency of apoptotic T cells was found compared to non-LGL patients 
and healthy controls. This finding may reflect strong in vivo proliferation of the LGL cells, potentially 
driven by viral Ags, leading to exhaustion and increased susceptibility to apoptosis. The observed 
relative impairment of NK cell cytotoxic activity against K562 cells in NK LGL patients could be due to 
a similar process. In line with these findings, both CD8+ T cells and NK cells expressed high levels of 
CD57 in patients with LGL expansions of the corresponding cell subsets. CD57 expression is a marker 
of replicative senescence and indicative of altered functional capacities (Brenchley, Karandikar et al. 
2003). However, this reduced cytotoxic activity was restorable after pre-treatment of NK cells with IL-2, 
which argues for a transient effect with sustained functionality as typifies recently primed or anergic 
cells. 
The increased IP-10, IL-6, MIG and IL-2R levels observed in LGL patients could conceivably 
contribute to improved therapeutic responses because these cytokines/chemokines direct the 
chemotaxis of monocytes, T cells, NK cells and dendritic cells. Such chemotactic effects have been 
shown to be relevant for leukaemia control (Sun, Finger et al. 2005; Choi, Hildebrandt et al. 2007). Of 
note, some of these soluble factors are typically produced by Ag-specific CD8+ T cells during viral 
infections and are associated with anti-viral processes. Indeed, a causative role for infections with 
herpes viruses has already been postulated in the pathogenesis of LGL expansions (Swa, Wright et 
al. 2001). The elevated cytokine/chemokine levels in LGL patients could therefore indicate a higher 
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degree of viral Ag-driven cellular immune activation enhanced by an intrinsic dysregulation of 
homeostasis. Consistent with these ideas, the highest levels of IP-10, IL-6, MIG and IL-2R were 
observed in the plasma of LGL patients with symptomatic CMV reactivation. Notably, CD8+ T cells 
specific for the leukaemia-associated Ag PR1 were detected in 3 LGL patients with complete 
remission status despite initially poor prognoses. Such CD8+ T cell populations are difficult to detect in 
peripheral blood (Melenhorst, Scheinberg et al. 2009); it is therefore possible that larger numbers of 
these cells might reside in the bone marrow of patients with dasatinib-associated LGL, contributing to 
the link between elevated levels of cytokines/chemokines and favourable outcome.  
In summary, the expanded lymphocyte populations in dasatinib-associated LGL patients are primarily 
CD27- and CD57+, a phenotype associated with late differentiated effector memory cells. This finding 
is in general agreement with previous descriptions of anergic clonal T cell expansions in other 
malignant diseases such as multiple myeloma (Sze, Giesajtis et al. 2001), myelodysplastic syndrome 
(Epling-Burnette, Painter et al. 2007) and Waldenstrom's macroglobulinaemia (Li, Sze et al. 2010). In 
addition, strong evidence is provided that the LGL expansions, which are linked to a favourable 
outcome during dasatinib therapy, are associated with CMV reactivation. A causative role for CMV in 
this process has yet to be proven, but the possibility that a recrudescent virus can elicit cellular 
immune responses capable of controlling leukaemia is worthy of further study.  
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CHAPTER 
7 
Discussion 
7.1 Discussion 
In this thesis, T cell responses to chronic antigenic stimulation were investigated in a variety of 
settings to generate insights into the processes that regulate T cell memory. The in vivo turnover 
(rates of proliferation and cell death) of antigen-specific and phenotypically defined T cell populations 
was studied in transgenic mice and HIV-1-infected humans, respectively. In addition, memory CD8+ T 
cell expansions were examined in MCMV-infected mice and patients with dasatinib-induced LGL.  
 
Other investigators have published discrepant results on the issue of whether continuous s.c. 
administration of peptide without adjuvant leads to T cell tolerance or immunity / inflammation. In 
chapter 3 of this thesis, experiments were performed using intact TCR tg mice to resolve these 
discrepancies in an appropriately controlled setting. Use of a murine model was necessary to study 
the cellular composition of the thymus and sort sufficient numbers of Ag-specific TM and TN cells to 
assess label enrichment after in vivo labelling. The main objectives were to study the in vivo 
proliferation rates of naïve and effector memory Ag-specific T cells, and to study the expansion of 
these cells, as well CD4+CD25highFoxP3+ TREG cells, in terms of complete organ counts. In vitro, the 
number of T cell divisions has been used as an argument for or against tolerance. Specifically, 
tolerized T cells are thought to undergo fewer divisions than non-tolerized T cells. The data presented 
here show that immunological tolerance is established through “aborted” immune activation in 
DO11.10 CD4+ TCR tg mice during and after s.c. administration of peptide without adjuvant. 
Significantly, the in vivo T cell labelling data indicate that Ag-specific CD4+ T cells divide initially even 
when Ag is given without adjuvant, which suggests the occurrence of active priming. However, the 
efficacy of priming and peripheral expansion was limited and confined to the peripheral LNs. This 
finding is in line with recent data showing that the induction of CD4+ T cell tolerance versus priming in 
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vivo is independent of the rate and number of cell divisions (Adler, Huang et al. 2000). It is also 
consistent with the possibility that tolerized T cells are impaired with respect to T cell trafficking 
(Marelli-Berg, Okkenhaug et al. 2007). In this context, it is feasible that Ag given without adjuvant 
failed to upregulate and subsequently downregulate the expression of activation markers, such as 
CD69, a process that is thought to be necessary for the initiation of T cell trafficking (Shiow, Rosen et 
al. 2006). Unfortunately, however, CD69 cell surface expression was not assessed in the presented 
study. Conversion of TN to memory/effector phenotype T cell subsets was also limited and not 
sustained in the absence of adjuvant. Furthermore, TREG cells were induced and increased both 
numerically and relatively in peripheral LNs, and relatively in PBMCs and the spleen. In addition, a 
significant transient depletion of CD4+ T cells was observed under these conditions, which might have 
contributed to immunological tolerance. The data described here also show that cognate Ag given with 
adjuvant leads to the systemic induction and expansion of all memory/effector phenotype T cell 
subsets studied (at the expense of naïve T cells) in CD4+ TCR tg mice and that this immunological 
response is accompanied by typical symptoms, such as scruffy fur and weight loss, suggestive of a 
state of heightened immune activation. The latter finding is unexpected had one believed the 
assumptions of Kearney et al. (Kearney, Pape et al. 1994). Indeed, the data presented in this thesis 
likely represent the first demonstration that immune responses can be generated in TCR tg mice with 
considerable similarities to those observed in wild-type mice. 
 
CD57 expression has been associated with CD8+ T cell senescence (Brenchley, Karandikar et al. 
2003), one feature of which is the inability of cells to further divide. Ex vivo, CD57+ memory CD8+ T 
cells appeared to proliferate much less than other memory T cell subsets in response to non-specific 
stimuli (Brenchley, Karandikar et al. 2003). Memory CD8+ CD57+ T cells would therefore be expected 
to proliferate less in vivo than their CD57- counterparts. The preliminary in vivo labelling data shown in 
chapter 4 suggest that long-term 2H2O labelling needs to be carried out to resolve this issue 
definitively. Short-term labelling gave less consistent results. One relevant consideration here is the 
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fact that memory CD57+ and CD57- CD8+ T cells are more heterogeneous than the two other 
populations studied, namely CD3+CD8+CD45RA-CCR7-CD57+ T cells and CD3+CD8+CD45RA-CCR7-
CD57- T cells. The labelling curves for the latter two populations suggest that CD3+CD8+CD45RA-
CCR7-CD57+ T cells indeed proliferate less than CD3+CD8+CD45RA-CCR7-CD57- T cells, but further 
experiments are needed to consolidate these findings. 
 
CMV expresses a viral homologue of the anti-inflammatory cytokine IL-10. However, little is known 
regarding the role of IL-10 in the regulation of CMV-specific memory CD8+ T cell responses, including 
the phenomenon of inflation, a characteristic of CMV infection in both humans and mice whereby 
antigen-specific T cells progressively accumulate over time (Gillespie, Wills et al. 2000; Sylwester, 
Mitchell et al. 2005). In chapter 5, the effect of IL-10 on memory CD8+ T cells, including Ag-specific 
CD8+ T cells, was studied. The data clearly show that IL-10 suppresses CMV-specific memory T cell 
inflation. Chronic/latent MCMV infection was associated with IL-10 production by macrophages and 
virus-specific IFN-γ-expressing CD4+ T cells. The induction of Th1-like cells that express IL-10 is likely 
due to chronic antigenic stimulation, as shown for parasitic infections (Anderson, Oukka et al. 2007; 
Jankovic, Kullberg et al. 2007). In addition, prolonged stimulation of HCMV-specific CD4+ T cells in 
vitro induces IL-10/IFN-γ co-expression (Haringer, Lozza et al. 2009). Another finding was that mice 
deficient in IL-10 exhibited a profound increase in MCMV-specific CD8+ T cell accumulation and 
antiviral cytokine production, even though inflationary CD8+ T cells expressed low levels of IL-10R and 
may, therefore, have been refractory to direct IL-10-mediated effects. However, as inflationary T cell 
responses are partially dependent upon CD4+ T cells (Humphreys, Loewendorf et al. 2007; Snyder, 
Loewendorf et al. 2009), elevated CD4+ T cell help in IL-10-/- mice probably promotes CD8+ T cell 
expansion as well as increased cytokine production. Furthermore, IL-10 deficiency was associated 
with IE3-specific CD8+ T cell expansion, which suggests that IL-10 preferentially promotes inflation of 
defined specificities. MCMV viral genome load was reduced in IL-10-/- mice, most likely due to 
enhanced memory CD8+ T cell expansion as well as more potent effector outputs (for example greater 
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cytokine production). The latter was recapitulated by delayed IL-10R blockade in wild-type mice. 
Collectively, these data demonstrate that IL-10 restricts the accumulation of functional MCMV-specific 
memory T cells during MCMV infection. These findings may also have direct therapeutic implications.  
 
The cancer drug dasatinib is an oral BCR/ABL and Src family tyrosine kinase inhibitor approved for 
use in patients with CML after imatinib (a specific BCR/ABL tyrosine kinase inhibitor) treatment and in 
patients with Ph+ ALL. Dasatinib treatment of patients with CML is associated with the occurrence of 
LGL expansions. Antigenic stimulation from latent pathogens such as CMV may drive these LGL 
expansions in some cases, and this could be related to the published dose-dependent 
immunosuppressive effects of dasatinib that have been observed in vitro. Indeed, one could envisage 
a scenario in which latent virus reactivation occurs due to dasatinib-mediated immunosuppression, 
consequently leading, to Ag-driven immune activation and the expansion of granular CD8+ T cells and 
NK cells. The data presented in chapter 6 suggest that this scenario is likely to happen in vivo, as 
high frequencies of CD8+ T cells specific for CMV pp65495-503 (NLVPMVATV) were observed in LGL 
patients. Furthermore, symptomatic CMV reactivation was observed during dasatinib therapy in 31% 
of LGL patients. Monoclonal or oligoclonal LGL expansions have been observed in states of reduced 
immunity, for example after stem cell transplantation (Mohty, Faucher et al. 2002), and during chronic 
viral infections (Strickler, Movahed et al. 1990; Rossi, Franceschetti et al. 2007). Of note, LGL 
expansions have also been associated with long-term remission in leukaemic states (Mohty, Faucher 
et al. 2002), and a favourable outcome also applies to dasatinib-treated patients as shown both in this 
thesis and in previous reports (Kim, Kamel-Reid et al. 2009; Mustjoki, Ekblom et al. 2009; Kreutzman, 
Juvonen et al. 2010). It is also notable that the majority of patients studied in chapter 6 were HLA-
A*02+. In the setting of allogeneic transplantation, CMV-seropositive HLA-A*02+ patients show 
improved survival rates (Nachbaur, Bonatti et al. 2001). The reason for this favourable response is 
currently under investigation. Potential contributory factors include cross-reactivity of expanded T cell 
clones that respond to viral Ags and heightened immune activation due to viral reactivation. 
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In summary, this thesis examined: (i) the impact of continuous antigenic stimulation on Ag-specific 
naïve and memory CD4+ T cell turnover; (ii) a subset of CD8+ T cells that are assumed to be 
senescent T cells and that accumulate in humans harbouring chronic viruses, such as CMV and HIV; 
(iii) the impact of the immunosuppressive cytokine IL-10 on the inflation of CMV-specific CD8+ T cell 
populations; and, (iv) the detailed phenotypic and functional characteristics of T and NK cells in 
leukaemic patients with LGL expansions during dasatinib treatment. First, it was found that continuous 
antigenic stimulation without adjuvant leads to increased in vivo turnover of Ag-specific CD4+ T cells in 
TCR tg mice, but that adjuvant is needed for expansion of all memory/effector CD4+ T cell subsets in 
this setting. Only in the presence of adjuvant did the mice exhibit any symptoms that would suggest 
immune activation, such as weight loss and inflammation at the site of continuous Ag administration. 
In other words, continuous antigenic stimulation lead to aborted immune activation. Second, it does 
indeed appear as if CD57+ T cells turnover less in vivo than their CD57- counterparts, at least in the 
CD8+ T cell compartment. However, more data are needed to confirm this finding and work is ongoing 
in this respect. Third, chronic/latent MCMV infection was found to be associated with the production of 
IL-10 by macrophages and virus-specific Th1-like cells, and that IL-10 suppresses memory T cell 
inflation. Conversely, mice deficient in IL-10 exhibited a profound increase in MCMV-specific CD8+ T 
cell accumulation and antiviral cytokine production, even though inflationary CD8+ T cells expressed 
low levels of IL-10R and may therefore have been refractory to direct IL-10-mediated effects. Defined 
T cell specificities were inflated in mice with IL-10 deficiency, and MCMV viral genome load was 
reduced in IL-10-/- mice, most likely due to enhanced memory CD8+ T cell expansions with more 
potent antiviral weaponry. Lastly, evidence is presented that dasatinib-associated LGL expansion is 
linked to CMV reactivation, at least in the cohort of patients studied here, which could represent a 
potential mechanism for this phenomenon. The expanded cells, which were either of T cell or NK cell 
origin, exhibited a late differentiated (CD27-CD57+) phenotype, which suggests that these cells were 
expanded due to antigenic stimulation. In addition CD8high and CD8low T cells were observed in the 
whole CD8 compartment as well as in the CMV-specific CD8+ T cell populations of LGL patients, and 
plasma levels of pro-inflammatory cytokines were significantly increased, all of which are consistent 
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with Ag-driven activation. 
  
7.2 Future work 
Future work has already begun and is focussed on understanding memory T cell differentiation and 
senescence in more detail. In particular, long-term isotope labelling studies combined with accurate 
measurements of telomere length and telomerase activity within T cell subsets defined in high 
resolution multi-parametric space using advanced polychromatic flow cytometry are underway and 
should enable accurate determination of lineage relationships within the memory T cell pool. 
Experiments are also ongoing to identify the precise viral antigens that trigger LGL expansions and 
determine whether the expanded CD8+ T cells cross-recognize leukaemia-associated antigens.  
 
7.3 Concluding remarks 
The aim of this thesis has been to study Ag-specific T cell turnover (proliferation and death rates) and 
expansion in vivo under conditions of chronic antigenic stimulation. New insights have been gained 
into Ag-specific naïve and memory CD4+ T cell turnover in mice during chronic immune stimulation 
with cognate peptide in the presence and absence of adjuvant. In addition, the turnover of memory 
CD57+CD8+ T cells in humans was examined, although these data should be considered preliminary. 
Chronic antigenic stimulation in the presence of adjuvant, which is naturally present in persistent viral 
infection due to pathogen-expressed motifs that activate immune pathways, not only leads to 
increased T cell turnover, but also to T cell expansion. Further insights have been provided into how 
IL-10 influences T cell expansion and inflation during MCMV infection, with possible implications for 
immunotherapeutic interventions. Finally, this work has provided evidence that LGL expansions in 
leukaemia patients treated with dasatinib are associated with CMV reactivation and chronic stimulation 
with viral antigen.  
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